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ABSTRACT 
 Molecular imaging (MI) has revolutionized the visualization of complex biochemical 
processes in normal physiology and diseased states. Although still in its infancy, the data 
generated from MI studies aids in identifying sites of pathological involvement and provides key 
insight into the mechanisms that lead to the onset and progression of disease. Consequently, 
these techniques hold tremendous potential in the areas of diagnostics, therapy assessment, 
and drug development in the coming years.  
Amongst MI techniques, Positron Emission Tomography (PET) separates itself from the 
rest of the field with its exceptional sensitivity, near limitless depth of penetration and its ability 
to quantify metabolic processes in living patients. With the ability to visualize and quantify on an 
individualized basis, PET imaging has received considerable attention recently because of its 
potential for contributing to personalized medicine. Through better diagnosis, rational selection 
of targeted therapies, and individualization of therapy regimens for each patient, personalized 
medicine holds the promise of greatly improving patient outcomes as well as safeguarding 
against the use of unnecessary, harmful medical procedures.  
Given the current status of the PET field and the impact it has on many fields, significant 
effort is being made to expand the existing repertoire of imaging agents capable of further 
detailing pathophysiological processes beyond the most commonly used PET tracer, 
[18F]fluorodeoxyglucose, including the use of large, sensitive biomolecules such as peptides and 
antibodies, which may be of considerable clinical importance. However, the available 
methodology associated with PET isotope incorporation, specifically fluorine-18, involves rather 
harsh conditions that are incompatible with sensitive substrates, which restricts the availability of 
these agents and their subsequent clinical evaluation. Thus, there remains a tremendous need 
for rapid, mild and efficient methodology that can be used to label these previously inaccessible 
substrates in a direct, late-stage fashion. 
 Chapter 1 presents a brief introduction into molecular imaging and the techniques 
available for use in the preclinical and clinical setting as well as in drug development. 
Additionally, the basics of PET principles and radiochemistry are introduced, with a significant 
focus on the synthetic difficulties involved in working with the most commonly used PET isotope, 
fluorine-18, and why there is a need for improved methodology for its incorporation into new 
radiopharmaceutical agents, especially sensitive ones. 
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Chapter 2 details the development of methodology that targets the shortcomings of C-
18F strategies through Si-18F bond formation approaches. We have developed a simple and 
straightforward strategy in radiofluorinating complex substrates at a late stage, at room 
temperature, or in an aqueous environment in high radiochemical yields and specific activities 
through a reactive silyl acetate moiety. The utility and versatility of the approach is showcased in 
three main areas of research: small adaptor molecules, small molecules, and peptides. 
We have applied this Si-18F labeling strategy (Chapter 3) to prepare a fluorine-18 labeled 
version of 17α-ethynylestradiol conjugated PAMAM dendrimer that can be used for in vivo 
distribution studies of this novel hormone-polymer conjugate. Through biodistribution studies, 
we have found that the EDC, a dendrimer-bound estrogen that provides selective 
cardiovascular protection without classical stimulation of uterus and mammary tissues, also 
shows selective, ER-mediated uptake and retention by the vascular target tissues, heart and 
aorta, but not the classical target, the uterus. These findings suggest that the selective 
cardiovascular protective effect of EDC is the result of two factors, one mechanistic (selective 
stimulation of the extra-nuclear pathway of ER action) and one pharmacokinetic (selective 
accumulation of EDC in vascular targets). This points to a new dimension for extending the 
selective, potentially beneficial actions of estrogens. 
Chapter 4 details the synthetic approaches towards the radiosynthesis a promising ER 
imaging agent, 2-[18F]fluoroestradiol, and illustrates the most well-known difficulty encountered 
in fluorine-18 chemistry, specifically the radiofluorination of electron-rich aromatic rings. Efforts 
have focused on the use of diaryliodonium salts which has afforded synthetically useful 
radiochemical yields of the desired compound and is currently being scaled up, in terms of 
radioactivity, for evaluation in animal studies.  
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CHAPTER 1 
INTRODUCTION 
I. MOLECULAR IMAGING BACKGROUND 
A. Background 
Advances in minimally invasive imaging technologies have opened up endless 
opportunities for molecular diagnostic and therapeutic regimens.1 Traditionally, the primary role 
of molecular imaging has been to assist medical diagnosis as a confirmation tool of diseased 
states through the in vivo visualization of the presence and extent of pathologies. More recently, 
the functional information of diseased states elucidated through imaging techniques has 
significantly transformed medical diagnosis from a mere identification tool towards the ability to 
characterize the molecular processes involved with disease progression.2 Consequently, this 
will have a tremendous impact on patient care and treatment in the coming years, especially in 
the development of personalized medicine, in addition to becoming an indispensable research 
tool for drug development.3,4  
B. Molecular Imaging and Personalized Medicine 
 Molecular imaging enables the visualization, characterization, and measurement of in 
vivo biological processes in living systems through the use of specific imaging probes. It 
comprises a range of techniques (Table 1.1), but the premise is basically the same throughout: 
an optimally designed tissue- or receptor-specific compound provides an analytical signal (e.g., 
positrons, gamma rays) that is detected by a given detector, which after using complex 
computational algorithms, yields a two- or three-dimensional detailed image of the targeted 
structure or biological process under study.5  The proper choice among the available imaging 
techniques ultimately depends on the particular biological process to be visualized and the data 
that is needed from the study.6  
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Modality 
Spatial 
Resolution 
Sensitivity 
Safety 
Profile 
Used  
Clinically 
Quantification 
Computed 
Tomography 
(CT) 
 
0.5-1 mm 
Not  
Determined 
Ionizing 
Radiation 
 
Yes 
 
- 
Magnetic 
Resonance 
Imaging (MRI) 
 
1 mm 
 
10-3-10-5 M 
No Ionizing 
Radiation 
 
Yes 
 
Fair 
Positron 
Emission 
Tomography 
(PET) 
 
2`-7 mm 
 
10-11-10-12 M 
Ionizing 
Radiation 
 
Yes 
 
Very Good 
Single Photon 
Emission 
Computed 
Tomography 
(SPECT) 
 
8-10 mm 
 
10-10-10-11 M 
Ionizing  
Radiation 
 
Yes 
 
Good 
Ultrasound (US) 1-2 mm 10-12 M 
Good Safety  
Profile 
Yes Poor 
Optical 
Fluorescence 
Imaging (OFI) 
 
2-3 mm 
 
10-9-10-12 M 
Good Safety  
Profile 
 
Emerging 
 
Poor to Fair 
 
Table 1.1 Comparison of the different molecular imaging techniques available. 
 
Molecular imaging has played a key role in translational biomedical research and 
diagnostic clinical studies. Imaging the presence and functionality of a given diseased state 
provides tremendous insight into the mechanisms leading to disease onset and progression. 
Although similar information in certain cases can be obtained through tumor biopsies and 
subsequent histopathological evaluations, it is difficult and risky to obtain biopsies from some 
tumor sites, such as those present in the brain; so, less invasive approaches are needed. 
Additionally, tumor heterogeneity,7,8 biopsy sampling errors,9 and varying expression profiles 
between primary and metastatic sites10,11 further complicate matters and thus may not yield a 
true representation of the diseased state. Advances in medical imaging, however, can provide 
detailed biochemical information at the earliest stages of disease onset, often before any 
observable symptoms are seen in the patient. Early detection before the disease has 
progressed can improve the prognosis and also can allow for the customization of appropriate 
therapeutic regimens to the individual patient. Such advances hold tremendous potential for 
accelerating appropriately designed targeted therapy through personalized medicine that not 
only can serve to reduce high medical care costs but more importantly, safeguards against the 
use of unnecessary, harmful medical procedures.  
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Our group has utilized a similar PET imaging strategy to understand the molecular 
characteristics of a breast tumor before starting treatment in order to establish the most 
appropriate therapy for patients with advanced ER+ breast cancer. Specifically, the levels of 
estrogen receptor in a breast tumor have been shown to be important prognostic indicators for 
the progression of the disease, and the presence of the receptor is used to guide the treatment 
regimen. Tumor uptake using the most promising high affinity ER agent to date, 16α-
[18F]fluoroestradiol (Figure 1.1., [18F]FES, 1), as measured by PET imaging, aids in the 
confirmation of ER expression in the tumor (more accurately than from standard 
immunohistochemical studies) and thus serves as a strong predictor for the success of hormone 
therapy.12,13 Although these studies can confirm the presence of ER in tumors, they do not 
establish that this ER is functional, and thus uncertainty remains as to whether hormone therapy 
will be beneficial. The functionality of the receptor can be assessed by an additional hormone 
challenge test that uses [18F]FDG-PET (2) to monitor a metabolic flare in terms of enhanced 
uptake after a 1-day estradiol treatment in breast patients in which tumor ER is functional.14 
Taken together, both approaches aid in the selection of patients that will most likely benefit from 
ER-targeted therapies and such strategies have already been implemented within the clinic.15-17 
Thus, in this instance, confirmation of the presence and function of ER through FES- and FDG-
PET imaging studies enables selected patients to undergo less toxic endocrine therapies 
instead of the more costly and morbid cytotoxic therapy. By individualizing treatment plans such 
as this one, the expectation is that patient outcomes will be greatly improved.  
 
Figure 1.1. Structures of 16α-[18F]fluoroestradiol (FES, 1) and 2-[18F]fluoro-2-deoxyglucose  
(FDG, 2). 
 
C. Impact of Molecular Imaging on Drug Development 
Beyond clinical applications, molecular imaging has become an important component in 
the drug development process.18,19 The cost of bringing a drug onto the market has been 
steadily rising and is expected to continue to rise in the coming years, with the average cost 
estimated around 1 billion dollars.20,21 Therefore, the development of more cost-effective 
strategies aimed at accelerating the drug development process are highly desired. Molecular 
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imaging is now anticipated to play a key role in this process. After optimization of a radiotracer’s 
in vivo behavior, it is possible to determine the occupancy of the drug candidate at the target 
site through kinetic modeling studies in addition to the duration of target engagement.22,23 Such 
studies are aimed at investigating the relationship between receptor occupancy levels of the 
drug in order to establish dose selection and to observe any pharmacological effects at a given 
dose. This data not only enables a better understanding of the in vivo pharmacokinetics of the 
drug and the required drug levels needed to obtain pharmacological effects, but more 
importantly, it provides invaluable insight into potential toxicity or side effects associated with the 
drug. This in turn facilitates the opportunity for drug companies to halt lead drug candidates that 
fail to exhibit the desired in vivo behavior or may possess unanticipated toxicity that otherwise 
would have not been discovered until potentially the costly Phase 3 trials. This leads to an 
enormous cost savings aimed at circumventing the failure of drug candidates in late stages of 
clinical trials, while at the same time, allowing for the acceleration of those that appear 
promising.   
 
II. POSITRON EMISSION TOMOGRAPHY 
A. Background  
Positron Emission Tomography (PET) is a powerful, minimally invasive imaging 
technique that is used to visualize and characterize human physiology. Unlike Magnetic 
Resonance Imaging (MRI) and Computed Tomography (CT), which provide detailed anatomical 
images associated with structural abnormalities related to pathologies, PET separates itself 
from the rest of the field with its exceptional sensitivity towards positron detection and its ability 
to measure metabolic processes in living patients. By monitoring the biodistribution and uptake 
of a positron emitting radiotracer in the body over a given time period, PET enables researchers 
to quantitate important physiological and biochemical information about the onset and 
progression of diseased states.24  
B. PET Imaging of Disease 
 PET has a tremendous impact as both a medical and research tool.25  By far, the most 
commonly used PET tracer for medical imaging is [18F]fluorodeoxyglucose ([18F]FDG, 2).26 
[18F]FDG-PET exploits the upregulated glucose transport and glycolysis pathway of tumors, 
where, after undergoing an initial phosphorylation, the labeled agent becomes irreversibly 
entrapped in tumor tissues. The subsequent elevated accumulation leads to an imaging contrast 
between cancerous and normal tissues.27 As a result, [18F]FDG has been extensively used as a 
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biomarker in oncology, including the detection of breast, lung, and colorectal cancers.28 In 
neurology, PET has proved useful for the imaging and characterization of early onset 
neurodegenerative disorders, such as Alzheimer’s29,30 and Parkinson’s diseases.31,32 The 
extensive use of PET in neuroimaging is most likely due to the inability of accessing brain tissue 
except through autopsies, and thus enables diagnosis in living patients. PET has also been 
extensively utilized in cardiology as a myocardial imaging tool to characterize coronary heart 
disease.33  
Given the current status of PET and the impact and potential that it has on various fields 
of medicine, there is a significant effort among researchers to expand the existing repertoire of 
imaging agents capable of further detailing pathophysiological processes that may be of 
considerable clinical importance. Because of this, there is immense interest of the development 
of more specific imaging probes that can potentially provide additional biological information 
than what is currently already known for tracers such as FDG.   
C. Principles of PET 
PET imaging probes are radiolabeled with positron-emitting radionuclides which decay 
by the emission of a positively charged particle called the positron, the antimatter of an electron, 
which has identical mass but contains a positive charge. Schematically, the decay process for 
this nuclear transformation is shown below (Figure 1.2): 
 
                           aX
m   a-1Y
m + β+ + v 
 
a = Atomic Number 
m = Mass Number 
X = Parent Nuclide 
Y = Daughter Nuclide 
β+ = Positron 
v = Neutrino 
 
Figure 1.2. The decay process for positron-emitting radionuclides. 
 
All positron emitters contain nuclei that are proton-rich and emit excess protons in an 
attempt to reach nuclear stability through two different processes: positron emission and 
electron capture. Positron emission tends to occur in lower atomic weight nuclei (e.g., 18F, 11C), 
while the predominant mode of decay in higher atomic weight nuclei (e.g., 123I) is electron 
capture. 
As the radionuclide undergoes positron-emission decay, the emitted positron, being 
highly interactive, is not detected directly but traverses a short distance (typically 0.5-2.0 mm 
depending on radionuclide and positron energy) and, due to interactions with the surrounding 
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medium, decelerates to an energy minimum where it then interacts with an electron. The 
collision produces an annihilation event from which the two particles yield two gamma photons 
of 511 keV, which are emitted at approximately 180o to each other (Figure 1.3). It is the 
simultaneous detection of the two emitted gamma photons along a line of coincidence that 
enables statistical analysis to reconstruct the location of the annihilation event. The resulting 
image details the approximate accumulation of the PET radiotracer within a given tissue, and 
interpretation can facilitate patient diagnosis and possible therapeutic regimen.34  
 
Figure 1.3. Schematic representation of a positron decay and the annihilation event that result  
in a PET image. The 11C (blue dot) nucleus emits a positron (red ball) which interacts with 
an electron (green ball) to produce two gamma photons that are detected by the PET 
instrument (red blocks).35 
 
III. RADIOSYNTHESIS WITH SHORT-LIVED PET ISOTOPES 
A. Available Positron Emitters and Synthetic Aspects  
One of the more attractive features of PET is its use of radionuclides (Table 1.2) that are 
isotopes of the main elements found in biomolecules (e.g., C, N, and O). This enables the 
radiosynthesis of labeled probes to be chemically indistinguishable from their nonradioactive 
counterparts and thus to function without altering the in vivo biological properties of the original 
compound. Fluorine is normally not found naturally in biomolecules, but the exchange of a 
hydrogen or an oxygen atom for a fluorine is one of the more commonly applied bioisoteric 
replacements, especially in drug development,36 and at times, this substitution can exhibit 
improved in vivo behavior when compared to their non-fluorinated analogues.37  
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Radionuclide Half-Life (min) 
Maximum Energy 
(MeV) 
Mode of Decay 
Decay 
Product 
11C 20 0.97 β+(99%) 11B 
13N 10 1.20 β+(100%) 13C 
15O 2 1.74 β+(100%) 15N 
18F 110 0.64 
β+(97%) 
EC (3%) 
18O 
 
Table 1.2. Nuclear properties of commonly used positron-emitting radionuclides. 
 
The incorporation of short-lived radioisotopes into tracers for PET imaging, however, is 
not a trivial task: the labeled probe must be synthesized, purified, characterized, and 
reformulated for human injection, all within two or three half-lives of the PET isotope in use. This 
demands rapid synthetic sequences, with the isotope being introduced as late as possible into 
the scheme. Typically, a large excess of precursor (often, 103-104-fold higher than the 
concentration of the isotope) is used to effectively drive the reaction to completion within the 
short time frame. To further complicate matters, the presence of ionizing radiation emitted from 
the radionuclides poses serious health concerns, and because of this, radiosynthesis differs 
significantly from mainstream organic chemistry. First, all chemical transformations are 
performed in lead-lined fume hoods called hot cells. These cells are relatively bulky and difficult 
to work in because they obstruct optimal access to the reaction vessel and require specific 
handling procedures. Second, standard workup and purification practices in bench top 
chemistry are unsuitable to the radiochemist. The dangerous radiation necessitates maintaining 
adequate distances from the radionuclide to limit the absorbed dose; thus, one cannot touch 
anything inside the hot cell where the isotope is present. Lastly, the production of radioisotopes 
typically yields only picomolar to nanomolar amounts of activity. Radiochemists often refer to 
this chemistry as working on tracer levels due to the miniscule amounts of the isotope present. 
One would imagine that the vast stoichiometric excess of starting material used would only 
serve to benefit the radiosynthesis. Unfortunately, working at tracer levels can differ significantly 
from cold chemistry and often involves considerable manipulation of reaction conditions to 
obtain any successful incorporation.  
B. Radiochemical Yields 
 Radiochemical yields (RCYs) can be reported two ways: decay-corrected and non-decay 
corrected yields. Decay corrected yields, which are calculated back from the end of 
bombardment of the target, are indicative of the success of the radiochemical reaction and are 
most often cited in the development of new methodology. Non-decay corrected yields are much 
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more useful and informative in the preparative potential of a synthetic scheme, and they aid in 
determining the amount of activity of a radiotracer after purification.  
C. Specific Activity 
 A key component associated with PET imaging is the calculated specific activity of the 
radiotracer. The term specific activity (SA) denotes the amount of radioactivity per mass of 
compound (both labeled and unlabeled) and is typically expressed in Ci/mmol or GBq/µmol. 
Radiochemists strive for high SA radiotracers, which contain mainly the desired isotope with 
minimal non-radioactive nuclide contamination in the desired material. This is critical, especially 
with receptor-based PET imaging, because of the low physiological concentrations of receptors 
present within the body and thus, the limited availability of binding sites that can be occupied by 
the radioligand. Low specific activity material, which contains significant amounts of unlabeled 
mass as compared to the radiotracer itself, can lead to saturation of these binding sites at low 
activity levels, resulting in a reduction of signal-to-noise ratios and essentially no image contrast. 
Moreover, the additional injected mass may be at high enough concentrations to cause 
pharmacological or toxic side effects. Typically, SA values over 1000 Ci/mmol are deemed 
suitable for PET imaging studies. 
 Specific activities can also be defined as effective specific activities. This is the specific 
activity of a radiotracer that has been determined by a biological assay. Additional mass may be 
present in the final radiotracer preparation which contains similar biological properties to that of 
the desired radiopharmaceutical and is taken into account for this calculation. 
 Several factors contribute to the SA values of labeled compounds. First, these values 
are directly dependent on the radionuclide’s half-life, with the shorter the half-life having higher 
theoretical specific activities. Second, the ubiquitous presence of nonradioactive nuclides 
present in glassware, solvents etc., which can also be incorporated into the radiotracer, can 
significantly reduce activity levels. Lastly, the vast excess of starting materials needed to drive 
the reaction to completion can complicate purification efforts, and difficulties in fully separating 
the radiolabelled product from abundant quantities of the unlabeled precursor or other reaction 
products can also have a detrimental effects, especially if they are able to compete with the 
labeled radiotracer for the target site of imaging.  
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IV. CHEMISTRY OF [18F]FLUORIDE ION 
A. Background 
Of all the available positron nuclides employed in PET, fluorine-18 is often considered 
the isotope of choice for PET imaging because of its ideal nuclear properties. Its sufficiently long 
half-life (110 min) allows for complex, multi-step syntheses, extended in vivo imaging studies, 
and from a practical point of view, commercial distribution to satellite clinical PET centers that 
lack F-18 production facilities. Furthermore, the clean decay properties (97% β+) and relatively 
low positron energy results in PET images of the highest quality. Moreover, the low abundance 
of fluorine-19 in the environment enables the synthesis of F-18 labeled compounds in high 
specific activity, a perquisite for receptor-based imaging.  
However, despite these positive and laudable properties of F-18, the radiochemistry 
associated with its introduction is far from ideal, especially in the context of direct labeling of 
sensitive biomolecules such as peptides and proteins. The variety of synthetic methods by 
which F-18 can be introduced is rather limited and can be divided into two distinct areas: an 
electrophilic method utilizing [18F]F2 directly or less reactive electrophilic reagents derived from 
the gas itself, and a nucleophilic [18F]fluoride anion derived from an aqueous target. 
B. Electrophilic [18F]Fluorinations 
 Although a majority of F-18 radiochemistry in PET relies on nucleophilic [18F]fluoride 
anion, electrophilic fluorinating agents have played a key role in the development of clinically 
relevant 18F-radiopharmaceuticals. For instance, [18F]F2 gas was used in the initial synthesis of 
[18F]fluorodeoxyglucose ([18F]FDG, 2, Scheme 1.1) because its regioselective addition to one 
face of the double bond afforded the required configuration in the 18F-labelled sugar product.38 
Due to its high reactivity, [18F]F2 is typically converted to less reactive and more selective 
reagents, such as acetyl hypofluorite (CH3CO2[
18F]F),39 xenon difluoride (Xe[18F]F2)
40 and 
fluorosulfonamides (R-SO2-NR[
18F]F),41 which are commonly utilized in direct electrophilic 
substitutions with electron-rich substrates (e.g., alkenes, aryl groups).  
 
Scheme 1.1. Radiosynthesis of 2 with electrophilic [18F]fluoride ion.38  
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The most obvious shortcoming of the electrophilic method is the low specific activities of 
the [18F]fluorinated products. The issue stems from how [18F]F2 gas is produced. Two of the 
more common strategies involve the nuclear reactions, 20Ne(d,α)18F or 18O(p,n)18F, and in order 
to prevent the [18F]fluoride ion from being fully adsorbed on the target walls, 19F gas (0.1-2%) is 
added, diluting the original high specific activity [18F]fluoride anion with now carrier added 19F to 
afford the 18F-19F gas. Thus, in reactions involving the 18F-19F gas, the maximum radiochemical 
yield (RCY) is 50% since only one [18F]fluoride can be incorporated into the desired product, but 
in practice, specific activities are very low because of the large excess of [19F]F2 gas needed in 
production of the [18F]F2 gas. Even with the monofluorinated agents, such as acetyl hypofluorite 
(CH3CO2[
18F]F) where the theoretical RCY can be 100%, these agents are also prepared from 
the 18F-19F gas; so, the maximum RCY is still at most 50% in these instances. Specific activity 
values from all of these electrophilic fluorination methods are typically less than 10 Ci/mmol, 
thereby rendering the corresponding [18F]fluoroproducts unsuitable for PET studies involving 
saturable receptors.  
 Despite these shortcomings, the electrophilic method still possesses tremendous clinical 
value in those applications that do not require high specific activity. Currently, it remains the 
preferred method, due to the synthetic ease over multi-step nucleophilic syntheses, for the 
routine syntheses of common radiopharmaceuticals for patient use, including [18F]fluoro-L-
dopa42 ([18F]FDOPA, 5, Scheme 1.2) and [18F]fluorotyrosine ([18F]FT). 
 
Scheme 1.2. Radiosynthesis of [18F]FDOPA (5) from organotin precursor (4) by direct 
fluorination with [18F]F2.
42 
 
Recently, two influential studies have been reported to address the specific activity 
issues of [18F]F2 gas, and both hold promise for the use of electrophilic F-18 as a viable 
synthetic alternative. In the context of improving the specific activity of [18F]F2 gas, significant 
improvements have been achieved through the use of [18F]fluoromethane, prepared from no-
carrier-added [18F]fluoride anion and H2[
18O]O as the target, where, after electrical discharge in 
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the presence of miniscule amounts of 19F2 gas, affords [
18F]F2 gas in high specific activity (1500 
Ci/mmol).43 In comparison, the previously highest reported SA was 55 Ci/mmol.44  
 Ritter and coworkers reported45 the first electrophilic [18F]fluorination reagent (Scheme 
1.3), an in situ generated [18F]fluoropalladium (IV) species (7), prepared from no-carrier-added, 
high specific activity [18F]fluoride anion. The chemistry works exceptionally well in late-stage 
[18F]fluorination of complex substrates, including efficient reactions with electron-rich aromatic 
rings (9), in satisfactory RCYs. The generation of such electrophilic species from the widely 
available [18F]fluoride anion, as opposed to the less accessible [18F]F2 gas, affords synthetically 
useful electrophilic 18F equivalents in a facile and concise manner with sufficiently high reactivity 
under mild conditions of late-stage, complex substrates. Consequently, access to conventionally 
unavailable radiotracers through this method will greatly expand potential PET applications.  
 
Scheme 1.3. Late-stage [18]fluorination of complex substrates with electrophilic [18F]fluoride  
(7).45 
 
C. Nucleophilic Chemistry  
 The nucleophilic method is the method of choice for the radiosynthesis of 18F-labelled 
tracers in high specific activity. [18F]Fluoride anion may be produced by several methods,46 but 
by far, the most common is through proton irradiation of 18O-enriched water.47 An enrichment of 
>95% H2[
18O]O (occurs naturally in ~0.2%) is required because 16O can also undergo a nuclear 
reaction within the target to produce nitrogen-13 (t1/2 = 9.96 min), although the byproduct has 
essentially no effect on the chemistry itself. Overall, this nuclear reaction, 18O(p,n)18F, is 
intrinsically high yielding from small, compact cyclotrons, with several Curies (Ci) of activity 
being routinely produced in about an hour. Moreover, the method of production involves no 
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carrier addition, enabling the production of [18F]fluoride ion at high specific activities. This factor 
alone explains its clear preference over electrophilic methods as it enables production of PET 
probes that can be used for receptor-based imaging studies. Also, the resulting [18F]fluoride ion 
is obtained as an aqueous solution, affording a product that is considerably easier to handle and 
work with as compared to [18F]F2 gas.  
 However, the aqueous [18F]fluoride obtained is a poor nucleophile because of its tightly 
bound hydration sphere, and thus one must undertake a tedious, time-consuming drying step in 
order to produce a sufficiently anhydrous [18F]fluoride ion for nucleophilic substitution reactions 
to proceed. Key to this step is the addition of an appropriate base to afford a reactive, organic 
soluble fluoride source. Traditionally, slightly soluble inorganic fluoride sources such as K[18F]F 
were utilized, but the slow and inefficient reactions were hampered by the low solubility of the 
potassium salts. More recently, activation of the [18F]fluoride ion through the use of cryptands48 
has significantly enhanced fluoride solubility and in turn, has greatly improved radiochemical 
yields. By far, the most popular method employs the aminopolyether, 4,7,13,16,21,24-hexaoxa-
1,10-diazabicyclo[8.8.8]hexacosane (Figure 1.4, K222, 10), that can effectively complex the 
potassium counter ion in K[18F]F to produce a highly nucleophilic, organic soluble “naked” 
fluoride anion. Other alkali metals (i.e., Cs, Rb) or quaternary ammonium fluoride salts, obtained 
from their respective carbonates, bicarbonates, or hydroxides, have also been utilized with 
varying success. Overall, the choice of cation often plays a critical role in the success of 
radiofluorination reactions, but definitive guidelines for correctly choosing any of the available 
options do not exist and more often, one must screen the reaction to find the optimal base. 
 
Figure 1.4. Structure of 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (K222). 
 
 In a typical drying step (Scheme 1.4), the water is removed by repeated azeotropic 
distillation in the presence of acetonitrile, base (e.g., K2CO3) and phase-transfer catalyst under a 
stream of nitrogen and thermal drying at temperatures between 80-110 oC (left side). More 
recently, the use of anion-exchange cartridge chemistry49 (right side) has become more popular, 
due to the cost effectiveness in recycling the [18O]H2O for future F-18 production. Technically 
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speaking, the drying step is not vigorous enough to remove all waters of hydration, and as a 
result, a truly anhydrous [18F]fluoride ion source (12) has never been achieved. Consequently, 
this can directly affect the reactivity of the [18F]fluoride anion, and RCYs can suffer dramatically. 
Also, the addition of base, required to prevent the release of [18F]HF during the drying, can 
further complicate matters with base-sensitive precursors. Nevertheless, this is the standard 
protocol for the vast majority of 18F-labelling methods, and at this point, the dried [18F]fluoride 
source is ready for use (12). 
 
Scheme 1.4. Schematic of drying step from time of bombardment to a dried [18F]fluoride source  
(12); x = fully hydrated [18F]fluoride ion; y = amount of hydration (less than x). 
 
The vast majority of 18F-labelling strategies involve two methods: nucleophilic 
substitution on aliphatic and on electron-deficient aromatic systems. In the aliphatic series, 
substitution is typically performed on halogenated derivatives or sulfonates (i.e., tosylates, 
mesylates, triflates, or nosylates), with the radiosynthesis of [18F]FDG being the most well-
known example (Scheme 1.5).50 The main drawback of this method is the competing elimination 
reaction to afford the undesired alkene. However, recent studies have found the addition of tert-
butanol can significantly suppress the elimination pathway and greatly improve radiochemical 
yields.51,52  
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Scheme 1.5. Radiosynthesis of [18F]FDG (2) with [18F]fluoride anion.50 
 
 Direct nucleophilic aromatic substitution reactions provide an expedient entry into 
complex systems in a one-step process. However, the reaction is only feasible if the aryl system 
is sufficiently electron deficient. Strong electron-withdrawing substituents such as -CN, -CHO,    
-COR, and -CF3 in the ortho and para positions have been commonly utilized, and the leaving 
groups are typically nitro and trimethylammonium groups. Other heteroaromatic systems such 
as the electron-poor pyridine series (14), however, do not require activation, and as a result, the 
simplicity of the method has led to its popularity, especially for the preparation of neurological 
imaging tracers (Scheme 1.6).53  
 
Scheme 1.6. Nucleophilic aromatic substitution using an electron-poor pyridine substrate (14).53 
  
 As highlighted previously, nucleophilic aromatic substitutions proceed smoothly on 
electron-deficient arenes. Unfortunately, similar high-yielding strategies for electron-rich 
systems are lacking. Thus, the efficient radiofluorination of electron-rich species represents a 
significant methodological gap within PET chemistry. To date, the use of diaryliodonium salts 
represents the lone method that can be used for radiofluorination of electron-rich aryl rings in 
sufficiently high RCYs and specific activities. First reported by Pike,54 the use of these salts has 
enabled reliable 18F-labelling of both unactivated or electron-rich [18F]fluoroaromatic 
compounds, although most have been relatively simple substrates.55,56 An interesting feature of 
these compounds is the regioselectivity of the reaction, where fluorinations tend to favor ortho-
substituted phenyl groups (aka the “ortho effect”) (Scheme 1.7, left side, 16).55 In the absence of 
an ortho substituent, fluorination favors the least electron-rich ring. Consequently, the use of 
unsymmetrical diaryliodonium salts where one aryl group is an electron-rich p-methoxyphenyl or 
2-thiophene group results in selective fluorination to the other, less electronically rich arene 
(Scheme 1.7, right side, 18).57,58  
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Scheme 1.7. Left Side: Transition state in the radiofluorination of diaryliodonium salts that  
favors [18F]fluoride incorporation on the aryl ring bearing an ortho substituent; Right side: 
Use of unsymmetrical diaryliodonium salts where [18F]fluorination prefers the less 
electronically rich ring.58 
 
The short half-lives of positron-emitting nuclides requires concise radiosynthetic 
sequences involving as few steps as possible to isolate high activity levels of the purified 
radiotracer. In addition to the large excess of unlabeled precursor as mentioned previously, 
reaction temperatures typically vary from 120-150 oC and can exceed 190 oC in order to rapidly 
drive the reaction to completion. Consequently, direct [18F]fluorination strategies are not 
universally suitable for all 18F-applications, especially with those containing sensitive organic 
functionality, because of these harsh reaction conditions (i.e., high temperatures, highly basic 
media). More often, milder, indirect methods have been employed with 18F-labelled small 
organic compounds, commonly referred to as prosthetic groups. Standard protocols generally 
involve first direct incorporation of the [18F]fluoride anion into a more structurally robust 
prosthetic group, which is then appended to the biomolecule of interest through alkylation, 
acylation, amination, photochemical or click reactions. A variety of [18F]fluorinated precursors 
are now well established (Figure 1.5) and includes 2-[18F]fluoroethyl-tosylate ([18F]FETos, 
(19)),59 N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB (20)),60 4-[18F]fluorobenzaldehyde 
([18F]FBA (21)),61 and 4-[18F]fluorophenacyl bromide ([18F]FPB, (22)).62 The main shortcomings 
of prosthetic groups are the relatively complex, multistep synthetic sequences needed for their 
radiosyntheses, and quite often, the radiolabel is incorporated within the first step, which can be 
methodologically awkward. Ideally, short-lived isotopes should always be incorporated as late 
as possible in the sequence.  
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Figure 1.5. Structures of 18F-labelled prosthetic groups used for coupling to biomolecules. 
 
V. CONCLUDING INTRODUCTORY REMARKS 
 Although the development of PET radiopharmaceuticals has been ongoing for decades, 
many of these agents reside in the preclinical stage, with only a handful of them actually being 
used in the clinic. Of these, almost 90% of all PET scans conducted worldwide involve a single 
radiotracer, [18F]FDG.63 Despite its popularity, the use of [18F]FDG is not without its flaws: it has 
nonselective uptake in noncancerous conditions (i.e., infection, inflammation),64 low uptake in 
certain cancers (i.e., bronchoalveolar cancer),65,66 and low contrast ratios in several areas of 
imaging including the brain. Consequently, this can often lead to difficulty in correctly assessing 
(or staging) a particular diseased state. By improving the specificity and sensitivity beyond what 
[18F]FDG affords, beneficial outcomes will be two-fold: the improved characterization of the 
diseased state will significantly increase the overall diagnostic accuracy while also giving rise to 
the possibility of tailoring therapeutic regimens to the individual. 
 Of the three components that comprise the translational PET imaging process, target 
discovery and software/hardware development significantly outpace the advancement of novel 
imaging probes. The key to advancing translational PET is overcoming the barrier that has 
impeded the field: the lack of synthetic approaches for late-stage radiofluorination of complex 
substrates in a mild and efficient manner. Mainstream organic chemistry is inundated with 
chemical building blocks and synthetic methods that have enabled almost any imaginable 
molecule to be constructed, yet radiochemists are restricted to a single, low-reactivity 
nucleophilic [18F]fluoride salt. Moreover, the harsh conditions (i.e., high temperatures, basic 
conditions) associated with existing C-18F approaches are incompatible with sensitive 
substrates, including large biomolecules. This then necessitates time-consuming, multi-step 
strategies, which further limit the practicality of the approach, especially when working with 
short-lived isotopes. To satisfy the growing demand for novel PET tracers (including peptides 
and proteins), there is a tremendous need for rapid and efficient methodology in an ideal one-
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step, aqueous approach that is amenable to virtually any potential substrate in a late-stage 
context. Al-18F, B-18F, and Si-18F bonds are intriguing possibilities in this area.  
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CHAPTER 2 
DEVELOPMENT OF NOVEL SILICON PRECURSORS FOR RAPID AND EFFICIENT 
RADIOFLUORINATION REACTIONS 
 I. INTRODUCTION 
A. Background 
By far, the most widely utilized radiotracer in clinical PET imaging is the glucose 
analogue, [18F]fluorodeoxyglucose ([18F]FDG).1 Many would agree that the development of the 
field would have not been possible without the discovery of [18F]FDG. Its widespread 
applications in oncology have justified the installation of the expensive production and imaging 
infrastructure needed within hospitals, and as a result, [18F]fluoride ion is now readily available, 
even from commercial suppliers. With the proper infrastructure in place, clinical research has 
focused primarily on other small molecules as potential imaging agents to address the 
limitations of PET imaging with [18F]FDG.2-4 More recently, however, the radiolabeling of large 
biomolecules, such as peptides, proteins, and antibodies, has also been proposed to expand 
imaging applications well beyond [18F]FDG.5,6 What has impeded and still remains a significant 
challenge in accessing these new applications are the mild and efficient radiofluorination 
reactions that are needed for radiolabeling these sensitive, polyfunctional substrates. 
Unfortunately, current labeling conditions restrict the use of the more desirable one-step 
strategy in favor of the multi-step, indirect prosthetic group labeling approach. Consequently, the 
additional steps required add a further level of synthetic difficulty and increase the absorbed 
dose by the radiochemist, in addition to raising the problem of overconjugation of the 
biomolecule with prosthetic group, all of which conspire to severely limit the practicality of this 
approach. 
The synthetic problems associated with the radiolabeling of sensitive biomolecules using 
[18F]fluoride ion are in stark contrast to other isotopic labeling methods, especially those using 
Cu-64. Despite the less than ideal nuclear properties (i.e., multiple decay processes, isotopic 
impurities,7 undesirable transchelation of 63Cu/64Cu in vivo8), Cu-64 is becoming an attractive 
alternative in recent years due to the ease of isotopic incorporation. Typically, Cu-64 
radiolabeling methods involve a simple and straightforward one-step, wash-in protocol where an 
aqueous solution of [64Cu]-cupric ion is incorporated into chelators appended on biomolecules 
(i.e., NOTA, DOTA) in high RCYs under mild conditions (Scheme 2.1).9,10 The use of aqueous 
conditions without the need for a time-consuming, basic drying step, elevated temperatures or 
23 
 
organic solvents is highly attractive, especially when working with water-soluble proteins and 
antibodies. At present, analogous approaches with [18F]fluoride ion are underdeveloped, but 
strategies conceptually similar to those used for 64Cu-labelling are currently being investigated 
for F-18 using fluorophilic elements (i.e., Al, B, Si). 
 
Scheme 2.1. Incorporation of [64Cu]-cupric ion into complex peptide (2) in a mild, one-step 
process.9 
 
B. Al-18F Strategies  
Following the literature precedent of the chelation of radiometals as an effective strategy 
for radiolabeling peptides, an analogous approach, focused on targeting the high affinity of 
some metals for fluoride ion, has been achieved through aluminum-[18F]fluoride peptide 
complexes.11,12 The novel pentadentate bifunctional chelator, 1,4,7-triazacyclononane-1,4-
diacetate (NODA), to coordinate Al3+ ion provided an effective scaffold to capture aqueous 
[18F]fluoride anion in a single, high yielding step (55-89%) within 15 minutes at 110 oC, and more 
importantly, the corresponding bioconjugates (4) exhibited exceptional stability, with no 
defluorination observed for 4 hours in human serum at 37 oC (Scheme 2.2).12 This technically 
simple labeling procedure has led to the development of labeling kits,13 similar to those used 
with 99mTc, that will aid in streamlining reactions and facilitate product purification and isolation.14 
As a result, this has enabled rapid and reproducible labelings of peptides in high RCYs and 
specific activities through a simple, one-step process to afford 18F-labelled products that are 
compliable with good manufacturing practices (GMPs) and ready for patient injection within 30 
minutes. Of these three new strategies, the Al-18F approach is the most recently introduced and 
while still in its infancy within the development process, possesses the greatest likelihood of 
benchtop-to-patient translation, especially with their kit formulations.  
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Scheme 2.2. One-step chelation of aqueous [18F]fluoride anion with Al3+-NODA.12 
 
C. B-18F Strategies 
Trivalent organoboranes, particularly alkyl- and alkynylboranes, exhibit poor stability 
under atmospheric conditions, thereby making handling of these reagents extremely difficult. 
The 1960s discovery and subsequent development, most notably by Molander, of potassium 
organotrifluoroborates as superior alternatives to their trivalent counterparts, however, has 
transformed the field.15,16 These reagents exhibit exceptional stabilities towards nucleophiles, air 
and water, and can be handled on the benchtop without special precautions, all without altering 
their high reactivity, particularly in palladium-catalyzed cross coupling reactions.17 The 
translation into tracer level chemistry with F-18, however, has only recently been realized. 
 Ting and coworkers were the first to report the 18F-labelling of aryl boronic esters, under 
carrier added conditions (KH19F2) to afford [
18F]-aryltrifluoroborates.18 Similar to the aluminum 
chemistry described previously, the attractiveness of the method resides in the simple, one-step 
protocol, performed under aqueous conditions, which is ideally compatible with water-soluble 
biomolecules and also alleviates the need for the time-consuming drying step. The initial 
practicality of the approach was validated through the radiosynthesis of a biotinylated [18F]-p-
aminophenyltrifluoroborate (6, Scheme 2.3) and has since led to the development of additional 
boronic ester bioconjugates, including peptides and nucleic acids, and bifunctional linkers for 
other potential applications of this chemistry.19 Additionally, the reported in vivo evaluations to 
date have revealed no skeletal uptake of radioactivity, demonstrating the exceptional stability of 
the B-18F bond.20  
 
Scheme 2.3. Formation of [18F]-aryltrifluoroborates (6) from aqueous [18F]fluoride ion.18 
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 Despite the attractiveness of the simple, aqueous radiochemistry and high in vivo 
stability of the corresponding radiotracers, this approach still suffers from two glaring 
weaknesses which must be overcome before routine production is possible. First, the reaction 
with [18F]fluoride ion (and KH19F2) is inherently slow (~2-3 hours), and attempts to address this 
issue with higher concentrations of reagents and small reaction volumes (~10 µl) only further 
impede the practicality of this method. Second, any carrier-added radiosyntheses are inherently 
limited to low specific activities. Unfortunately, in this case, the addition of cold [19F]fluoride ion 
is required to achieve moderate RCYs of the desired R-B18F19F2K (6) salt; thus, further design of 
suitable precursors and optimization of reaction conditions without carrier added are needed to 
realize the full potential of this method.  
D. Si-18F Strategies  
 For decades, chemists have exploited the silicon-fluoride bond as a facile method for the 
deprotection of silyl ethers to the corresponding alcohols.21 Interestingly, radiochemists have 
only recently been able to develop similar silyl-based methods to incorporate [18F]fluoride ion. 
Rosenthal reported22 the first Si-18F bond with [18F]fluorotrimethylsilane, but preliminary in vivo 
experiments in rats revealed significant bone accumulation, demonstrating the low stability of 
the Si-18F bond in the body and the need for sterically hindered substituents around the silicon 
atom to prevent hydrolysis. In addition to their B-18F work, Ting18 also investigated the potential 
of tetrafluorosilcates (8, Scheme 2.4) as imaging agents, but the need for carrier added (KH19F2) 
and moderate stabilities of the corresponding [18F]fluoroproducts severely limit the practicality of 
this approach and call for further experimental and precursor design.  
 
Scheme 2.4. Formation of [18F]-aryltrifluorosilicates (8) from aqueous [18F]fluoride ion.18 
 
 In an attempt to gain better insight into the stabilities of Si-18F bonds, Hohne and 
coworkers utilized density functional theory (DFT) models to estimate the hydrolytic stability of 
appropriately designed silyl-based precursors; their work revealed the need for at least two tert-
butyl groups (t1/2 of Si-F bond = >300 h) or two isopropyl groups flanked by two methyl groups 
(t1/2 of Si-F bond = >300 h) in order to provide adequate stabilization.
23 This approach was 
pursued further through the use of bifunctional triorganosilanes (9), based on alkoxy, hydroxy, 
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and hydride leaving groups. Initial studies yielded conversion rates of up to 96% for [18F]fluoride 
incorporation into relatively simple substrates within 20 minutes in DMSO with catalytic amounts 
of acetic acid (Scheme 2.5).24,25 Additional investigations into the hydrolytic stabilities of the 
corresponding [18F]fluorosilane products (10) showed strong correlations with the previous 
computational data, suggesting that the presence of more sterically demanding substituents 
(e.g., tBu) generates [18F]fluoroproducts that are more hydrolytically resistant under 
physiological conditions.  
 
Scheme 2.5. Acid-promoted formation of Si-18F bonds.24 
 
 Application of this approach to more structurally complex substrates, such as peptides 
(11, Scheme 2.6), yielded synthetically useful RCYs (~50%) after 15 minutes and in sufficiently 
high specific activities (1600 Ci/mmol). Although the chemistry cannot be performed with 
aqueous [18F]fluoride as in previous cases (therefore requiring a drying step), the most 
significant shortcoming of this strategy is the issue of effective specific activity. Specifically, with 
large, complex substrates such as 11, the conservative exchange of a hydrogen (11) for a 
[18F]fluorine atom (12) does not provide sufficiently high structural and electronic differences 
between starting material and product that would enable effective separation during HPLC 
purification. As a result, the large excess of starting material (at times, up to 5 mg needed) will 
most likely not be fully separated from the [18F]fluorosilane product. Thus, there will be 
considerable contamination of the final radiotracer (12) with starting material (11). Because the 
starting material is structurally related to the tracer and will most likely compete with the tracer 
for binding to a receptor target, this will greatly reduce the “effective” specific activity of the 
labeled material, which could compromise its usefulness in PET imaging of limited capacity 
targets.      
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Scheme 2.6. Acid-promoted formation of a complex 18F-labelled peptide (12) through a direct,  
one-step process.25 
 
A highly promising Si-18F variant method, developed by Schirrmacher and coworkers,26-
30 relies on the facile isotopic exchange between [18F]fluorine ion and trialkyl-[19F]fluorosilane 
precursors (Scheme 2.7). The exchange process is surprisingly efficient, with nanomole 
quantities of starting material (13), proceeding rapidly at room temperature in high RCYs 
(>90%) within 15 minutes.26 Unfortunately, the method is inherently limited to low specific 
activities because of the inability to separate the [18F]fluorosilane product from the chemically 
identical [19F]fluorosilane starting material, which is in large excess in order to achieve high 
RCYs. The chemistry works best in a two-step approach to label biomolecules through the use 
of bifunctional triorgano-[18F]fluorosilane derivatives (15), each containing a range of coupling 
functionality, including aldehydes, thiols, amines, alcohols, isothiocyanates, carboxylic acids, 
and maleimides.  
 
Scheme 2.7. Left side: isotopic exchange of [18F]fluoride ion with Ar-(tBu)2-Si-
19F precursor (13); 
Right Side: different [18F]fluorosilane products exhibiting a range of coupling functionality.26 
 
 However, in the presence of complex, polyfunctional biomolecules such as peptides (16, 
Scheme 2.8), RCYs suffer significantly in direct, one-step processes, and any appreciable gain 
in yields can only be achieved through the use of additional amounts of [19F]-starting material 
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(16). Consequently, specific activities of the [18F]fluorosilane product (17) are extremely low 
(<100 Ci/mmol), well below the threshold for receptor-based imaging studies, and as a result, 
isotopic exchange has limited applicability within this area.26 
 
Scheme 2.8. Isotopic exchange of [18F]fluoride ion into a complex, polyfunctional peptide (17).26 
 
II. CONCLUDING INTRODUCTORY REMARKS 
In coordination with our group’s goal of developing ER PET imaging agents, we were 
intrigued by the advantages of the Si-18F chemistry over the aluminum and boron strategies 
mainly because it appeared to us that the bulky appended chelator, Al3+-NODA, designed to 
capture aqueous [18F]fluoride, in addition to the negative charges associated with the Al-18F and 
B-18F complexes would most likely have minimal, if any, affinity for the nuclear ERs. 
Furthermore, the formation of Si-18F bonds has been reported to be extremely rapid and 
efficient, proceeding in high radiochemical yields at room temperature, and can even be 
conducted in an aqueous environment. The Si-18F labeling methods used so far, however, have 
disadvantages. Although the exchange is facile with Ar-(tBu)2-Si-
19F precursors, an excess of 
19F-starting materials is often needed, especially with radiolabeling peptides, and this restricts 
access to high specific activity 18F-labelled products. An alternative approach involving reaction 
of [18F]fluoride ion with hydrosilanes, Ar(R)2Si-H, required a troublesome optimization process 
for each reaction and was slow and relatively inefficient, with remaining precursor difficult to 
separate from the product. In an attempt to improve on the existing methods, we sought the use 
of silyl acetates as exceptional alternatives for Si-18F radiochemistry.  
Herein, we describe a vastly improved version of Si-18F bond formation through our silyl 
acetate moiety, and we demonstrate its utility and flexibility in small molecules and large, 
polyfunctional biomolecules. These precursors have proven to be extremely reactive to 
[18F]fluoride ion and tolerant of protic functionality and water to provide an ideal one-step 
approach to functionally complex substrates in a late-stage fashion in high radiochemical yields 
and specific activities.  
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III. RESULTS 
*Portions of the synthesis work, notably preparation of the precursors [22-26, 29, 30, 38-44, 46-
51, 52-59, 61] were done by Dr. Sung Hoon Kim. All of the radiolabeling work was done by the 
author of this thesis. 
A. Small Adaptor Si-18F Molecules 
 The practicality of F-18 methodology for labeling PET agents relies heavily on simple 
and straightforward approaches that are needed to incorporate the isotope. Thus, the direct, 
one-step approach is much preferred over multi-step syntheses. More often, however, the 
incompatibility of certain sensitive substrates to F-18 labeling conditions or the low yields 
associated with a direct, one-step methods complicates production of the desired tracer and as 
a result, the multi-step approach is typically favored, especially for large biomolecules. 
Unfortunately, the complexity of these radiosyntheses complicates transition to clinical 
production and thus restricts their availability and evaluation in patients.  
As discussed previously, the strategy involves initial incorporation of the isotope into 
small adaptor precursors, which are then readily appended to large, sensitive biomolecules 
through a variety of methods. Of those reported, the most commonly used adaptor molecule is 
N-succinimidyl 4-[18F]fluorobenzoate, (21, [18F]-SFB), and its use nicely exemplifies the 
deficiencies in this approach. First, the radiosynthesis of [18F]-SFB (21) alone involves three 
steps (Scheme 2.9), with an additional step needed to append 21 to the biomolecule of interest, 
for a total of at least four steps to access the desired tracer.31 
 
Scheme 2.9. Radiosynthesis of N-succinimidyl-[18F]fluorobenzoate (21) for conjugation to  
biomolecules through a multi-step approach.31 
 
Moreover, the isotope is incorporated in the first step of the sequence (19), and the 
additional manipulations restrict access to extremely high activities of 21, which are required in 
the clinic. Finally, the multi-step sequence is technically challenging to perform (Figure 2.1). 
Although high yielding, each step is rather involved and requires purification either using a filter, 
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cartridge, or extraction from the previous step, leading to undesired absorbed hand and body 
doses and extreme difficulty in translating the chemistry to automated modules for clinical 
production.  A typical [18F]-SFB production protocol is given below. 
18
F-Fluoride solution (300–400 µL) was transferred to the first reaction vial, without trapping on an 
anion exchange cartridge, followed by the addition of K2CO3 (8.63 mg/mL, 5 mmol) and Kryptofix 
2.2.2 (4.5 mg, 12 mmol) in 10% water:acetonitrile solution. Then, water and acetonitrile were 
azeotropically evaporated by heating the reactor to 120 
o
C under a stream of argon followed by a 
vacuum. Further azeotropic drying was accomplished by the addition of 0.5 mL of acetonitrile. The 
dried K
18
F • Kryptofix 2.2.2 complex was then dissolved in 400 mL of acetonitrile containing 5 mg 
(14.7 mmol) of pentamethylbenzyl 4-(N,N,N-trimethylammonium)benzoate 
trifluoromethanesulfonate. The reactor was sealed and heated to 105 
o
C for 10 min, to yield 4-
18
F-
fluorobenzoic acid pentamethylphenylmethyl ester. Then, the reactor was cooled to 10 
o
C and 0.8 
mL of diethyl ether was added. The crude 4-
18
F-fluorobenzoic acid pentamethylphenylmethyl ester 
solution was then transferred through the silica cartridge to the second reaction vial. The first 
reaction vial and silica cartridge were washed with an additional 0.8-mL portion of diethyl ether. The 
diethyl ether was evaporated for 5 min at 35 
o
C under a stream of argon. Then the reaction vial was 
cooled to 25 
o
C, and 0.15 mL of 99.9% trifluoroacetic acid (TFA) was added. The 
pentamethylbenzyl deprotection proceeded for 2 min to yield 4-
18
F-fluoro-benzoic acid (
18
F-FBA). 
Thereafter, the reaction vial was cooled to 4 
o
C, and TFA was evaporated under a stream of argon, 
followed by the addition of 3 mg of 4-(dimethylamino)pyridine and 5.2 mg of N,N-disuccinimidyl 
carbonate. The reactor was sealed and heated to 100 
o
C for 5 min. The reaction vial was then 
cooled to 30 
o
C, and the crude 
18
F-SFB was diluted with 20 mL of water and passed through an 
activated C18 cartridge. The cartridge was washed with 10 mL of water and 1.8 mL of petroleum 
ether. Finally, the 
18
F-SFB was eluted from the cartridge with 1 mL of dichloromethane. The solvent 
was removed by a stream of argon at 25 
o
C. 
Figure 2.1 Reported method detailing the difficulty in the radiosynthesis of N-succinimidyl-
[18F]fluorobenzoate (21).31  
 
 In an effort to simplify existing labeling chemistries, we sought to address the 
deficiencies in C-18F approaches through the use of our silyl acetate precursors (28, Scheme 
2.11). As shown in Scheme 2.10, the initial preparation of the desired silyl acetates 28 
commenced with lithiation of bromide 22, followed by condensation with di-tert-
butylchlorosilane, to provide hydrosilane 23. Hydrolysis of acetal 23 and subsequent Jones 
oxidation afforded acid 25, which readily underwent ester formation (26) under DCC-mediated 
conditions. The corresponding hydrosilanes (24 and 26) were converted to the desired silyl 
acetates (28) in high yields through a Pd-mediated process (Scheme 2.11). 
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Scheme 2.10. Synthesis of hydrosilane precursors for silyl acetate products. (a) (i) nBuLi, THF,  
-78 oC; (ii) (tBu)2-SiH-Cl, TEA, THF, -78 
oC rt; (b) SiO2, rt; (c) Jones reagent, acetone, 0 
oC; 
(d) DCC, DMAP, DCM, 0 oC. 
 
 The silyl acetate products have proven to be quite useful. First, the silyl acetates can be 
rapidly accessed, and the flexibility of the preparative sequence enables the generation of 
products that exhibit a wide range of different coupling functionality that would be utilized in a 
two-step labeling approach. Moreover, the production method can be used to incorporate other 
coupling functionality (i.e., alkynes for click chemistry), depending on the particular need. 
Secondly, the silyl acetates are extremely bench-stable, and they tolerate exposure to air and 
water, and silica gel purifications. Traditionally, Si-Cl bonds epitomized reactive silyl 
functionality, but their sensitivity towards hydrolysis to the unreactive silanol limits their utility in 
our [18F]fluorination conditions. Likewise, Si-Cl precursors would need to be purified by 
distillation, since they are unstable on silica gel; thus, they would be limited to relatively small 
substrates and would require multi-step [18F]fluorination approaches.  However, the exceptional 
stability of the Si-OAc bond enables silica gel purification, which expands their applicability for 
the preparation of a wide variety of potential substrates, including complex, polyfunctional 
peptides, by direct [18F]fluorinations. Even with this elevated stability of the starting material, 28 
reacted rapidly with cold fluoride anion at room temperature within 5 minutes, with benzene 
being the optimal solvent (Scheme 2.11). More importantly, the fluorination of silyl acetates had 
minimal effect on the sensitive coupling functionality (i.e., NHS ester). This was key, since in 
previous methods, sensitive ester functionality was incompatible with the conditions required for 
radiofluorination. In addition, our interest in amine-reactive functionality was rooted in our desire 
to label a poly(amido)amine (PAMAM) dendrimer to understand the biodistribution of this 
interesting ER-targeted biopolymer. The NHS ester, in this case, was found to be the superior 
functionality over other potential strategies (i.e., reductive amination with CHO derivative), in 
terms of efficiency and reactivity, for this transformation.  
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Scheme 2.11. Pd-mediated synthesis of silyl acetates (28) and cold fluorination with TBAF. (a) 
Pd(OAc)2, AcOH, PhH, reflux; (b) TBAF, PhH, rt. 
 
The translation of the fluorination chemistry in Scheme 2.11 to tracer-level chemistry 
with [18F]fluoride anion proved to be challenging. First and foremost, the initial re-solubilization 
of the fluoride salt, TBA18F (from TBA[HCO3]), which was found to be the best fluoride source in 
our original cold fluoride screen, was far from ideal (Scheme 2.12). Initially, this remained a 
significant limitation of our approach, since most of the expensive [18F]fluoride isotope would be 
stuck to the reaction vial and therefore, unreactive, and eventually would be discarded as waste. 
Resolubilization is a fairly standard problem after the drying step is completed, and one of the 
main reasons that radiochemists prefer polar aprotic solvents (i.e., ACN, DMF, DMSO) is 
because of their ability to successfully re-dissolve the [18F]fluoride source from the glass 
surface. However, our cold chemistry screen of solvents with TBA19F revealed far superior 
yields with less polar solvents, with benzene being the optimal solvent. Unfortunately, these 
non-polar aprotic solvents were not efficient for re-dissolving the dried TBA18F, although the low 
levels of activity that were solubilized did provide promising yields of the desired compound, 
especially with PhH and DCM. Thus, we began to investigate other strategies in an attempt to 
discover a more organic-soluble [18F]fluoride source.  
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Solvent 
Total Activity of 
TBA[18F]F (mCi) 
TBA[18F]F in 
Solution (mCi) 
TBA[18F]F  
on Vial (mCi) 
% in 
Solution 
RCY 
Benzene 5.34 1.32 4.02 24.7 61 
DCM 5.18 2.75 2.43 53.1 72 
Isoamyl Alcohol 5.62 0.18 5.44 3.20 32 
Diethyl Ether 4.97 0.36 4.61 7.24 46 
 
Scheme 2.12. Evaluation of the solubility and reaction with 30 of TBA[18F]F in various organic 
solvents. 
 
 Of the commonly used [18F]fluoride sources (i.e., TBA[18F]F, Cs[18F]F, Rb[18F]F), by far 
the most widely used is the K[18F]F-K222 complex. Initial attempts to replicate previous protocols 
(K2CO3 (1 mg) and K222 (7 mg)) afforded a highly soluble [
18F]fluoride source in PhH (70-80% of 
activity in solution), but the excess base proved detrimental to the stability of the product 31. As 
shown in Figure 2.2, the crude radio-HPLC revealed multiple 18F-products, with the desired 
product (31) being retained at 4.15 minutes. After continued analysis over a 30 minute time 
period, 31 completely decomposed with a subsequent increase in the radio-peak to the right 
(4.66 minutes). This was not too surprising since the reaction is conducted under basic 
conditions in the presence of a base-sensitive NHS ester functionality, and it was assumed that 
the increase of the radio-peak at 4.66 minutes was the carboxylic acid derivative. However, 
synthesis of the cold fluorine standard of the acid and co-injection with the reaction mixture 
revealed elution of the acid to the left of the product peak. Identification of the product to the 
right of 31 still remains undetermined.   
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Figure 2.2. Radio-HPLC of the [18F]fluorination of 30 with K[18F]F-K222 showing the base 
sensitivity of 31 and the formation of multiple side [18F]fluoroproducts. Product elutes at 4.15 
minutes with the remaining other [18F]fluoroproducts being undetermined. 
 
 The initial investigations in the radiofluorination of 30 led to two main conclusions: low 
solubility of TBA[18F]F in the preferred solvent, PhH, and sensitivity of the NHS ester to the 
added base. The simple solution to these problems would be to essentially eliminate TBA[18F]F, 
PhH, and added base from being factors in the success of the reaction. Unfortunately, there 
was little precedent in the literature for this approach to work since almost every [18F]fluorination 
reaction involves a drying step, a [18F]fluoride salt, and an organic solvent under scrupulously 
dry conditions. However, our anticipated reaction conditions would be the exact opposite of how 
classical C-18F strategies are performed: no drying step or [18F]fluoride salts, and a reaction to 
be conducted in an aqueous environment.  
 Preliminary investigations revealed a critical dependence of the reaction temperature to 
afford high RCYs, starting from the cyclotron-produced aqueous [18F]fluoride source without any 
added base or a drying step (Scheme 2.13). The attractiveness of targeting silicon with 
[18F]fluoride is due to the mildness of the reaction conditions and the hope that they would be 
compatible with the efficient radiolabeling of sensitive substrates that had proved to be 
incompatible with conventional C-18F labeling approaches. Unfortunately, attempts to 
successfully [18F]fluorinate 30 at room temperature afforded no conversion to the desired 
product, but when the reaction was heated to 105 oC, excellent yields could be obtained. 
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Temperature 5% H2O-ACN 10% H2O-ACN 20% H2O-ACN 
rt 0% 0% 0% 
88 oC 33.7% 60.1% 65.9% 
105 oC 63.2% 75.3% 92.1% 
 
Scheme 2.13. Screening of the optimal water concentration and temperature for the 
radiofluorination of 30.  
 
Nevertheless, the radiofluorination of 30 is highly attractive because of its simplicity. The 
labeling is rapid and efficient, producing the 18F-labelled product in high radiochemical purity, 
with only one major F-18 product being formed, as shown in the radio-HPLC of the crude 
reaction mixture (Figure 2.3). This is one of the first reported cases in which the cyclotron-
produced 18F-aqueous solution could be used directly as an off-the-bench reagent, without the 
need for the tedious drying step; this significantly reduces precious reaction time and drastically 
improves the reliability of the [18F]fluorination. To date, this reaction has been performed over 10 
times without a single RCY under 90%. Also, in stark contrast to [18F]-SFB (26), the 
radiosynthesis is technically simple: the aqueous [18F]fluoride is placed in a glass vial, an ACN 
solution with dissolved 30 is added, heated to 105 oC for 10 minutes, and injected directly into 
the HPLC for purification. Overall, we can rapidly access 35-40 mCi of 31, starting from only 50-
55 mCi of aqueous [18F]fluoride within 1 hour after HPLC purification. 
 
Figure 2.3. Crude radio-HPLC trace of the [18F]fluorination of 30 (retention time = 4.82 minutes) 
under aqueous conditions. 
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The original objective of the project was to develop mild and efficient methodology 
through Si-18F bond formation to address the shortcomings of C-18F strategies. Although the 
base-free, 105 oC reaction can be considered a milder alternative to the exceedingly harsh 
temperatures (in excess of 130 oC) and basic conditions (pH ~9) required for the C-18F 
approaches, our present reaction was still far from the ideal room temperature reactions we had 
initially envisioned. We began to re-investigate this possibility through two strategies. First, we 
drastically reduced the amount of added base in the drying step, which had originally caused 
extensive decomposition, such that only 0.1 mg and 1 mg of K2CO3 and K222 respectively were 
used. Secondly, to improve the re-solubilization of the [18F]fluoride salt with PhH, we switched 
the glass vial for a plastic one, since it was hypothesized that the anion would have less affinity 
for the plastic and therefore might be more readily redissolved into the PhH solution. 
 In the midst of finding the best vial for this purpose, we initially chose an unknown, clear 
plastic vial that maintained full integrity of the vessel wall during the drying step (ACN, 105 oC, 
0.1 mg K2CO3 and 1 mg K222). Upon addition of the precursor in PhH, however, portions of the 
vessel wall appeared to dissolve, and it was belatedly realized that the unknown vial was 
polystyrene-based. Quite surprisingly though, in the presence of miniscule amounts of dissolved 
polystyrene, RCYs were high (in excess of >90%), with a significant reduction in side product 
formation, as determined by the radio-HPLC trace. After considerable screening of amounts and 
other polymers (i.e., PEG2000), we found that 25-50 µg of polystyrene was sufficient to maintain 
high RCYs (Scheme 2.14), albeit in slightly longer reaction times (15 minutes); this amount was 
also sufficient to inhibit the undesired decomposition previously seen (Figure 2.2) and to afford 
high radiochemical purity (Scheme 2.14, bottom) in the crude radio-HPLC trace.  
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Scheme 2.14. Room temperature [18F]fluorination of 30 in the presence of lowered base and 
polystyrene. Bottom: Crude radio-HPLC of the [18F]fluorination showing an efficient 
formation of a single desired 18F-compound (Retention time = 3.93 minutes). 
 
 Overall, we have established a superior method in the realm of Si-18F bond formation 
strategies through the use of silyl acetates, which have proven to stable yet extremely reactive 
to [18F]fluoride anion, through two approaches to afford rapid and efficient formation of the 
desired [18F]fluorosilane products in high RCYs (>90%) and specific activities (3500-3800 
Ci/mmol). To demonstrate the utility of this approach, we prepared a 18F-labelled version of an 
estrogen dendrimer conjugate (EDC, 32) to evaluate its in vivo biodistribution in the context of 
the cardiovasculature (Scheme 2.15).32-34 A simple dilution of the 18F-H2[
18O]O water with 
acetonitrile and dissolved NHS-silyl acetate (6) and heating at 105 oC for 10 minutes yielded 31 
in high RCY. After cooling to room temperature, the reaction mixture, without any extraction, is 
injected directly into the HPLC to afford 7 in high radiochemical purity (>99%) and specific 
activity. The purified [18F]fluorosilane product can be readily appended to EDC (32) within 10 
minutes, albeit in somewhat varying RCYs of 33 (60-98%). The attractiveness of the approach 
lies heavily in the efficiency of the radiofluorination reaction: beginning with 50 mCi, the reaction 
sequence can reliably afford 15 mCi of the desired compound (33) after 2 hours. This is a highly 
attractive feature, especially when conducting time-sensitive animal studies that are dependent 
on sufficient amounts of activity of the radiotracer at a specified time. 
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Scheme 2.15. Radiosynthesis of [18F]EDC through the Si-18F approach. (a) MeOH, rt. 
 
 Of the necessary steps for radiotracer production, the HPLC purification step is by far 
the most time-consuming. The process involves exceedingly long retention times (20-30 
minutes), especially for short-lived isotope work, which is generally needed to effectively 
separate the large excess of precursor from the [18F]fluoroproduct. Most HPLC purifications 
involve reverse phase conditions, and therefore, the collected fractions of the radiotracer are 
present in varying concentrations of acetonitrile and water. The volume of the liquid can be quite 
high (~10 mL), and because the amount of organic solvent present is not compatible with 
animal work, it must be removed. The standard procedure typically involves dilution of the 
collection activity with water to a total volume of 50 mL which is then passed through an intricate 
array of Teflon tubing to capture the radiotracer on a C18 cartridge. After additional washings 
with water, drying over a stream of nitrogen and elution of the labeled organic species with 
ethanol, this step alone consumes 30 minutes. Moreover, the dilution step causes loss of 
activity from precipitation on the vial wall, and at times, the C18 cartridge is not fully effective at 
capturing the radiotracer. Overall, both complicated steps involve at least 45-60 minutes of 
effort, which equates to approximately a quarter of the activity being lost from decay processes 
alone, in addition to the losses within the tubings and vials. Thus, a more efficient protocol is 
needed to maximize retrieval of the desired radiotracer. 
 In an attempt to circumvent these shortcomings and bypass this HPLC purification 
process altogether, we have modified our original silyl acetate moiety with acid units that are 
either tethered to beads or chromatographically distinct (made extremely polar with polyethylene 
glycol chains) (Scheme 2.16). Because reaction of the silicon atom with [18F]fluoride ion will 
release the labeled [18F]fluorosilane, any remaining precursor should be easily separable by 
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solid-phase extraction in the case of polar esters or removed by simple filtration in the case of 
the beads. In fact, the bead technology could be adapted to precursor cartridges, where the 
fluoride ion is introduced by flow, and only labeled product emerges from the cartridge. If 
successful, this will enable kit-like protocols that will streamline reactions and facilitate rapid 
product isolation and purification. 
 
Scheme 2.16. Proposed HPLC-free strategy for the synthesis of 31 through the use of polar 
PEG chains or a bead system. 
 
To date, this technology is still under development, but promising results have already 
been obtained. As shown in Figure 2.4, [18F]fluorination of the original silyl acetate NHS 
derivative (Scheme 2.13) yielded a HPLC UV chromatogram showing significant amounts of 
mass, including starting material and other decomposition products, that must be removed 
before the next conjugation step can be performed. However, when the PEG-based derivative 
(35) was utilized (Scheme 2.17), there is a tremendous reduction of mass in the UV trace with 
only two peaks present: solvent front (1.5 min) and residual PhH (2.5 min). Radiochemical 
yields (50-70%) and specific activities appear promising, with the radiochemical purity being the 
only limiting factor to date (~85%).  Nevertheless, in the event of high radiochemical purity, this 
highly encouraging approach would be a significant advancement for the field since 
[18F]fluorosilane products could be rapidly accessed within minutes, devoid of the time-
consuming HPLC purification process, and used directly in the next conjugation step. In the 
case of the EDC labeling procedure (Scheme 2.15), where total production time is 2 hours, 
application of the PEG-based strategy could significantly reduce the whole process down to 20 
minutes. Further investigations into the factors contributing to the undesired decomposition of 
31 are needed for this goal to be realized. 
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Figure 2.4. UV trace of the radiofluorination of 30 using the aqueous [18F]fluoride method 
showing significant mass with the product present at 16 minutes.  
 
 
 
Scheme 2.17. UV trace of the radiofluorination of 35 showing negligible mass peaks of other 
products. 
 
B. Si-18F Small Molecules 
A significant portion of PET agent development involves small-molecule research. The 
approach is largely conducted through nucleophilic alkyl chain displacement, aromatic 
substitution or diaryliodonium salt C-18F bond formation strategies; however, besides the 
problems associated with the high temperatures and basicity seen previously, these approaches 
also necessitate the use of protecting groups, which can potentially complicate efforts. A typical 
nucleophilic aromatic substitution reaction is shown in Scheme 2.18 (unpublished work), 
showing the minimum 2-step sequence with the isotope being introduced early in the sequence 
and a final deprotection step. Consequently, this approach restricts access to the more 
desirable one-step, late-stage [18F]fluorination strategies that would be optimum for short-lived 
isotope work. 
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Scheme 2.18. Example of a required two-step approach for nucleophilic aromatic substitution. 
 
Moreover in this sequence, the conditions (AlBr3, dodecanethiol) needed for removal of 
the methyl ethers caused complete decomposition of the substrate. Attempts to perform the 
reaction in the absence of protecting groups were also unsuccessful, leading only to the 
formation of undesired [18F]fluoroproducts. Switching to a more acid-labile tetrahydropyran 
(THP) group afforded a simple solution to this problem; however, similar solutions are restricted 
to relatively simple small molecule substrates. These synthetic issues become more 
complicated with complex, polyfunctional substrates since the flexibility and available 
protection/deprotection synthetic options become rather limited, and ultimately this leads to 
additional steps or harsh conditions that are most likely incompatible with these substrates. 
Protecting group-free strategies would render these problems obsolete and access substrates in 
a rapid, late-stage fashion. The use of Si-18F bonds provides an intriguing solution to this 
problem. 
In an effort to develop silicon-based ER PET imaging agents, we focused on appending 
the (tBu)2-Si-OAc moiety at the 17α position of estradiol since this position is known to tolerate 
large substitution and produce ligands that still retain high affinity for the estrogen receptor.35 
Beginning with alkylation of the iodophenol (39) with the Boc-protected bromide (38), acid 
hydrolysis of the Boc group, followed by a Sonogashira reaction with commercially available 
ethynyl estradiol (42), afforded the requisite amine 43, which reacted readily with the NHS ester 
30 to yield the desired precursor (44) for [18F]fluorination (Scheme 2.19).  
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Scheme 2.19. Synthesis of the small molecule [18F]fluorination precursor for Si-18F-based ER 
PET imaging agents. (a) K2CO3, DMF, 55 
oC; (b) SiO2, rt; (c) piperidine, CuI, PdCl2(PPh3)4, 
ACN, 55 oC;  (d) 30, TEA, DMF, rt. 
 
Similar to the radiosynthesis of 30, we subjected silyl acetate 44 to the two originally 
discovered conditions, and in both instances, high radiochemical yields and specific activities 
were obtained (Scheme 2.20). Under the aqueous [18F]fluoride method, 44 reacted rapidly in 
near quantitative yield with only a single [18F]fluorinated product being formed, as shown in the 
radio-HPLC of the crude reaction product (Scheme 2.20, bottom). The efficiency of this 
protecting group-, drying step-, and base-free reaction is exemplified by the preparative 
recovery of 45, where over 60% (non-decay corrected) of the starting activity is present in the 
desired compound. In contrast to the protecting group strategies, the silyl acetate moiety 
enables a direct, one-step [18F]fluorination into a complex substrate in the presence of acidic 
functionality in a highly efficient (one [18F]fluorinated product, only 45 minutes total), late-stage 
fashion.  
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Scheme 2.20. Radiosynthesis of Si-18F-based ER small molecule (45). Top: Method A- K[18F]F, 
K2CO3, K222, DMSO, rt, 10 min, RCY: 86.8% (n=2); Method B: 
18F-H2[
18O]O, ACN, 105 oC, 
10 min, RCY: 94.4% (n=2); SA = 2300-2500 Ci/mmol. Bottom: crude radio-HPLC of the 
reaction showing only a single 18F-product being formed (Retention time = 22.4 minutes). 
 
The only difference from the original conditions was the use of DMSO rather than PhH in 
the room temperature method. Use of PhH was initially attempted, and a quantitative conversion 
to a [18F]fluorinated product was observed by radio-TLC; however, co-injection with the cold 
standard revealed a different and still unidentified product. Switching the solvent to DMSO, 
however, afforded the desired compound in high radiochemical yields.   
 
C. Masking the High Lipophilicity of the (tBu)2-Si-
18F Group with PEG Chains 
From a chemical perspective, the silyl acetates have proven to be ideal substrates: 
easily prepared and bench stable, yet highly reactive to [18F]fluoride ion and able to give labeled 
products in exceptional RCYs and SAs, even in the presence of water and protic functionality. 
Despite these merits, a major shortcoming of this approach is the high lipophilicity of the 
corresponding products, which can significantly alter the in vivo behavior of a tracer, especially 
for compounds of low molecular weight. Previous investigations of similar [18F]fluorosilane 
products showed poor biodistributions, with high accumulation in the liver and excessive 
nonspecific binding to nontarget tissue.36 Moreover, the presence of the two bulky tert-butyl 
substituents significantly reduces the likelihood of receptor tolerance, and binding affinities can 
suffer considerably.  
However, modification of the original tert-butyl design with smaller substituents (e.g., 
methyl groups) revealed significant hydrolysis, indicating that the tert-butyl groups are required 
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for engendering high in vivo stability of the Si-18F bond. Attempts to counter the lipophilicity of 
the group with more polar PEG chains, carbohydrates, or quaternary ammonium salts have 
afforded only minor improvements in the behavior of these agents.37,38 Therefore, strategies 
aimed at masking the high lipophilicity of the (tBu)2-Si-
18F moiety to improve the in vivo 
pharmacokinetics and biodistributions of these agents are needed.   
Our original attempt to develop silicon-based ER imaging agents (Scheme 2.20) yielded 
potential tracers with negligible affinity for the receptor (RBA: ERα, ERβ = <0.1%) and thus were 
of little utility to us. To improve binding affinities for ER, we became interested in a common 
nonsteroidal motif, based on a 1,1-diarylethylene unit, that is well-known to afford potent 
estrogens having high affinity for the receptor.39 For our purpose, we focused on the 
adamantane derivative, which is a minor modification of the well-known nonsteroidal estrogen, 
cyclofenil (Figure 2.4).40 To provide an attachment point for our silyl acetate moiety, we 
appended ethylene glycol chains of varying length bearing a reactive terminal amine group for 
reaction with the NHS ester 27, and we evaluated their relative ligand binding affinities for the 
estrogen receptor in competitive radioligand binding assays using [3H]-17β-estradiol (E2) as a 
tracer and full-length human estrogen receptors, ERα and ERβ. The results, as shown in Figure 
2.5, are expressed as relative binding affinities (RBAs) and are referenced to the affinity of E2, 
which is set to 100%. The hydrosilane derivatives (47, 49, and 51) were used in these studies 
due to their ease of preparation, handling and enhanced stability during the assay itself. Due to 
the similar nature of the hydrosilanes, it is hypothesized that the fluorine derivatives will have 
comparable values. 
Modification of the original high affinity compound (46) with the silane moiety, (tBu)2-Si-H 
(47), resulted in a significant reduction in the affinity for the receptor. Extension of the amine 
side chain with a single tetraethylene glycol (TEG) linkage (49) afforded minor improvements in 
affinity, albeit still considerably less than the underivatized compound (48). Only when an 
additional TEG chain was attached could sufficiently high binding affinity be obtained (51). A 
possible reason for the tolerance of the bulky silane moiety and subsequent increase in RBA in 
the presence of the di-TEG moiety is the result of the ability of this moiety to enwrap the 
hydrophobic silane group, removing it from the unfavorable aqueous environment and 
ensconcing it in a more organic-friendly environment as a result of multiple oxyethylene group 
interactions between the cyclofenil and glycol chain. Such possibilities were confirmed through 
2-dimensional NMR studies. 
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Figure 2.5. RBAs of various silyl-based adamantane compounds showing the needed for a 
diTEG linkage to obtain high affinity estrogens. 
 
The preparation of diTEG silyl acetate 59 commenced from mesylate 52 (Scheme 2.21). 
The formation of phthalimide 54, followed by selective mono-alkylation of diphenol 55 and acid 
deprotection, afforded amine 57 in high yield. An iterative double amidation/deprotection 
sequence afforded the requisite free amine 58 from which the silyl acetate 30 could be 
appended. 
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Scheme 2.21. Synthesis of the diTEG-adamantane compound (59). (a) DMF, 50 oC; (b)  
K2CO3, DMF, 75 
oC; (c) H2NNH2, MeOH, rt; (d) NHSCO-diTEG-NHBoc, TEA, DMF, rt; TFA, 
DCM, rt; (e) 30, TEA, DMF, rt.  
 
Application of the aqueous [18F]fluoride method afforded exceptional RCYs (Scheme 
2.22). Key to the success of this approach was effective separation of starting material (59) from 
the [18F]fluorosilane product 60. Since these are relatively high molecular weight compounds 
and the reaction involves only a minor substitution for [18F]fluoride ion, it is critical to obtain 
clean separation of the two in order to reach high effective specific activities. Additional 
investigations are still needed to find the optimal HPLC conditions for this important separation. 
The promise of this strategy as a viable masking approach to counter the high lipophilicity of the 
[18F]fluorosilane moiety is still currently being evaluated in animal models. 
 
Scheme 2.22. Radiosynthesis of 51. (a) 18F-H2[
18O]O, ACN, 105 oC, 10 min, RCY: 91.6% (n=2). 
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D. Direct, One-Step Labeling of Peptides Through Si-18F Bonds 
 [18F]Fluorinated peptides have been a focal point of a great deal of research in recent 
years in an attempt to improve and expand on the successes of [18F]FDG. Their tremendous 
potential has been demonstrated in imaging several diseases, especially cancers, due to their 
favorable pharmacokinetics, metabolic stabilities and higher tolerance towards bulky 
substitutions.41 However, progress in the area has been exceedingly slow: Only a few 18F-
labelled peptides have been evaluated in humans,42-44 and this has been largely attributed to the 
lack of efficient methodology to access these agents for clinical use.  
 To demonstrate the versatility of the silyl acetate moiety for radiolabeling peptides and to 
improve on the existing methodology,25,26 we became interested in the direct radiofluorination of 
an RGD peptide. Cyclic RGD pentapeptides are well-known to have high binding affinity and 
selectivity for the most well-known member of the integrin family, αvβ3.
45,46 Studied mainly for its 
role in tumor growth, progression, and angiogenesis, αvβ3 is a target for radiotracers that has 
the potential for early detection of metastatic tumors, and for monitoring tumor growth, 
metastasis and therapeutic response by PET imaging.47,48 
 Application of the (tBu)2-Si-OAc moiety for peptide labeling commenced with NHS ester 
30 being coupled to the free –NH2 of the lysine residue of commercially available cRGD to 
afford the desired [18F]fluorination precursor (61, Scheme 2.23). The initial difficulty in assessing 
the success of the radiofluorination reaction was due to the inability of the [18F]fluorosilane 
product (62) to move on a silica gel TLC plate. Due to the safety hazards of working with 
positron emitters, radiochemists are rather limited by the availability of analytical instruments 
that can be utilized for product detection. The setups for traditional analytical instruments (NMR, 
UV-Vis, IR, and MS (unless coupled to a HPLC)) are incompatible with the specific safety and 
handling procedures that are demanded by PET isotopes. As a result, radio-TLCs and –HPLCs 
are two of the most common instruments available to radiochemists for product analysis.  
 A radio-TLC is a straightforward method for analyzing the conversion of [18F]fluoride ion 
into [18F]fluoroproducts. Key to this is the fact that unreacted [18F]fluoride ion remains at the 
baseline of a silica gel TLC plate, while any F-18 organic products will move with the solvent 
front as is typical for traditional TLC development. After development, the plate is then placed 
on a TLC scanner, which can detect the activities along the path length (Figure 2.6). Since the 
resolution between unreacted and reacted 18F-peaks is not ideal (peaks are generally very 
broad), TLC development often involves very polar solvent conditions, such as 100% EtOAc or 
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5%MeOH/DCM. Consequently, a single peak may comprise of multiple [18F]fluoroproducts. 
Thus, radio-TLCs are only useful for determining conversion rates, and the corresponding yields 
are not representative of the true radiochemical yields of the desired compound or 
radiochemical purities. Injection of the reaction mixture into the HPLC and analysis of the trace 
is a better indicator of both RCY and RCP, since it allows for better resolution of the 
[18F]fluorinated products. 
 
Figure 2.6. Depiction of a radio-TLC analysis. Left: peak remains at the baseline and is 
indicative of unreactive [18F]fluoride (35 mm). Right: reaction analysis showing unreacted 
[18F]fluoride (35 mm) and [18F]fluoroproduct (55 mm). 
 
In the case of the radiofluorination of cRGD (61, Scheme 2.23), the corresponding 
product (62) did not move on the TLC plate, possibility indicating no conversion to 62. However, 
injection of the cold standard with the reaction mixture revealed co-elution with a single 
radioactive peak in the radio-HPLC, suggesting product formation. Since the product did not 
move on the TLC plate, it was also difficult to ascertain incorporation yields. After extensive 
screening of elution solvents and TLC plates, we were able to find conditions (C18 plate, 80% 
ACN, 20% H2O, 0.1% TFA) that could be used to analyze the reaction, albeit in low but 
workable resolution.  
Similar to the [18F]fluorination of the small-molecule example (Scheme 2.20), DMSO was 
the preferred solvent for 61 (Scheme 2.23) and resulted in excellent yields of 62 within 15 
minutes, giving a product in high radiochemical purity before further purification. The reaction 
times were slightly longer than the previous examples, and this is most likely attributed to the 
nature of the peptide, but further analysis of the reaction revealed high RCYs (in excess of 60%) 
within 5 minutes with only a slight increase in the yield with an additional 10 minutes.  
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Scheme 2.23. Direct, one-step radiosynthesis of a complex peptide 62. Method A: 18F-H2[
18O]O, 
ACN, MeOH, 105 oC, 10 minutes, RCY: 81.1% (n=2); Method B: K[18F]F, K2CO3, K222, 
DMSO, rt, 15 minutes, RCY: 85.7% (n=2). Bottom: radiochemical purity after purification of 
62 (retention time = 12.6 minutes). 
 
The aqueous [18F]fluoride protocol required a minor modification, the addition of MeOH 
as a cosolvent, since the original conditions could not fully solubilize the peptide. Nevertheless, 
61 reacted rapidly in high RCY within 10 minutes, with a single [18F]fluorinated product being 
formed. Even with the rather harsh, elevated temperature (105 oC), no decomposition of the 
sensitive peptide substrate was observed, most likely the result of the short reaction time. Upon 
cooling to room temperature, the crude reaction mixture can be injected directly into the HPLC 
without the need for any additional purification, and the peak activity is collected on a C18 
cartridge and eluted with ethanol, ready for animal injection in less than 1 hour.  
The recovery yields were not exceedingly high or representative of the radio-TLC and  
-HPLC analysis. Although yields were in excess of 80% with a single product being formed, only 
4 mCi were obtained from 20 mCi of starting activity. The most likely source of loss in this case 
was in the HPLC column. After injection and recovery of 62, subsequent counting of the HPLC 
column with a Geiger counter revealed significant amount of activity stuck in the column. It 
seems as though the product precipitates within the HPLC column after removal of the DMSO 
from elution and mixing with the HPLC eluent (ACN/H2O/TFA solution). This is a difficult 
problem to solve, and switching to a more polar solvent is not the simple solution. Since there is 
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a large excess of starting material, typical HPLC retention times are deliberately long (20-30 
minutes) to provide sufficient separation of the two materials and often involve more aqueous-
based reverse phase conditions. Switching to a more organic-based condition will decrease 
retention times, hamper separation, and ultimately result in contamination of the 
[18F]fluoroproduct with starting material. When working with high molecular weight substrates 
such as this, long retention times are essential for separation since the structural and electronic 
differences are exceedingly small. Attempts at varying the HPLC conditions resulted in lower 
specific activities, and the original conditions are currently the best available for this application.  
 
IV. DISCUSSION 
 The potential impact of PET imaging on the fields of medical care and drug development 
is undeniable. In the clinic, the functional information of diseased states obtained through PET 
imaging techniques has significantly transformed medical diagnosis from a mere identification 
tool towards characterizing the molecular processes involved with disease progression.49 The 
ability to characterize disease at the molecular level through imaging provides an indispensable 
clinical tool that can aid in the diagnosis, prognosis, and the design of proper therapeutic 
regimens for a particular diseased state.50,51 As a result, PET imaging has received significant 
attention recently due to the possibility of developing medicine that is personalized for each 
patient.51 By individualizing treatment plans, the expectation is that patient outcomes will be 
greatly improved through better diagnosis and targeted therapies, as well as safeguarding 
against the use of unnecessary, harmful medical procedures. This enticing possibility, however, 
relies on the clinical availability of well-designed radiotracers for specific biomarkers or diseased 
states that can yield the desired information for personalized medicine to develop. 
Unfortunately, the availability of such agents are lacking, and the field continues to be 
dominated by a single, nonspecific agent, [18F]FDG.1  
 Of the multiple components that encompass the PET imaging process, target discovery 
and software/hardware development significantly outpace the advancement of novel imaging 
probes. A significant impediment to the field is the lack of synthetic approaches that can access 
these desired probes in a mild and efficient manner that is demanded by the sensitivity of many 
of these substrates. Consequently, the lack of compatible and efficient methodology restricts 
their clinical evaluation and development. Mainstream organic chemistry is dominated by an 
innumerable amount of synthetic building blocks and methodology that has enabled the 
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construction of almost any imaginable structure. However, the 18F-labelling chemistry, reactions 
are limited to a single entity, [18F]fluoride anion, and incorporation of the isotope is not trivial. 
Consequently, the available methodology is extremely limited and as a result, tracer 
development is exceedingly slow. 
 A significant portion of radiofluorination reactions are predicated on C-18F bond 
formation. Although successfully employed for decades, this approach is not without its issues. 
First, this approach is only well-established in two areas: Sn2 alkyl displacement and 
nucleophilic aromatic substitution. Access to agents not included in these strategies involves 
indirect, multi-step approaches that are time-consuming and inefficient, and ultimately limit the 
practicality of these approaches. Second, the conditions for incorporation of the isotope are 
often harsh (basic, high temperatures) and require protecting groups. As a result, these 
conditions restrict the use of most substrates, especially biomolecules, for the ideal, one-step 
approach and complicate synthetic efforts significantly. Consequently, the incompatibility of 
complex, polyfunctional biomolecules has necessitated the use of alternative strategies to 
access these agents in a rapid, late-stage fashion.  
Interest in Al-18F, B-18F, and Si-18F bonds has been largely driven by the potential of 
peptides, proteins, and antibodies as imaging agents and the need for these substrates to be 
radiolabeled under mild conditions, preferably in an aqueous environment. Our interest in the 
field was spurred on by the rapid and efficient manner of Si-18F bond formation and the most 
likely compatibility of the corresponding Si-18F products (over the Al-18F and B-18F ones) within 
the estrogen receptor system. Of the reported conditions, both are inherently limited to low 
specific activity and have little value in receptor-based PET imaging. Consequently, we sought 
to improve on the existing methodology through the use of our silyl acetate precursors which 
have proven to be ideal substrates: easily prepared and bench-stable, yet highly reactive to 
[18F]fluoride ion, giving high radiochemical yields and specific activities. The versatility of the silyl 
acetate moiety was demonstrated in three main active areas of research: adaptor molecules, 
small molecules, and peptides.  
Although a direct, one-step radiofluorination is highly desirable, the incompatibility of 
some substrates or the difficulty associated with a one-step approach demand a synthetically 
simpler indirect, multistep strategy through the use of small adaptor molecules. However, the 
existing available chemistry is flawed by complex, inefficient sequences that make translation to 
the clinic exceedingly difficult, especially since the isotope is incorporated very early in the 
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sequence. Alternatively, our NHS ester 30 reacts rapidly with aqueous [18F]fluoride ion without 
the need for the time-consuming drying step or added base. Exceedingly high levels of activity 
of 31 (35-40 mCi from starting 50-55 mCi of activity) can be quickly accessed within 45 minutes 
after HPLC purification. The utility of the method was demonstrated in the radiosynthesis of 
[18F]-EDC where 15 mCi of material can be routinely synthesized from 50 mCi of activity within 2 
hours.  
To illustrate the utility of the approach for radiolabeling of small molecules, we became 
interested in developing Si-18F–based ER PET imaging agents. The problem with small- 
molecule radiosyntheses is their multi-step approaches which typically involve deprotection 
steps and/or functional group manipulations and restricts the use of direct, late-stage 
[18F]fluorinations to rapidly access functionally complex agents. The protection/deprotection 
sequences are usually amenable to relatively simple small molecules, but this becomes more 
complicated with complex substrates and only further undermines the practicality of the 
approach. However, the Si-OAc moiety facilitates a protecting group-free strategy to generate a 
complex [18F]-estrogen (45) in high RCYs and preparative yields through a simple, late-stage 
aqueous [18F]fluorination. We also developed a complementary room temperature 
[18F]fluorination method for those substrates that may not be compatible with the higher 
temperatures required in the previous method. Similarly, the reaction proceeds smoothly, in the 
presence of protic functionality, with the K[18F]F-K222 cryptate in high RCYs within 10 minutes.  
One of the more active areas of research is the radiolabeling and in vivo investigations 
of peptides. However, despite their attractive in vivo properties, 18F-labelled peptides have had 
limited success, with only a few being evaluated in humans.42-44 The dismal success rate has 
largely been attributed to the lack of methodologies that would enable more convenient and 
efficient preparation of these agents. Because of this, a majority of the peptides are radiolabeled 
with a useful “wash-in” of radiometals, especially with Cu-64, despite their less than ideal 
nuclear properties.54 The direct, one-step labeling of silyl peptides with [18F]fluoride ion has only 
recently been demonstrated as a viable strategy, albeit in low specific activities in most 
instances.26 Application of the silyl acetate chemistry, however, afforded high RCYs of cRGD 62 
through both methods and in contrast to those previously reported, in high SAs. This is one of 
the first reported cases of high RCYs and SAs in a one-step [18F]fluorination of peptides and 
should hold tremendous potential for future applications in this area.  
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Although the (tBu)2-Si-OAc moiety has proven to be highly efficient at capturing 
[18F]fluoride ion, the required two tert-butyl groups that are required to provide high hydrolytic 
stability to the Si-18F bond can also have a tremendous impact on the in vivo behavior of the 
radiotracer, especially those of low molecular weight. Efforts to counter the high lipophilicity with 
PEG chains, sugars, or ammonium salts have yielded minimal success.37,38 Our efforts to mask 
the impact of this group through the use of tetraethylene glycols has afforded extremely potent 
estrogens which can be readily labeled with F-18. This approach relies on the more polar TEG 
chains to effectively solvate the hydrophobic silane entity away from the unfavorable aqueous 
environment and into a more organic-friendly setting. This strategy appears to work best with a 
diTEG linkage, which provides significant improvements in the binding affinities for the receptor, 
as compared to the original silyl-estrogen. Unfortunately, high RBAs do not necessarily predict 
in vivo behavior, and further animal studies are still needed to validate this approach as an 
effective means to counter the problems associated with the (tBu)2-Si-
18F moiety. 
A concern for the majority of radiofluorination reactions is the purification process and 
specific activities, as the large excess of starting materials needed to drive the reaction to 
completion often can complicate purification efforts and generate tracers with low SA or 
effective SA. A notable feature of these silyl acetates is the low amount of precursor needed for 
the reaction. Traditionally, typical amounts of precursor range from 1-2 mg and can exceed 5 
mg, especially when using iodonium salts or the hydrosilane chemistry. Since these reactions 
usually form nano-to-pico mole amount of [18F]fluoroproducts, it is not difficult to see why the 
purification problem is so severe. However, the silyl acetates in all cases react rapidly in 
extremely low amounts (NHS ester (30, 0.1 mg, 0.28 µmol), EE2 (44, 0.3 mg, 0.39 µmol), and 
peptide (61, 0.3 mg, 0.33 µmol)), which facilitates much easier purifications and ultimately is one 
of the main reasons for our high specific activities. Also, the problem with starting material 
contamination only serves to validate the PEG- and bead-based approaches as viable 
strategies, since this would eliminate the HPLC purification process altogether and allow for only 
the [18F]fluorosilane product to be eluted off the cartridge, devoid of any starting material. 
Further studies are still needed to improve radiochemical purities. 
Due to the presence of harmful ionizing radiation, 18F-labelling demands significantly 
different handling and tracer production protocols compared to mainstream organic chemistry. 
Even relatively simple purifications, such as extractions, are extremely difficult to perform, 
especially in relation to safety considerations. In almost all instances, production in the clinic is 
performed in automated synthesizers called modules to eliminate human error and maintain 
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reliable availability of tracers for patient use. These relatively simple machines serve as an all-
in-one module for routine production from the end of bombardment to the final HPLC purification 
step and work especially well for standard procedures such as for [18F]FDG, but the transition to 
more challenging protocols is not as straightforward. The machine functions through an intricate 
array of lines, filters, pumps, and columns and any additional step such as a simple extraction 
requires modification of the existing module. Minor modifications (i.e., extraction) can be readily 
accommodated into the machine, but the number of available options is rather limited, and at 
times, these modifications can often be a source of production failures. Consequently, the 
translation into the clinic demands simple and straightforward protocols. The silyl acetate moiety 
provides just that. A simple dilution of the cyclotron-produced aqueous [18F]fluoride source and 
subsequent heating for 10 minutes enables rapid and efficient fluorination of precursors in high 
RCYs. After cooling and without any other manipulations, the reaction mixture is injected directly 
into the HPLC and provides the purified radiotracer within 1 hour. Application of the method, in 
the event of a suitable Si-18F radiotracer, should provide a facile transition into the clinic. 
 
V. CONCLUSION 
In summary, we have developed a rapid and efficient Si-18F bond formation protocol 
based on silyl acetate precursors that is broadly applicable to small molecules and peptides. 
This method is particularly noteworthy given its experimentally simple, exceptional generality, 
and high level of functional group tolerance which permits entry to once previously inaccessible 
sensitive substrates, including complex, polyfunctional biomolecules, in a direct, late-stage 
approach to radiolabeling with F-18. The corresponding [18F]fluorosilane products were obtained 
in high yields and specific activities, and the utility of the method was demonstrated in labeling a 
challenging biopolymer, an estrogen dendrimer conjugate (EDC), allowing its in vivo evaluation 
within the cardiovascular system. Current efforts have focused on addressing the high 
lipophilicity of the (tBu)2-Si-
18F with ethylene glycol chains and is currently being validated in  
animal models as a viable approach. 
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VI. METHODS 
Materials 
All reactions were carried out under a nitrogen atmosphere with dry solvents using anhydrous 
conditions unless otherwise stated. Solvents used in the reactions were dried in a solvent 
delivery system (neutral alumina column). Reagents were purchased from Aldrich and used 
without further purification, unless otherwise stated. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogeneous materials, unless otherwise stated. Reactions were 
monitored by thin layer chromatography (TLC) carried out on Merck silica gel 60 F254 
precoated plates (0.25 mm) using UV light as the visualizing agent and ceric ammonium 
molybdate and heat as developing agents. Flash column chromatography was performed on 
Silica P Flash silica gel (40-64 μM, 60 Å) from SiliCycle. 1H NMR spectra were recorded at 23 
oC on a Varian Unity-400, Varian Inova-500 or Varian Unity-500 spectrometer and are reported 
in ppm using residual protium as the internal standard (CHCl3, δ = 7.26, CD2HCN, δ = 1.94, 
center line, acetone-d6, δ = 2.05, center line). The following abbreviations were used to denote 
the multiplicities: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = 
multiplet and b = broad. Proton-decoupled 13C NMR spectra were recorded on a Varian Unity-
500 (126 MHz) spectrometer and are reported in ppm using solvent as an internal standard 
(CDCl3, δ = 77.16, CD3CN, δ = 1.30, center line, acetone-d6, δ = 29.80, center line). High 
resolution mass spectra were obtained at the University of Illinois School of Chemical Sciences 
Mass Spectrometry Laboratory. No-carrier-added [18F]fluoride was produced at Washington 
University Medical School by the 18O(p,n)18F reaction through proton irradiation of enriched 
(95%) [18O]H2O using a RDS111 cyclotron. Screw-cap test tubes used for drying fluoride and 
radiolabeling were purchased from Fisher Scientific (Pyrex No. 9825). Radiochemical 
purification utilized a reverse-phase semi-preparative HPLC column (HPLC: Thermo P2000, 
Column: Agilent Zorbax SB-C18, 5 µm, 9.4 X 250 mm, Product #: 880975-202, λ = 254 nm, 
ACN/H2O). For quality control, the radiochemical purity was determined by analytical HPLC 
(HPLC: P4000, Column: Altima C18, 5 µm, 250 mm, Product #: 88056). C18 Sep-Pak cartridges 
were purchased from Waters Corporation (Milford, MA, USA). For the thin-layer 
chromatography (TLC) analyses, EM Science Silica Gel 60 F254 TLC plates were purchased 
from Fisher Scientific (Pittsburgh, PA, USA). Radio-TLC was accomplished using a Bioscan 200 
imaging scanner (Bioscan, Inc., Washington, DC, USA). Radioactivity was counted with a 
Beckman Gamma 8000 counter containing a NaI crystal (Beckman Instruments, Inc., Irvine, CA, 
USA). 
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Estrogen Receptor Binding Affinity Assays 
Relative binding affinities were determined by a competitive radiometric binding assay 
using 10 nM [3H]estradiol as tracer (Amersham Biosciences, Piscataway, NJ), and purified full-
length human ERα and ERβ (PanVera/Invitrogen, Carlsbad, CA). Compounds were assayed 
from 10-4 to 10-9 M as equivalents of estradiol (20-fold lower than the molar concentration of the 
dendrimer itself). Incubations were for 18-24 h at 0 °C, and the bound compound-receptor 
complexes were absorbed onto hydroxyapatite (BioRad, Hercules, CA), and the unbound 
compound was washed away. The binding affinities are expressed as relative binding affinity 
(RBA) values, with the RBA of estradiol for both receptors being set at 100. The values given 
are the average ± range or SD for two or more independent determinations. Estradiol binds to 
ERα with a Kd of 0.2 nM and to ERβ with a Kd of 0.5 nM. 
 
4-(Di-tert-butylsilyl)benzaldehyde (24): To a solution of 4-bromobenzaldehyde dimethyl acetal 
(1.20 g, 5.20 mmol) in THF (10 mL) at -78 oC was added nBuLi (3.20 mL, 5.12 mmol, 1.6 M in 
hexanes) and left to stir at this temperature for 1 h. Triethylamine (0.86 mL, 6.26 mmol) was 
added into the reaction mixture before injecting di-tert-butylchlorosilane (3.25 g, 18.2 mmol) at   
-78 oC. The reaction was left to warm to room temperature over 10 h before being quenched 
with EtOAc (50 mL) and sat. aq. NH4Cl (50 mL). The crude reaction was further extracted with 
EtOAc (40 mL), and the combined organic extracts were dried over MgSO4 and concentrated in 
vacuo. Purification by column chromatography (Hex:EtOAc, 1:0 1:1) afforded 24 (0.84 g, 
65.0%) as a white solid. Due to air sensitivity, the product was immediately used in the next 
reaction. 1H NMR (500 MHz, CDCl3):  10.0 (s, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 
2H), 3.93 (s, 1H), 1.07 (s, 18H); 13C (126 MHz, CDCl3):  192.9, 144.7, 136.8, 136.5, 128.6, 
29.1, 19.3. 
4-(Di-tert-butylsilyl)benzoic acid (25): To a solution of 24 (0.49 g, 2.00 mmol) in acetone (10 
mL) at 0 oC was added dropwise a freshly prepared Jones reagent until a reddish color 
remained before being quenched with MeOH (10 mL). The crude reaction was extracted with 
EtOAc (2 X 50 mL) from water (50 mL), and the combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Purification by column chromatography (Hex:EtOAc,3:2) 
afforded 25 (0.45 g, 85.4%) as an off-white solid. 1H NMR (500 MHz, CDCl3): 12.50 (br, 1H), 
8.06 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 3.90 (s, 1H), 1.04 (s, 18H); 13C (126 MHz, 
CDCl3): 172.9, 143.6, 136.1, 129.8, 129.0, 29.0, 19.2; ESI (m/z): 263.1 [M + 1]. 
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2,5-Dioxopyrrolidin-1-yl 4-(di-tert-butylsilyl)benzoate (26): To a solution of 25 (0.26 g, 1.0 
mmol) in DCM (20 mL) at 0 oC was added cat. DMAP (5 mg) and N,N’-dicyclohexylcarbodiimide 
(0.21 g, 1.0 mmol). The resulting mixture was left to stir until the acid disappeared on TLC and 
quenched upon filtering off the dicyclohexyl urea. Purification by column chromatography 
(Hex:EtOAc,3:2) afforded 26 (0.35 g, 98.2%) as an off-white solid. 1H NMR (500 MHz, CDCl3): 
8.09 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 3.92 (s, 1H), 2.92 (s, 4H), 1.06 (s, 18H); 13C 
(126 MHz, CDCl3):  169.5, 145.4, 136.3, 129.3, 125.6, 29.0, 25.9, 19.2; HRMS (ESI) calc’d for 
C19H28NO4Si [M + 1] 362.1788; found 362.1788. 
2,5-Dioxopyrrolidin-1-yl 4-(acetoxydi-tert-butylsilyl)benzoate (28): To a solution of 27 (0.10 
g, 0.25 mmol) in PhH (1 mL) at room temperature was added Pd(OAc)2 (34 mg, 0.15 mmol) and 
acetic acid (15 mg, 0.25 mmol). The resulting black mixture was heated at 85 oC before being 
filtered at room temperature. Purification by column chromatography (Hex:EtOAc,3:2) afforded 
28 (85 mg, 82%) as clear oil. 1H NMR (400 MHz, CDCl3): 8.09 (d, J = 8.0 Hz, 2H), 7.72 (d, J = 
8.0 Hz, 2H), 2.89 (s, 4H), 2.34 (s, 3H), 1.08 (s, 18H); 13C (100 MHz, CDCl3): 170.1, 169.4, 
162.1, 142.6, 135.2, 129.2, 125.9, 28.1, 25.9, 23.2, 20.9; HRMS (ESI) calc’d for C21H30NO6Si [M 
+ 1] 420.1842; found 420.1840. 
2,5-dioxopyrrolidin-1-yl-4-(di-tert-butylchlorosilyl)benzoate (63): Cl2(g) was bubbled into 
CCl4 (20 mL) at -78 
oC to capture Cl2 (g) and determine the concentration as 3.5 mM. To a 
solution of 26 (0.36 g, 1.0 mmol) in DCM (0.50 mL) at -78 oC was added the Cl2 in CCl4 (0.50 
mL, 1.75 mmol). After 5 min, the solvent was evaporated with a stream of N2(g) and then 
applied onto a SiO2 prep-TLC plate, followed by elution with Hex:EtOAc (3:2) to afford 63 (0.34 
g, 85%) as an off-white solid. 1H NMR (500 MHz, CDCl3): 8.13 (d, J = 8 Hz, 2H), 7.92 (d, J = 
8.0 Hz, 2H), 2.92 (s, 4H), 1.11 (s, 18H); 13C (126 MHz, CDCl3): 169.4, 162.1, 142.3, 135.5, 
129.4, 126.2, 28.1, 25.9, 22.3. 
Di-tert-butyl(4-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)phenyl)silyl 2,5,8,11,14-pentaoxa- 
heptadecan-17-oate (35):  To a solution of 63 (40 mg, 0.10 mmol) in EtOAc (1 mL) at room 
temperature was added TEA (42 µL, 0.30 mmol) and 3-(-methyl)tetraethylene glycolyl-
propionic acid (70 mg, 0.25 mmol). The resulting mixture was left to stir at room temperature for 
4 h before being directly applied to a SiO2 prep-TLC plate. 
1H NMR (500 MHz, CDCl3): 8.10 
(d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 3.83 (t, J = 6.0 Hz, 2H), 3.66-3.61 (m, 10H), 3.56-
3.54 (m, 2H), 3.37 (s, 3H), 2.92 (s, 4), 2.79 (t, J = 6.0 Hz, 2H), 1.10 (s, 18H); 13C (126 MHz, 
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CDCl3): 170.7, 169.4, 162.2, 142.5, 135.2, 129.2, 125.9, 72.2, 70.9, 70.8, 70.8, 70.7, 67.2, 
59.3, 37.3, 28.2, 25.9, 20.9; ESI-MS [M + 1] 640.3. 
Bead-(tBu)2Si-OAc (34): To solution of Novasyn-CO2H resin (0.10 g, 0.03 mmol, 
Novabiochem, carboxy terminated PEG resin, 0.28 mmol/g) in THF (1 mL) and DCM (1 mL) 
was added 63 (27 mg, 0.07 mmol) and TEA (5.8 µL, 0.04 mmol). The reaction mixture was left 
shaking at room temperature for 1 d before being passed through a sintered glass filter and 
washed with DCM (4 X 10 mL). The resin was dried under vacuum for 1 d and used for reaction.  
 
2,5-Dioxopyrrolidin-1-yl 4-(di-tert-butylfluorosilyl)benzoate (29): To a solution of 28 (2.0 mg, 
4.8 µmol) in DCM (0.20 mL) was added TBAF.3H2O. The resulting mixture was left to stir at 
room temperature for 5 min before being passed directly through a silica gel plug to afford 29 
(1.7 mg, 95%) as a colorless liquid. 1H NMR (500 MHz, CDCl3): 7.67 (d, J = 8.0 Hz, 2H), 7.13 
(d, J = 8.0 Hz, 2H), 2.93 (s, 4H), 1.07 (s, 18H); 13C (126 MHz, CDCl3): 169.4, 167.6, 143.1, 
136.4, 134.5, 129.5, 27.4, 25.9, 20.5; 19F (470 MHz, CDCl3): -188.9; HRMS (ESI) calc’d for 
C19H27NO4SiF [M + 1] 380.1693; found 380.1689. 
5-(4-Iodophenoxy)pentan-1-amine (40): To a solution of 4-iodophenol (0.22 g, 1.0 mmol) in 
DMF (1 mL) was added K2CO3 (0.15 g, 1.1 mmol) and 5-t-butoxycarbonylamino-pentylbromide 
(0.32 g, 1.2 mmol). The resulting mixture was left to stir for 1 h at 55 oC before being quenched 
with sat. NH4Cl (40 mL). The crude reaction was extracted with EtOAc (2 X 75 mL), and the 
combined organic extracts were dried over MgSO4 and concentrated in vacuo. After 
evaporation, the crude material was redissolved in TFA-DCM (10 mL, 1:1) and left to stir at rt for 
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1 h before being quenched with sat. NaHCO3. The crude reaction was extracted with CHCl3 (2 X 
75 mL), and the combined organic extracts were dried over MgSO4 and concentrated in vacuo. 
Purification by column chromatography (CHCl3:MeOH (10%)) afforded 40 (0.22 g, 73%) as a 
white powder. 1H NMR (500 MHz, CDCl3 + CD3OD): 7.45 (d, J = 8.0 Hz, 2H), 6.58 (d, J = 8.0 
Hz, 2H), 3.84 (t, J = 8.0 Hz, 2H), 2.83 (t, J = 8.0 Hz, 2H), 1.72 (q, J = 7.0 Hz, 2H), 1.63 (q, J = 
7.0 Hz, 2H), 1.46 (q, J = 7.0 Hz, 2H); 13C (126 MHz, CDCl3 + CD3OD): 158.9, 138.3, 116.9, 
82.8, 67.6, 39.6, 28.6, 27.3, 23.1; HRMS (ESI) calc’d for C11H17NOI [M + 1] 306.0346; found 
380.0344. 
(13S,17S)-17-((4-((5-Aminopentyl)oxy)phenyl)ethynyl)-13-methyl-7,8,9,11,12,13,14,15,16, 
17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (43): To a solution of 41 (0.20 g, 
0.65 mmol) in ACN (15 mL) at room temperature was added 17α-ethynylestradiol (0.15 g, 0.5 
mmol), CuI (10 mg, 0.05 mmol), piperidine (2 mL), and PdCl2(PPh3)2 (10 mg, 0.01 mmol). The 
resulting mixture was stirred for 4 h at 55 oC before being evaporated at room temperature. The 
crude material was redissolved in EtOAc (2 X 50 mL), washed with brine, and the organic layers 
were combined and concentrated in vacuo. Purification by column chromatography 
(CHCl3:MeOH (10%)) afford 43 (0.15 g, 65%) as a pale yellow solid. 
1H NMR (500 MHz, CDCl3 
+ CD3OD): 7.33 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 2H), 6.60 (td, 
J = 8.0, 2.0 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H), 3.90 (t, J = 8.0 Hz, 2H), 0.88 (s, 3H); 13C (126 
MHz, CDCl3 + CD3OD): 159.2, 154.6, 138.2, 133.2, 131.9, 126.6, 115.6, 114.6, 113.0, 91.8, 
85.7, 80.3, 67.9, 49.9, 47.8, 43.9, 41.7, 39.8, 39.2, 33.3, 32.8, 29.9, 29.1, 27.6, 26.8, 23.5, 23.1, 
13.2; HRMS (ESI) calc’d for C31H40NO3 [M + 1] 474.3008; found 474.3017. 
Di-tert-butyl(4-((5-(4-(((13S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]phenanthren-17-yl)ethynyl)phenoxy)pentyl)carbamoyl) 
phenyl)silyl acetate (44): To a solution of 43 (20 mg, 0.04 mmol) in DMF (0.10 mL) was added 
30 (21 mg, 0.05 mmol) and TEA (7 µL, 0.05 mmol) at room temperature. The resulting mixture 
was left to stir at this temperature for 1 h before the solvent was removed under a stream of N2 
(g). Purification by prep-TLC (Hex:EtOAc, 3:2) afforded 44 (23 mg, 75%) as a white solid. 1H 
NMR (500 MHz, CDCl3):  7.70 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 
2H), 7.12 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 2H), 6.62 (dd, J = 8.0, 2.0 Hz, 1H), 6.55 (d, J = 
2.0 Hz, 1H), 3.93 (t, J = 8.0 Hz, 2H), 3.46 (q, J = 8.0 Hz, 2H), 2.81-2.74 (m, 2H), 2.40-2.29 (m, 
2H), 2.22 (s, 3H), 0.89 (s, 3H); 13C (126 MHz, CDCl3): 170.4, 167.9, 159.2, 153.9, 138.4, 
137.5, 135.6, 135.0, 133.3, 132.4, 126.7, 125.8, 115.2, 114.6, 112.9, 91.5, 96.0, 80.6, 67.9, 
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49.9, 47.8, 43.8, 40.1, 39.7, 39.3, 36.8, 33.3, 29.9, 29.6, 29.0, 28.2, 27.4, 26.7, 23.7, 23.3, 23.1, 
20.9, 13.1; HRMS (ESI) calc’d for C48H64NO6Si [M + 1] 778.4503; found 778.4521. 
4-(Di-tert-butylfluorosilyl)-N-(5-(4-(((13S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14, 
15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl)ethynyl)phenoxy)pentyl) 
benzamide (64): To a solution of 44 (5 mg, 6.4 µmol) in DCM (0.20 mL) was added TBAF.3H2O 
at room temperature. The resulting mixture was left to stir at this temperature before being 
directly applied to a SiO2 prep-TLC plate. Purification (Hex:EtOAc, 3:2) afforded 64 (4.0 mg, 
85%) as a white solid. 1H NMR (500 MHz, CDCl3): 7.76 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 8.0 
Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 8.0Hz, 2H), 6.83 (dd, J = 
8.0, 2.0 Hz, 1H), 6.58 (d, J = 2.0 Hz, 1H), 6.16 (t, J = 5.0 Hz, 1H), 3.99 (t, J = 8.0 Hz, 2H), 3.53 
(q, J = 8.0 Hz, 2H), 2.90-2.80 (m, 2H), 2.40-2.29 (m, 2H), 2.22 (s, 3H), 0.95 (s, 3H). HRMS (ESI) 
calc’d for C46H59NO3SiF [M + 1] 720.4248; found 720.4250. 
RGD-(tBu)2-Si-OAc (61): To a solution of RGD peptide (3 mg, 3.9 µmol) in DMF (0.10 mL) was 
added 30 (2 mg, 4.8 µmol) and TEA (1 µL). The resulting mixture was left to stir at room 
temperature for 15 min before being quenched upon diethyl ether addition (20 mL). The crude 
reaction was then centrifuged to afford 61 (2.8 mg) as a colorless solid. HRMS (ESI) calc’d for 
C44H65N9O10Si [M + 1] 908.4702; found 908.4709.   
RGD-(tBu)2-Si-F (65): To a solution of 61 (0.5 mg, 0.6 µmol) in DMSO (0.10 mL) was added 
TBAF.3H2O. The resulting mixture was left to stir at room temperature for 5 min before being 
quenched upon diethyl ether addition (20 mL). The crude reaction was then centrifuged to afford 
65 as a colorless solid. HRMS (ESI) calc’d for C44H63N9O8SiF [M + 1] 868.4553; found 
868.4564. 
Radiochemical Syntheses 
2,5-Dioxopyrrolidin-1-yl-4-(di-tert-butyl-[18F]fluorosilyl)benzoate (31): 51 mCi of [18F]fluoride 
in 200 µL [18O]H2O was eluted into Pyrex vial (No. 9825) and used as is without any drying step 
or added base. The syringe was rinsed with dry 500 µL ACN, and any residual activity was 
added to vial. 30 (1 mg, 2.81 µmol) was dissolved in dry 300 µL ACN, added to the reaction vial,  
the vial was capped firmly and placed in an oil bath at 105 oC for 10 minutes (RCY: 93.5%, n = 
3, SA = 3500-3800 Ci/mmol). After 10 minutes, the vial was cooled at room temperature for 2 
minutes and the solvent was injected directly into the semi-preparative HPLC. The reaction vial 
was rinsed with 3 mL of the HPLC eluting solvent (80% ACN/ 20% H2O) and the rinse solvent 
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was added to the initial reaction mixture before injecting into HPLC. The purification was carried 
by a semi-preparative HPLC system (Agilent Zorbax SB-C18, 5 µm, 9.4 X 250 mm, Product #: 
880975-202), eluting with a gradient (A: 80% ACN 20% H2O   B: 90% ACN 10% H2O over 15 
min) at a flow rate of 4 mL/min and with the UV detector set at 254 nm. The radioactive peak 
corresponding to 31 was detected at 14 to 16 min and was collected in a large glass vial. The 
collected activity was diluted with 30 mL H2O and passed through a C18 column to capture the 
activity. The collection vial was rinsed with 3 mL H2O, which was also passed through the C18 
column. A nitrogen line was connected to the cartridge to dry as best as possible residual H2O 
captured in cartridge. The activity (35.9 mCi) was eluted from the column with Et2O (0.8 mL), 
and nitrogen was used to remove the solvent. The desired compound was obtained within 45 
minutes and the radiochemical purity was assessed by HPLC and was deemed suitable for the 
next conjugation step. Non-decay corrected yield = 70.4%. Decay-corrected yield = 93.5%. 
Radio-TLC of the radiofluorination of 30 with [18F]fluoride ion after 10 minutes: 
DONG: 81520111.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 5.3% 
Region 2 ([18F]fluoroproduct; 55 mm): 94.7% 
 
Prep HPLC purification of crude material: 
Conditions: A: 80% ACN 20% H2O   B: 90% ACN 10% H2O over 15 mins, flow rate = 4 mL/ 
min, λ = 254 nm 
 
UV trace: 
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Radioactivity trace (Product: 15.2 min): 
 
 
Quality Control analysis after purification: 
Conditions: 80% ACN, 20% H2O flow rate = 2 mL/ min, λ = 254 nm 
 
UV trace used for specific activity determination (Product: 4.51 min): 
 
UV trace of co-injection with cold standard for product (31) confirmation (Product: 4.56 
min): 
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Radioactivity trace of co-injection with cold standard for product (31) confirmation and 
radiochemical purity: 
 
 
 [18F]-EDC (33): To a dried solution of 31 in 40 µL MeOH was added EDC (32, 6 nmol in 10 µL 
MeOH) at room temperature and left to stir for 10 mins (RCY: 60-98%). The reaction mixture 
was added directly to a G25 column (PD Minitrap G-25, Sephadex G-25 medium, Product #: 28-
9180-07), and 33 was eluted with PBS buffer (~1.5 mL, in 0.5 mL increments) to obtain 15.1 
mCi in ca. 80 min from end of bombardment. The isolated yield (without decay correction) was 
29.4%, with a radiochemical purity of >99% and specific activity of 2500 mCi/µmol (92.5 
GBq/µmol); Decay-corrected yield = 48.6%. 
[18F]-EDC purity determined by radio-TLC: 
DONG: 81520113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% MeOH 
Region 1 (35 mm; [18F]-EDC): 100% 
 
2,5-Dioxopyrrolidin-1-yl-4-(di-tert-butyl-[18F]fluorosilyl)benzoate (31): To a plastic vial was 
added 5.51 mCi of [18F]fluoride in 50 µL [18O]H2O, 0.1 mg K2CO3 (solution: 1 mg/50 µL in H2O), 
and 1 mg K222 (solution: 56 mg/1000 µL in ACN). The vial was placed in an oil bath at 105 
oC 
and the water was removed by azeotropic evaporation with ACN (1 mL) using a stream of 
nitrogen. This was repeated twice more with 1 mL increments of ACN until the [18F]fluoride 
source was deemed dry. The residue containing the [18F]F.K222 cryptate was redissolved in 0.3 
mL PhH (0.289 mCi stuck in vial) and transferred to a glass vial containing 30 (1 mg, 2.81 
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µmol), 0.025 mg polystyrene, and 0.2 mL PhH. The reaction was maintained at room 
temperature for 10 minutes and monitored by radio-TLC (RCY: 94.8%, n = 2). Confirmation of 
product (31) and the purity was assessed as above.  
 
Radio-TLC of the radiofluorination of 30 with [18F]fluoride ion after 10 minutes: 
DONG: 6320113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
3.0e3
6.0e3
9.0e3
1.2e4
1.5e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 3.9% 
Region 2 ([18F]fluoroproduct; 60 mm): 96.1% 
 
Radioactivity trace (Product: 3.93 min): 
 
 
2,5-Dioxopyrrolidin-1-yl-4-(di-tert-butyl-[18F]fluorosilyl)benzoate (31): To a plastic vial was 
added 1.036 mCi of [18F]fluoride in 25 µL [18O]H2O, 0.1 mg K2CO3 (solution: 1 mg/50 µL in H2O), 
and 1 mg K222 (solution: 56 mg/1000 µL in ACN). The vial was placed in an oil bath at 105 
oC 
and the water was removed by azeotropic evaporation with ACN (1 mL) using a stream of 
nitrogen. This was repeated twice more with 1 mL increments of ACN until the [18F]fluoride salt 
was deemed dry. The residue containing the [18F]F.K222 cryptate was redissolved in 0.3 mL PhH 
(0.211 mCi stuck in vial) and transferred to a glass vial containing 35 (1 mg, 1.75 µmol) and 0.2 
mL PhH. The reaction was maintained at room temperature for 2 minutes, injected onto and 
eluted from a silica gel plug (Hexanes:EtOAc, 4:3, 2 mL). Confirmation of product (31) and 
purity was assessed as above.  
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Radio-TLC of the radiofluorination of 35 with [18F]fluoride ion after 10 minutes (left) and 
after silica gel purification (right): 
DONG: 61620113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0
1000
2000
3000
4000
5000
6000
DONG: 71320113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0
1000
2000
3000
4000
5000
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 53.8% 
Region 2 ([18F]fluoroproduct; 55 mm): 46.2% 
 
Quality Control analysis after purification: 
Conditions: 80% ACN, 20% H2O flow rate = 2 mL/ min, λ = 254 nm 
 
UV trace: 
 
Radioactivity trace: 
 
 
EE2-(tBu)2-Si-
18F (45): 21.8 mCi of [18F]fluoride in 100 µL [18O]H2O was eluted into Pyrex vial 
(No. 9825) and used as is without any drying step or added base. 44 (0.3 mg, 0.3 µmol) was 
dissolved in dry 400 µL ACN, added to reaction vial, capped firmly and placed in oil bath at 105 
oC for 10 minutes (RCY: 94.4%, n = 2, SA = 2300-2500 Ci/mmol). After 10 minutes, the vial was 
cooled at room temperature for 2 minutes and then injected directly into the semi-preparative 
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HPLC. The reaction vial was rinsed with 1 mL of the HPLC eluting solvent (80% ACN/ 20% 
H2O) and added to the initial reaction mixture before injecting into HPLC. The purification was 
carried by a semi-preparative HPLC system (Agilent Zorbax SB-C18, 5 µm, 9.4 X 250 mm, 
Product #: 880975-202), eluting with a gradient (80% ACN 20% H2O) at a flow rate of 4 mL/min 
and the UV detector set at 254 nm. The radioactive peak corresponding to 45 was detected at 
22 to 24 min by the radioactivity detector and was collected in a large glass vial. The collected 
activity was diluted with 40 mL H2O and passed through a C18 column to capture the activity. 
The collection vial was rinsed with 3 mL H2O, which was also passed through the C18 column. 
A nitrogen line was connected to the cartridge to dry as best as possible residual H2O captured 
in cartridge. The activity (13.72 mCi) was eluted from the column with 2.0 mL, and nitrogen was 
used to remove the solvent. The desired compound was obtained within 45 minutes and the 
radiochemical purity was assessed by the HPLC. Non-decay corrected yield = 62.9%. Decay-
corrected yield = 84.0%. 
Radio-TLC of the radiofluorination of 44 with [18F]fluoride ion after 10 minutes: 
DONG: 22420122.R01 
0.0 15.0 30.0 45.0 60.0 75.0 90.0 mm
cnts
0
1500
3000
4500
6000
7500
9000
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 5.72% 
Region 2 ([18F]fluoroproduct; 55 mm): 94.28% 
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Prep HPLC purification of crude material: 
Conditions: 80% ACN 20% H2O, flow rate = 4 mL/ min, λ = 254 nm 
UV trace: 
 
Radioactivity trace (Product: 22.4 min): 
 
Quality control analysis after purification: 
Conditions: 100% ACN, flow rate = 1.5 mL/ min, λ = 254 nm 
 
UV trace used for specific activity determination (Product: 5.11 min): 
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UV trace of co-injection with cold standard for product (45) confirmation (Product: 5.01 
min): 
 
Radioactivity trace of co-injection with cold standard for product (45) confirmation and 
radiochemical purity (Product: 5.12 min): 
 
 
EE2-(tBu)2-Si-
18F (45): To a glass vial was added 4.55 mCi of [18F]fluoride in 15 µL [18O]H2O, 
0.2 mg K2CO3 (Solution: 1 mg/ 50 µL in H2O), and 2 mg K222 (Solution: 56 mg/ 1000 µL in ACN). 
The vial was placed in an oil bath at 105 oC and the water was removed from azeotropic 
distillation with ACN (1 mL) using a stream of nitrogen. This was repeated twice more with 1 mL 
increments of ACN until the [18F]fluoride source was deemed dry. The residue containing the 
[18F]F.K222 cryptate was redissolved in 0.3 mL DMSO containing 44 (0.3 mg, 0.39 µmol). The 
reaction was maintained at room temperature for 10 minutes and monitored by radio-TLC (RCY: 
86.8%, n = 2). Confirmation of product (45) and purity was assessed as above.  
Radio-TLC of the radiofluorination of 44 with [18F]fluoride ion after 10 minutes: 
DONG: 52120121.R01 
0.0 15.0 30.0 45.0 60.0 75.0 90.0 mm
cnts
0
1000
2000
3000
4000
5000
6000
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 14.53% 
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Region 2 ([18F]fluoroproduct; 65 mm): 85.47% 
 
RGD-(tBu)2-Si-
18F (62): To a glass vial was added 19.75 mCi of [18F]fluoride in 15 µL [18O]H2O, 
0.1 mg K2CO3 (Solution: 1 mg/ 50 µL in H2O), and 1 mg K222 (Solution: 56 mg/ 1000 µL in ACN). 
The vial was placed in an oil bath at 105 oC and the water was removed by azeotropic 
distillation with ACN (1 mL) using a stream of nitrogen. This was repeated twice more with 1 mL 
increments of ACN until the [18F]fluoride source was deemed dry. The residue containing the 
[18F]F.K222 cryptate was redissolved in 0.3 mL DMSO containing 61 (0.3 mg, 0.33 µmol), left at 
room temperature for 15 minutes (RCY: 85.7%, n = 2) and then injected directly into the HPLC. 
The reaction vial was rinsed with 3 mL of the HPLC eluting solvent (45% ACN/ 55% H2O/ 0.1% 
TFA) and added to the initial reaction mixture before injecting into HPLC. The purification was 
carried by a semi-preparative HPLC system (Agilent Zorbax SB-C18, 5 µm, 9.4 X 250 mm, 
Product #: 880975-202), eluting with a gradient (45% ACN/ 55% H2O/ 0.1% TFA) at a flow rate 
of 4 mL/min and the UV detector set at 254 nm. The radioactive peak corresponding to 62 was 
detected at 18 to 20 minutes by the radioactivity detector and was collected in a large glass vial. 
The collected activity was diluted with 30 mL H2O and passed through a C18 column to capture 
the activity. The collection vial was rinsed with 3 mL H2O, which was also passed through the 
C18 column. A nitrogen line was connected to the cartridge to dry as best as possible residual 
H2O captured in cartridge. The activity (4.05 mCi) was eluted from the column with 2 mL EtOH, 
and nitrogen was used to remove the solvent. The desired compound was obtained within 45 
minutes and the radiochemical purity was assessed by the HPLC. Non-decay corrected yield = 
20.5%. Decay-corrected yield = 27.2%. 
Radio-TLC of the radiofluorination of 61 with [18F]fluoride ion after 15 minutes: 
DONG: 52420126.R01 
0.0 15.0 30.0 45.0 60.0 75.0 90.0 mm
cnts
0
500
1000
1500
2000
2500
3000
 
TLC Eluting Conditions: 45% ACN/ 55% H2O/ 0.1% TFA; C18 plate 
Region 1 (unreacted [18F]fluoride; 35 mm): 11.65% 
Region 2 ([18F]fluoroproduct; 45 mm): 88.35% 
Prep HPLC purification of crude material: 
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Conditions: 45% ACN 55% H2O 0.1% TFA, flow rate = 3 mL/ min, λ = 254 nm 
UV trace (Product: 5.11 min): 
 
Radioactivity trace: 
 
 
Quality control analysis after purification: 
Conditions: 60% ACN, 40% H2O flow rate = 1.5 mL/ min, λ = 254 nm 
 
UV trace used for specific activity determination (Product: 12.5 min): 
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UV trace of co-injection with cold standard for product (62) confirmation (Product: 4.61 
min): 
 
Radioactivity trace of co-injection with cold standard for product (62) confirmation and 
radiochemical purity (Product: 4.72 min): 
 
 
RGD-(tBu)2-Si-
18F (62): 2.31 mCi of [18F]fluoride in 20 µL [18O]H2O was eluted into Pyrex vial 
(No. 9825) and used as is without any drying step or added base. 61 (0.3 mg, 0.33 µmol) was 
dissolved in dry 200 µL ACN, 200 µL MeOH and 30 µL H2O added to reaction vial, capped 
firmly and placed in oil bath at 105 oC. The reaction was maintained at this temperature for 10 
minutes and monitored by radio-TLC (RCY: 81.1%, n = 2). Confirmation of product (62) and 
purity was assessed as above.  
Radio-TLC of the radiofluorination of 61 with [18F]fluoride ion after 10 minutes: 
DONG: 52520125.R01 
0.0 15.0 30.0 45.0 60.0 75.0 90.0 mm
cnts
0
100
200
300
400
 
TLC Eluting Conditions: 45% ACN/ 55% H2O/ 0.1% TFA; C18 plate 
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Region 1 (unreacted [18F]fluoride; 35 mm): 18.19% 
Region 2 ([18F]fluoroproduct; 60 mm): 81.81% 
 
Radio-TLC of the radiofluorination of 59 with [18F]fluoride ion after 10 minutes: 
DONG: 2212012E.R01 
0.0 15.0 30.0 45.0 60.0 75.0 90.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 5.69% 
Region 2 ([18F]fluoroproduct; 65 mm): 94.31% 
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 CHAPTER 3 
A NEW DIMENSION IN SELECTIVE ESTROGEN ACTION: A VASCULAR-PROTECTING 
ESTROGEN DENDRIMER CONJUGATE SHOWS SELECTIVE RECEPTOR-MEDIATED 
UPTAKE IN THE HEART AND VASCULATURE 
I. INTRODUCTION 
A. Background 
Discrepancies in the incidence of heart disease between males and females, and in pre- 
vs. postmenopausal women, illustrate the significant beneficial effect of estrogen on the 
cardiovascular system.1,2 Until recently, the cardioprotective effects of estrogen were originally 
attributed to its effects on serum lipid concentrations by modulating the hepatic expression of 
apoprotein genes.3 Large, randomized trials have revealed similar conclusions, documenting 
estrogen’s ability to increase the beneficial high-density lipoprotein (HDL) serum concentrations 
while decreasing harmful low-density lipoprotein (LDL) concentrations.4 Maintaining a proper 
balance between the two concentrations have been shown to be critical in preserving vascular 
health, with subsequent studies revealing that even minor disruptions can offset key signaling 
pathways within these tissues and eventually lead to the onset of atherosclerosis.5-7 However, 
only one-third of the observed clinical benefits of estrogen therapy are attributed to the lipid 
concentration alterations,3 suggesting a more direct interaction between estrogen and blood 
vessels in vascular health maintenance. Consequently, the estrogen receptor (ER) in the 
vasculature is now considered an important target for the beneficial actions of estrogens. 
B. Estrogen Receptor Signaling 
The physiological effects of both endogenous and synthetic estrogens are mediated 
through two estrogen receptors, ERα and ERβ, which are both members of the nuclear receptor 
superfamily of ligand-regulated transcription factors.8 The receptors are composed of five 
domains, each with a specific function including DNA and ligand binding, transcriptional 
activation and repression, and receptor dimerization.9 Upon ligand binding, the receptor 
undergoes major conformational changes to facilitate ER dimerization, binding to estrogen 
response elements (EREs) on target genes, and recruitment of coregulator proteins, thereby 
altering the expression of specific genes within the nucleus.10 ERs can also modulate 
transcription in the absence of ligand binding through protein-protein interactions with other 
transcription factors.11 However, many of the cardioprotective effects attributed to estrogen have 
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been largely mediated through an extranuclear signaling pathway with membrane-associated 
ERs.  
The estrogen receptor has traditionally been conceived to function exclusively through 
nuclear activation (“genomic pathway”).12 More recently, emerging data has identified an 
additional extranuclear role, capable of initiating diverse nongenomic cellular responses via 
activation of plasma membrane associated ERs (“nongenomic pathway”) (Figure 3.1).13 In 
contrast to the classical genomic pathway of estrogen action (i.e., several hours to days), these 
nongenomic responses are often extremely rapid, with biological effects typically observed 
within seconds to minutes. The rapid nature of this response system assisted in its initial 
discovery in 196714 when cyclic adenosine monophosphate (cAMP) levels were observed to 
significantly increase within 15 seconds upon intravenous administration of physiological 
amounts of 17β-estradiol (E2) and was further supported in other studies demonstrating rapid 
calcium responses to E2 in endometrial cells.
15 Compelling evidence now confirms the existence 
of the nongenomic pathway: rapid signaling has been identified in many different cell types 
including oocytes, osteoblasts, osteoclasts, breast cancer cells, adipocytes and endothelial 
cells, where it mediates ion fluxes, kinase cascades and enzyme activities.16-22 However, 
because of the difficulty in selectively activating the nongenomic over the genomic pathway (i.e., 
traditional estrogens are effective at stimulating both pathways), the extent to which the 
biological effects of estrogen are attributed to the nongenomic pathway and whether this 
pathway is operative and biologically relevant in vivo have remained unknown. Consequently, 
the mechanism of action and the cellular functions of these extranuclear ERs are now being 
defined, and this has since become an active area of investigation.13 
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Figure 3.1. Schematic depicting two mechanisms of estrogen signaling: nuclear, or genomic, 
signaling (green) and extranuclear, or nongenomic, signaling (yellow). 
 
C. Nuclear and Membrane-Associated ERs 
 Although it has yet to be sequenced, it appears membrane ERs are structurally very 
similar to nuclear ERs: immunohistochemistry studies shared the same epitope homology as 
nuclear ERα23 and the expression of ERα and ERβ in ER null cells resulted in the detection of 
both nuclear and membrane-localized pools of ERs.24 Furthermore, analysis of double knockout 
ERα/ERβ mice (DERKO) did not reveal a functional ER protein at the cell surface.25 Moreover, 
both nuclear and membrane-initiated signaling were eliminated in the presence of either small 
interfering RNA or antisense oligonucleotides directed against the proteins.25-27 Lastly, and 
perhaps the most convincing, membrane-extracted ERs displayed an identical mass to nuclear 
ERs by mass spectrometry and identical binding affinities for the endogenous ligand, 17β-
estradiol.27  
D. The Estrogen Receptor and the Cardiovascular System 
The many clinical and basic science investigations have demonstrated estrogen’s impact 
on cardiovascular health. In animal studies, estrogen has been shown to stimulate endothelial 
cell growth following denudation,28 inhibit the proliferation of vascular smooth-muscle cells29,30 
and attenuate arterial lesion sizes,31,32 all of which are key to maintaining the integrity of the 
blood vessel. Even minor disruptions to the wall can lead to vascular disease.33 Moreover, 
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additional investigations in specialized normolipidemic and hypercholesterolemic animal models 
revealed no effect of estrogen treatment on circulating lipid concentrations, further 
demonstrating the direct relationship between estrogen and the blood vessel wall.29,34,35   
Blood vessels are composed of smooth-muscle cells and an endothelial cell lining, with 
both ER subtypes being identified within each, as well as in myocardial cells.36 Although the 
absolute level of expression of ERα and ERβ is not well characterized, it is known that both 
endothelial and smooth muscle cells bind estrogen with high affinity.3 Upon binding, the clinical 
benefits of estrogen are at least partially related to its capacity to enhance the bioavailability of 
the powerful vasodilator nitric oxide (NO) through stimulation of endothelial nitric oxide synthase 
(eNOS).37,38 NO, produced from the conversion of L-arginine to L-citrulline by eNOS, is well-
known to provide significant benefits to the vasculature through regulation of blood pressure and 
platelet aggregation while maintaining the structural integrity of the vessel wall through the 
promotion of endothelial cell growth and migration, and attenuation of smooth muscle cell 
growth and migration.28,39,40  
Cell-based studies have further established the intricate relationship between the 
estrogen receptor and eNOS. In cultured endothelial cells, physiological concentrations of E2 
caused eNOS activation within 15 minutes of exposure to the hormone, which is consistent with 
studies in arteries, and the response is blunted by ER antagonism, suggesting an ER-mediated 
process.41,42 Furthermore, overexpression of ERα within these cells resulted in an enhancement 
of NO production. In COS-7 cells, which do not constitutively express ERα or eNOS, NO 
production could only be detected after cotransfection of ERα and eNOS cDNAs.5  
Vascular benefits of NO production are now well-documented, and it is becoming clear 
that estrogen binding with membrane-associated ERs and subsequent stimulation of eNOS play 
a key role in blood vessel health and have since provided the rationale for hormone 
replacement therapy (HRT) in cardiovascular maintenance.43 
E. Estrogen, Heart Disease, and Hormone Replacement Therapy 
Before menopause, the main endogenously derived circulating estrogen is 17β-estradiol, 
and depending on the age and stage of the menstrual cycle of a female, concentrations of this 
hormone can vary considerably: serum estradiol concentrations are low in preadolescent girls, 
ranges from 100 pg/mL in the follicular phase to 600 pg/mL at the time of ovulation in 
premenopausal women, and after menopause, declines to levels seen in men of similar age (2-
5 pg/mL).44 Correlation of serum estradiol concentrations to the incidence of heart disease in 
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women is quite striking: the incidence of heart disease is low in premenopausal women, 
comparable to those seen in men, steadily rises in postmenopausal women, and reverts back to 
premenopausal levels with estrogen replacement therapy.44 Such studies have demonstrated 
the significance of estrogen within the cardiovascular system and the need to maintain optimal 
serum estrogen concentrations to decrease the risk of developing heart disease.   
Unfortunately, a liability associated with estrogen administration for the maintenance of 
cardiovascular health is the global agonist effects estrogen has on the many and diverse 
estrogen target tissues. The beneficial effects in the vasculature can come at the expense of 
overstimulation of other estrogen-sensitive tissues, such as breast and uterus, which increase 
the risks of cancers in these tissues, as revealed by recent hormone replacement therapy (HRT) 
studies.45,46 Much effort has gone into the development of estrogens that have a more favorable 
profile of beneficial vs. detrimental effects in different target tissues.47,48 Such compounds, 
termed selective estrogen receptor modulators (SERMs), have a selectivity based on differential 
interaction with coregulator proteins that mediate the nuclear action of the ER, and though they 
represent an therapeutic advance, their desired beneficial agonist effects rarely match those of 
estradiol itself. The development of estrogens that selectively stimulate the extra-nuclear 
pathway, in the absence of nuclear activation, would provide intriguing and potentially safer 
alternatives to the estrogens and SERMs currently used in HRT regimens that non-selectively 
target both pathways.  
F. The Estrogen Dendrimer Conjugate (EDC) 
Currently, the only successful strategy to achieve selective activation of the extra-
nuclear pathway of estrogen action has been to tether estrogens to a large molecule that 
prevents its nuclear uptake. The most widely used are various commercial preparations of a 
conjugate between estradiol and bovine serum albumin (E2-BSA)
49-51 or, to a lesser extent, 
peroxidase (E2-peroxidase).
52-54 Numerous studies in cell culture have shown that E2-BSA is 
able to activate kinase cascades and other rapid cellular responses that are presumed to be 
mediated by extra-nuclear ER action. Nevertheless, E2-BSA has proved to be a troublesome 
reagent: its affinity for ER is limited and instability in the covalent link between estrogen and 
BSA releases active estrogens;55 furthermore, the protein nature of BSA makes it unsuitable for 
in vivo work. 
Recently, we reengineered such hormone-macromolecule conjugates by designing a 
more structurally robust system called the estrogen dendrimer conjugate (1, EDC, Figure 3.2).56 
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The EDC is constructed through the use of a high affinity estrogen, ethynyl estradiol, derivatized 
at the 17α-position of the steroid, a position known to tolerate large substitution and still retain 
high affinity for ER.57 The estrogen is attached through a short linker, that has been shown not 
to affect its binding affinity, to a large, positively charged, non-biodegradable generation-6 (G6) 
poly(amido)amine (PAMAM) dendrimer. Key to the design is the use of hydrolytically stable 
linkages between the estrogen and PAMAM dendrimer as any release of the estrogen would 
stimulate the undesired genomic pathway and reduce the selectivity for the preferred 
nongenomic pathway. 
 
Figure 3.2. Structure of the Estrogen Dendrimer Conjugate (EDC). 
 
 The synthesis of EDC is straightforward (Scheme 3.1).56 The benzaldehyde derivative 
(3) can be rapidly accessed through a Sonogashira reaction between commercially available 
ethynyl estradiol (2) and 4-bromobenzaldehyde and the degree of dendrimer substitution by the 
estrogen can be controlled simply by adjusting the molar ratios of aldehyde (3) to dendrimer (4) 
which in our case, 20 of the free 256 amines present on the PAMAM periphery were utilized for 
derivatization. In MeOH, imine formation was spontaneous; reduction with borohydride was 
quantitative, and the reaction could be monitored by aldehyde peak disappearance in the 1H 
NMR spectrum. The resulting EDC (1) then underwent 5 extensive rounds of rigorous 
purification to remove any unreacted estrogen, with the final ligand-to-dendrimer being 
determined by matrix-assisted laser desorption ionization (MALDI) which reflected the reaction 
stoichiometry.  
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Scheme 3.1. Synthesis of EDC (1).56 
 
 An attractive feature of the PAMAM dendrimer system is that its periphery can be further 
functionalized with fluorophores to follow the cellular distribution of EDC with confocal 
microscopy (Figure 3.3). In MCF-7 cells, a tetramethylrhodamine-labeled EDC (TMR-EDC) 
showed bright fluorescent speckles at the plasma membrane with no accumulation in the nuclei, 
which were stained blue. Replication of the same experiment with a 30-fold excess of estradiol 
as a blocking agent revealed a marked suppression in cellular fluorescence, suggesting the 
uptake in the previous experiment was most likely an ER-mediated process.58   
 
Figure 3.3. Fluorescence photomicrographs of MCF-7 cells treated with 100 nM (estrogen 
equivalents) TMR-EDC (A) or together with a 30-fold excess of E2 (B) after 45 minutes. Red 
fluorescence is from TMR-EDC; blue staining with 4’,6-diamidino-2-phenylindole indicates 
the nucleus.58  
 
 A key aspect of these types of estrogens is their ability to selectively activate the 
nongenomic pathway over the genomic pathway; thus, they can be used to understand the 
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biological significance of this pathway and to test whether it is a viable target for therapy. From 
the confocal microscopy studies, one would expect that an ER ligand that remains outside the 
nucleus, because of its size and charge, would have an attenuated capacity to activate nuclear 
activities. To assess genomic stimulation (Figure 3.4), the relative potency of E2 and EDC to 
regulate two known endogenous estrogen responsive genes (pS2 and WISP2)59 was evaluated 
in ER+ MCF-7 cells.58 Dose-response studies revealed a strong and pronounced stimulation by 
estradiol at very low concentrations (10-11-10-12 M), while in contrast, stimulation with EDC was 
only seen at much higher concentrations (10-7 M). To investigate the effectiveness of EDC in 
activating the nongenomic pathway (Figure 3.5), the time course and dose response of 
extracellular signal-regulated kinase (ERK) was monitored in MCF-7 cells, because this cell line 
has been shown to exhibit strong nongenomic responses to E2. In the presence of EDC at low 
concentrations (10-11-10-12 M), a very robust stimulation in the phosphorylation of ERK was 
observed, even more so than when compared to estradiol itself.58 These studies demonstrated 
the effectiveness of EDC in selectively stimulating the nongenomic pathway, in the absence of 
nuclear activation, and now serves as an ideal biological tool to probe the complexities of 
estrogen action in the context of both pathways. 
 
Figure 3.4. Regulation of estrogen-responsive genes pS2 (A) and WISP2 (B) in MCF-7/Her 2 
cells treated with E2, EDC, or empty dendrimer (Dend) for 8 hours at the indicated 
concentration.58 
 
 
Figure 3.5. Stimulation of ERK phosphorylation in MCF-7/Her 2 cells by E2 (10 nM) and EDC 
(10 nM estrogen equivalents) for 20 minutes.58  
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Although the desired selectivity between the two pathways was obtained, it still remained 
unknown whether the nongenomic pathway was operative in vivo. PAMAM dendrimers are 
commonly utilized as drug delivery systems60,61 and EDC would assume a similar role in 
interrogating the significance of extranuclear estrogen actions in vivo within the context of the 
cardiovascular system. In collaboration with Phil Shaul at UT Southwestern Medical Center,62 
the cardioprotective effects of EDC were assessed in a carotid injury mouse model, in which a 
mouse carotid artery underwent electric injury and the extent of repair was evaluated after three 
day treatment with E2 and EDC. Quite strikingly, as shown in Figure 3.6, EDC is nearly as 
effective at repairing the injury to the arterial wall, as depicted by the decrease in blue color as 
compared to the controls, vehicle or empty dendrimer.  
 
Figure 3.6. Non-nuclear ER signaling promotes endothelial monolayer in vivo in ovariectomized 
female mice following perivascular electric injury. Left: Vehicle versus E2 3 day treatment 
after injury. Right: Empty dendrimer versus EDC 3 day treatment after injury. Blue color 
indicates the extent of injury.62  
 
However, in order for EDC to possess any clinical value, it would need to retain these 
exceptional cardioprotective properties while having minimal effect on other estrogen-sensitive 
tissues (i.e., breast, uterus). This is exactly the problem with traditional HRT and the 
nonselective nature of the administered estrogens. Since the receptor is widely distributed 
within both males and females, the beneficial effects in one tissue, such as the vasculature in 
this case, can come at the expense of overstimulation in others and increase the risks of certain 
cancers.45,63 Selective agents for protection of the cardiovasculature, similar to those seen with 
bone-selective SERMs (i.e., raloxifene) used in the treatment of osteoporosis, are still in need of 
further development.64  
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Remarkably, EDC possesses exceptional selectivity in vivo: investigations in the 
stimulations of uterotrophic responses and MCF-7 cell breast cancer xenograft growth, which 
readily responded to E2 through genomic stimulation, revealed no stimulation by EDC (Figure 
3.7). As a result, the observed benefits are largely the result of the ability of EDC to selectively 
stimulate the nongenomic response, which is sufficient to provide protection of the 
cardiovascular tissue and more importantly, its inability stimulate estrogen sensitive tissues (i.e., 
breast, uterus) because of its attenuated capacity to activate the genomic pathway. These 
findings are quite significant and should have a tremendous impact on the development of ER-
targeted hormone replacement agents in the future. 
 
Figure 3.7. Non-nuclear ER signaling does not stimulate an uterotrophic response or breast 
cancer cell tumor growth. (A) Uteri from mice treated for 24 days with vehicle, E2, empty 
dendrimer, or EDC. (B) Evaluation of uterine wet weight to body weight ratios. (C) Extended 
uterotrophic study with ER antagonism, ICI. (E) MCF-7 cell tumor xenografts after 21 day 
treatment with E2, vehicle, empty dendrimer or EDC.
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II. CONCLUDING INTRODUCTORY REMARKS 
Overall, EDC has been found to retain good affinity for ER, but because of its size and 
charge, it is excluded from the nucleus. Consequently, EDC was found to possess minimal 
capacity for stimulating genomic activities, but a number of studies from our lab58,65,66 and 
others67-69 have shown that EDC effectively and selectively activates rapid extra-nuclear ER 
signaling in a variety of cellular response systems. More significantly, recent studies have 
demonstrated in two in vivo animal models that EDC provides cardiovascular protection 
equivalent to that of estradiol, yet unlike estradiol, does so without stimulating uterine growth or 
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breast tumor proliferation.62 These findings established that action only through the extra-
nuclear ER pathway, as stimulated by EDC, is sufficient to provide remarkably selective 
cardiovascular benefit, thereby avoiding undesired effects on other estrogen-responsive tissues. 
To investigate further the basis for the remarkable target-tissue selective activity of EDC, 
we have labeled this conjugate with fluorine-18 (F-18) and examined its biodistribution in vivo. 
We find that [18F]-EDC (8) is cleared rapidly from blood, and as expected for a particulate 
species, much activity becomes sequestered in spleen and liver. Nevertheless, significant 
uptake and retention are found in the heart and aorta, but by contrast, essentially no [18F]-EDC 
is taken up by the uterus. By comparing the uptake of [18F]-EDC with that of a structurally 
related analogue with little affinity for ER ([18F]-XDC, 21), we found that uptake in the heart and 
aorta appears to depend on the ER binding activity of EDC. These findings suggest that the 
selective cardiovascular protective effect of EDC is the result of two factors, one mechanistic 
(selective stimulation of the extra-nuclear pathway of ER action) and one pharmacokinetic 
(selective accumulation of EDC in vascular targets), and it points to a new dimension for 
extending the selective, potentially beneficial actions of estrogens. 
 
III. RESULTS 
A. Synthesis of [18F]-EDC 
EDC (1) was prepared as described previously;56 the degree of EE2 substitution was an 
average of 18 steroid molecules per dendrimer molecule, with a polydispersity index of 1.02, as 
determined by MALDI-TOF MS analysis. EDC was radiolabeled with fluorine-18 using two 
complementary methods based N-hydroxysuccinimide ester chemistry with either Si-18F or Cu-
click approaches. Both approaches utilized an indirect, multi-step sequence where fluorine-18 
was first introduced into small adaptor compounds and then appended to EDC through 
hydrolytically stable amide bonds. A direct approach was not attempted due to the inherent 
difficulty associated with radiolabeling a large nanoparticle such as EDC in a one-step process.  
The Si-18F approach has proved to be highly useful (Scheme 3.2). First and foremost, 
the aqueous [18F]fluoride source from the cyclotron can be used as an off-the-bench reagent, 
without having to resort to the tedious and time-consuming drying step required for classical C-
18F chemistry and the formation of a dried [18F]fluoride salt. A simple dilution of the [18F]F-
H2[
18O]O water with acetonitrile, dissolution of the NHS-silyl acetate (6), and heating at 105 oC 
for 10 minutes yielded 7 in high RCYs. After cooling to room temperature, the reaction mixture, 
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without any extraction, is injected directly into the HPLC to afford 7 in high radiochemical purity 
(>99%) and specific activity (3500-3800 Ci/mmol). The purified [18F]fluorosilane product can be 
readily appended to EDC (1) within 10 minutes, albeit in varying RCYs of 8 (60-98%). The 
sources of this variability have been difficult to ascertain, but appear to be dependent on the 
amount of H2O of 7 after purification, pH of the EDC solution, and precipitation issues from 
overconjugation. Nevertheless, the attractiveness of the approach lies in the high efficiency of 
the radiofluorination reaction: beginning with 50 milliCuries (mCi), the reaction sequence can 
reliably afford 15 mCi of the desired compound after 2 hours. This is a highly attractive feature, 
especially when conducting time-sensitive animal studies that are dependent on obtaining 
sufficient amounts of activity of the radiotracer at a specified time. 
 
Scheme 3.2. Radiosynthesis of [18F]-EDC (8) with the silyl acetate approach. (a) [18F]F-
H2[
18O]O, ACN, 105 oC, 10 min; (b) 1, 7, MeOH, rt, 10 min.  
 
 Of the available “click chemistry,” the most commonly used click-reaction is the Cu(I) 
catalyzed 1,3-dipolar cycloaddition of terminal alkynes with azides, called the Huisgen reaction, 
yielding 1,4-disubstitued 1,2,3-triazoles under mild conditions.70 The popularity of the reaction is 
attributed to its high efficiency, absence of protecting group protocols, chemical inertness of the 
azides and alkynes towards biological molecules and formation of an extremely stable triazole 
moiety, and it has since been used in numerous applications,71 but only recently have 
application in 18F-labelling been reported.72 Our approach takes advantage of the rapid and 
efficient manner of these reactions through a three-step sequence (Scheme 3.3): displacement 
of a tosylate to form the [18F]fluoroazide (10), Cu-mediated click reaction to afford triazole 12, 
and a final conjugation to EDC. Although an additional step is needed and lowered purified [18F]-
EDC-Click (13) activities, this approach has its own merits. The sequence still only requires one 
HPLC purification step, since the [18F]fluoroazide 10 can be readily distilled out of the reaction 
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mixture in high radiochemical purity. Due to the chemoselective nature of the click reaction, the 
next step can be performed directly, in the presence of other distilled mass from the previous 
step, without the need for HPLC purification. Consequently, sufficient amounts of 13 can be 
readily obtained in high SA (800-2600 Ci/mmol). 
 
Scheme 3.3. Radiosynthesis of [18F]-EDC-Click (13) with copper click approach. (a) K[18F]F, 
K2CO3, K222, ACN, 88 
oC, 5 minutes; (b) CuSO4, sodium ascorbate, BPDS, DMF, H2O, rt, 5 
minutes; (c) 1, 12, MeOH, rt, 10 minutes. 
 
To investigate non ER-mediated uptake of the EDC, we also prepared and radiolabeled 
an ER non-binding analogue of EDC, termed XDC (20, Scheme 3.5), in which the EE2 hormone 
was replaced by a biphenyl methyl ether analogue. We modified our original high affinity 
estrogen by blocking the energetically crucial hydrogen bond between A-ring phenol of estradiol 
and polar residues in the ER ligand binding pocket through methyl ether formation and further 
by flanking it with two ortho methyl groups. These changes, together with deletion of the B-ring, 
afforded 18 with very low ER binding affinity (<0.001% relative to estradiol, 100%), and after it 
was conjugated to the G6 PAMAM dendrimer, we found that XDC had an ER binding affinity 
that was more than 45-fold less than that of EDC (0.083% for XDC and 3.8% for EDC). 
The non-binding estrogen was rapidly accessed through a three-step sequence 
(Scheme 3.4) involving a Suzuki coupling between boronic acid 14 and bromide 15, Grignard 
addition to the ketone 16, and a Sonogashira reaction to afford the desired compound (18). This 
analogue (18) was designed to be matched with the original estrogen (7) in EDC in terms of 
lipophilicity (Figure 3.8: cLogPo/w 5.98 for 18 vs 5.53 for 19) to allow comparison of the two 
particles based solely on the affinity of the attached estrogens for ER and not from the 
differences in LogP, which can markedly perturb in vivo biodistributions.  
90 
 
 
Scheme 3.4. Synthesis of a non-binding estrogen (18). (a) Na2CO3, Pd(PPh3)4, DMF, 80 
oC; (b)  
TMSC CMgBr, THF, -78 oC; (c) 4-iodobenzaldehyde, piperidine, CuI, Pd(Cl2)(PPh3)4, THF, 
reflux. 
 
 
Figure 3.8. Structures for LogPo/w determinations: 5.98 for 18 vs 5.53 for 19.  
 
Under conditions identical to those previously used for [18F]-EDC, XDC (Scheme 3.5) 
was radiolabeled with our [18F]fluorosilane system in high radiochemical purity (>99%) and 
specific activity (1800 mCi/µmol; 67 GBq/µmol). The Si-18F approach was re-used in this system 
after 19F-NMR studies were inconclusive on the cause of defluorination and since the 
defluorination did not affect the biodistribution, it was the preferred method of choice since it 
was technically simpler and afforded EDC in higher specific activities. 
 
Scheme 3.5. Radiochemical synthesis of [18F]-XDC (21). (a) MeOH, rt, 10 min. 
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B. Biodistribution of [18F]-EDC 
After IV injection, the tissue distribution of [18F]-EDC (8) in adult female C57BL6 mice 
was determined at 30 minutes and 2 hour post injection, and tissue activity, expressed as the 
percent injected dose per gram of tissue, is shown in Figure 3.9. The highest initial uptake 
(%ID/g) of [18F]-EDC was localized in the spleen, followed by high levels in the liver and lung, 
consistent with the expected recognition and binding of an unprotected particle by opsonins and 
subsequent sequestration by the mononuclear phagocyte system (MPS) active in these 
tissues.73 In kidney and muscle, [18F]-EDC exhibited low uptake, with blood clearance occurring 
rapidly over the time course of the experiment, as relatively low activity was present at the 30 
minutes and clearance was almost complete within 2 hours.  
Strikingly, [18F]-EDC showed rapid and persistent accumulation in two presumed 
cardiovascular target tissues, heart and aorta. At 30 minutes, the %ID/g was 19.7 in the heart 
and 8.15 in the abdominal aorta, and unlike activity in blood, activity in these target tissues 
persisted at 2 hours with minimal clearance. In contrast to traditional 18F-labelled estrogens that 
often exhibit high uterine uptake in mice (10-15 %ID/g),74 [18F]-EDC shows minimal uptake in 
the uterus, most likely due to its particulate nature, which limits its access to the major pool of 
ERs in the nucleus. Taken together and outside of uptake in organs with high MPS activity, the 
tissue biodistribution of [18F]-EDC correlates well with the pattern of selective in vivo activity that 
we have reported.62 
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Figure 3.9. Biodistribution of [18F]-EDC in adult female C57BL6 mice (%ID/g). Mice were 
injected with 15-20 µCi of [18F]-EDC, and tissue distribution, determined at 30 minutes and 2 
hours, is expressed as % of injected dose per gram tissue (%ID/g). 
 
Although the EDC clearly is being rapidly sequestered by particle clearance organs, it is 
notable that even small molecule estrogens are rapidly lost from blood, so the blood clearance 
and tissue exposure is actually not all that different. The only difference resides in where the 
tracer becomes concentrated: small molecules typically clear through the liver and kidneys and 
are eliminated, but the EDCs become sequestered in the lung, liver, and spleen. The only 
legitimate concern from the initial biodistribution was the possible hydrolysis of the Si-18F bond 
as indicated by the elevated bone uptake (13% and 18% ID/organ at 0.5 and 2 hours, 
respectively). With the presence of numerous potential nucleophiles on the periphery of the 
PAMAM, the likelihood of amine attack on the silicon atom is not improbable, but did warrant 
further investigations with 19F NMR studies before continuing with this approach and we 
switched to the Cu-click strategy at this time. 
Following the same animal protocol used previously and the radiolabeling method in 
Scheme 3.2, the Si-18F and C-18F-labelled (13, Figure 3.10) EDCs showed remarkably similar 
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biodistributions: high uptake in the lung, liver and spleen, low uptake in the kidney, muscle, and 
uterus, and elevated activities in the cardiovascular tissues, heart and abdominal aorta. 
However, with the Si-18F labeled EDC, bone uptake was 13% and 18% ID/organ in female mice 
at 0.5 and 2 hours, but was only 2.8% and 2.5%ID/organ with the [18F]-EDC-Click material, 
suggesting that with time the Si-18F material is undergoing some progressive defluorination. 
Besides this unanticipated occurrence, loss of fluoride from the Si-18F material was relatively 
minor and did not perturb the overall distribution. This is not too surprising since the level of 
substitution from the 18F-conjugation is at most three appended groups and as a result, one 
would expect the conjugation not to alter the physical properties of the high molecular weight 
EDC (MW: 55,000) to any significant extent. 
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Figure 3.10.  Biodistribution of [18F]-EDC-Click (13) in adult female C57BL6 mice (%ID/g). Mice 
were injected with 15-20 µCi of [18F]-EDC-Click, and tissue distribution, determined at 30 
minutes and 2 hours, is expressed as % of injected dose per gram tissue (%ID/g). 
 
Blocking studies are often performed to validate receptor-mediated uptake. Typically, 
these studies involve two sets of injections. The first injection attempts to saturate the receptor 
binding sites with a large excess of either a chemically identical cold standard (only differs in the 
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isotope present) or a compound that is known to have high affinity for the receptor (i.e., E2 for 
ER) and the second injection introduces the radiotracer. Our strategy focused on saturating the 
available ER binding sites with E2 or unlabeled EDC to impede uptake in the heart and 
abdominal aorta in an attempt to confirm the observed elevated uptake was indeed ER-
mediated. 
Initially, we attempted to block the uptake of [18F]-EDC-Click (13) in the heart and aorta 
by co-administration of an excess of unlabeled estradiol (20-100-fold excess), but in both cases, 
the blocking was unsuccessful since high uptake was still seen in the heart and aorta. We 
believe that the lack of competition by estradiol represents simply its ineffectiveness as a 
monovalent ligand in competing with the multivalent ligand character of the EDC. Only when we 
used a 500-fold excess of unlabeled EDC could we effectively block the uptake, as shown in 
Figure 3.11. This study involved three different animal groups: a high dose, low dose, and EDC 
block group. The high dose group (30 µCi) served as a standard to confirm a similar 
biodistribution as the previous two cases and thus enables the blocking study results to be 
correlated to each study from before. The low dose group (3-5 µCi) was designed to ensure 
complete blockage of uptake if indeed it is ER-mediated. The EDC block involved a 500-fold 
excess of EDC, which equates to around 40 µg of material; this dose was injected into the 
mouse before any of the low dose was injected. At 2 hours post injection (Figure 3.11), the 
highest doses were concentrated in the liver and spleen but more importantly, when the EDC 
block was administered against the low dose, there is a significant reduction in EDC uptake 
within the heart and abdominal aorta, indicating the elevated uptake within these target tissues 
seen previously (Figure 3.8 and 3.9) was most likely ER-mediated.  
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Figure 3.11.  Biodistribution and blocking study of [18F]-EDC-Click (13) in adult female C57BL6 
mice (%ID/g). Mice were injected with 25-30 µCi of [18F]-EDC-Click for the high dose, 3-5 
µCi for the low dose and the block involved a 500-fold excess of unlabeled EDC and a 3-5 
µCi dose of labeled material. Tissue distribution, determined at 2 hours, is expressed as % 
of injected dose per gram tissue (%ID/g). 
 
To further investigate whether the selective uptake and retention of [18F]-EDC in the 
heart and aorta was mediated by binding to the ER, a biodistribution was also performed with 
the non-ER binding EDC analogue, [18F]-XDC (21); results are shown in Figure 3.12. Again, 
highest uptake of this particulate tracer was in spleen and liver, but notably, uptake in the heart 
and aorta at 30 minutes was 20-fold less than that of [18F]-EDC. Furthermore, even this reduced 
heart and aorta uptake of [18F]-XDC was essentially cleared by 2 hours, whereas the greater 
uptake of [18F]-EDC in these tissues was essentially unchanged at 2 hours. Thus, as shown in 
the expansion of the heart and aorta uptake data for the two agents (see Figure 3.12 inset), the 
non-ER binding [18F]-XDC showed much lower and less persistent uptake in the vascular target 
tissues than the ER binding [18F]-EDC, consistent with an ER-binding mediated 
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process.
 
Figure 3.12.  Biodistribution of [18F]-XDC (21) in adult female C57BL6 mice (%ID/g). Mice were 
injected with 15-20 µCi of [18F]-XDC, and tissue distribution, determined at 30 minutes and 2 
hours, is expressed as % of injected dose per gram tissue (%ID/g). Inset: comparison of 
uptake in the heart and abd. aorta between [18F]EDC (Figure 3.9) and [18F]-XDC. 
 
IV. DISCUSSION 
In this study, we have determined the biodistribution of EDC, a conjugate between EE2 
and a G6 PAMAM dendrimer, labeled with F-18 using two convenient and efficient methods. As 
is typical for a particulate species, the bulk of [18F]-EDC is rapidly taken up by the spleen and 
liver, presumably by an MPS-mediated process.73 The undesired uptake in these nontarget 
tissues still remains a significant obstacle for targeted-base drug delivery systems using these 
types of polymeric nanoparticles. The problem arises from their recognition as foreign particles 
in vivo and the defense mechanisms that designed for their removal. Upon injection, particles 
undergo opsonization, thereby rendering them visible to phagocytic cells and results in their 
very rapid removal from the bloodstream, typically within minutes.75 The particle then becomes 
engulfed through endocytosis by the phagocyte, which begins to secrete enzymes and other 
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chemical factors (i.e., hydrogen peroxide) to break down the foreign material.76 In our case, 
EDC is a non-biodegradable biopolymer and cannot be degraded significantly by this process. 
As a result, the particle becomes sequestered and stored in MPS organs, which explains the 
high uptake by the liver and spleen from our biodistributions. Several strategies of camouflaging 
(“stealth particles”) have been developed to bypass recognition and opsonization in an attempt 
to increase blood retention time and uptake in the desired target tissue, with PEGylation being 
the most well-known.77,78 Current efforts to redesign EDC with polyethylene glycol chains to 
extend blood circulation, minimize the undesired uptake in non-target tissue and increase 
uptake in the cardiovasculature are currently underway. 
Although the [18F]-EDC clearly is being rapidly sequestered by particle-clearance organs, 
it is notable that even small molecule estrogens are rapidly lost from blood, so the blood 
clearance and tissue exposure is actually not all that different; it is just that the small molecules 
clear through the liver and kidneys and are eliminated, but [18F]-EDC becomes trapped in the 
lung, liver, and spleen. However, very marked uptake and retention of [18F]-EDC is also noted in 
the heart and abdominal aorta, known target sites of the extra-nuclear action of estrogens. EDC 
uptake and retention in these sites appears to be ER mediated because a structurally matched, 
but non-ER binding EDC analogue, XDC, shows little uptake and rapid clearance. The ER-
mediated uptake of EDC in heart and aorta appears to be of a different nature than that of small 
molecule estrogens, which are most avidly taken up by the uterus, but not by heart and aorta; 
EDC, by contrast, shows no uptake and retention by the uterus. 
The negligible amount of activity present in the blood with the EDC block (Figure 3.11) is 
of interest and suggests that the high dose of EDC might be accelerating clearance processes, 
but since similar reductions of activity are not seen in other organs, this is most likely not the 
case; thus, the exact cause for the low blood activity is still unknown. Also, the increased uptake 
in certain tissues, including the uterus, bone and especially the kidney, is of note. However, the 
exceedingly high dose of material needed for the EDC block might be sufficient to cause some 
unanticipated pharmacological effects, which may lead to saturation of MPS organs and an 
increase uptake in nontarget tissue, although the mechanisms leading to this have yet to be 
determined. Nonetheless, cold EDC was effective at outcompeting [18F]-EDC to block ER-
mediated uptake and the unforeseen biodistribution concerns were only observed in the 
blocking study when EDC was present at much higher concentrations than in the previous 
studies (Figure 3.9 and 3.10). 
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It has been a longstanding challenge to develop estrogens that provide an ideal balance 
between beneficial vs. detrimental health effects in older women. While estrogen agonists like 
estradiol and conjugated equine estrogens suppress menopausal hot flush and maintain bone 
strength and cardiovascular health, they increase the risks of breast and endometrial cancers.79 
By contrast, antiestrogens, including SERMs, suppress estrogen-dependent cancers but 
generally exacerbate hot flush and are not fully protective of bone and vascular health.80 Thus, 
our recent report that EDC provided protection against cardiovascular injury equivalent to that of 
estradiol in two animal models—without stimulation of the uterus or mammary tissue—was a 
significant finding, because it indicated that pharmacological separation of these desired vs. 
undesired effects of estrogens could be cleanly achieved.62 
Mechanistically, this remarkable pharmacological separation appears to arise because in 
cells the EDC restricts estrogen stimulation only to the extra-nuclear signaling pathway, which 
appears sufficient to afford vascular protection but insufficient for stimulation of uterine and 
mammary tissues.58 The selective stimulation of the extra-nuclear over the nuclear ER signaling 
pathway appears to result from the unique subcellular distribution of EDC. Using fluorescence 
microscopy, we have shown that EDC labeled with rhodamine rapidly associates with the 
plasma membrane of ER-positive breast cancer and vascular endothelial cells, and with time 
enters the cytoplasm, apparently by endocytosis; however, it is never found in the nucleus, even 
after 24 hours.58  
In the animal studies showing vascular protection by EDC,62 the agent was administered 
continuously by an osmotic minipump at a dose that maintained blood levels of EDC presenting 
a concentration of tethered EE2 ligand equivalent to that of a protective dose of estradiol. In this 
study, the [18F]-EDC and [18F]-XDC agents were administered by IV injection, which is the route 
typically used to study the biodistribution of agents labeled with short-lived radionuclides. 
Remarkably, beyond the expected sequestration of these particulate species by liver and 
spleen, the [18F]-EDC, but not the [18F]-XDC, showed selective accumulation and retention in 
heart and aorta; this uptake appears to be ER mediated, yet there is essentially no 
accumulation in the uterus. Thus, in addition to selective ER pathway activation, the selective 
bioactivity of EDC in the vasculature may also originate from its selective biodistribution to these 
tissues.  
The contrast in the ER-mediated biodistribution of EDC (heart, aorta) vs. that of small 
molecule estrogens, such as the well-studied 16α-[18F]fluoroestradiol (FES) (uterus), is striking. 
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In principle, this difference could derive from access to the different cellular pools of ER, with 
small molecules like FES being able to access the larger nuclear pool of ER, but the more 
limited subcellular trafficking of EDC providing access only to the extra-nuclear or membrane 
fraction of ER. While the distribution of ER in the nuclear vs. extra-nuclear pools of the heart 
and vascular endothelium is not known, in cell culture extra-nuclear or membrane ER is 
considered to be a minor component of the total cellular ER (approximately 5-10% of ERα is 
present at the membrane).27 Nevertheless, in our studies, it appears to be adequate to mediate 
selective, ER-dependent uptake and retention of EDC in heart and aorta. 
There is increasing interest in the development of pharmaceuticals based on polymeric 
carriers such the PAMAM dendrimers;77,81,82 thus, it is conceivable of an agent like EDC that 
could be developed into a drug for human use. However, it is worthwhile to consider whether 
there are alternative strategies for developing an estrogen pharmaceutical with EDC-like 
selective cardiovascular protection without uterus and breast stimulation, whether it might be 
based on other, smaller polymers or might even be a small molecule that could be orally active. 
Agents based on estrogens covalently attached to alternative polymers would probably need to 
share with EDC the subcellular trafficking that restricts the hormonal element from engaging 
nuclear ER, which might depend on the inherent charge or polymer architecture of the PAMAM 
dendrimer. Because the extra-nuclear ER signaling pathway involves the engagement of ER 
with tethering and coregulator components that are distinct from those utilized in the nuclear 
pathway, it is conceivable that a small molecule estrogen might stabilize an ER conformation 
that can selectively activate those cofactors necessary for extra-nuclear activity and not those 
responsible for nuclear activity. Small molecules of this nature have been explored to some 
extent in other systems (bone),64 but it is important that any such small molecule, even if it has 
selective activity itself, not be prone to metabolism to more conventional and non-selective 
hormonal agents.  
In conclusion, through biodistribution studies, we have found that the EDC, a dendrimer-
bound estrogen that provides selective cardiovascular protection without classical stimulation of 
uterus and mammary tissues, also shows selective, ER-mediated uptake and retention by the 
vascular target tissues, heart and aorta, but not the classical target, uterus. Thus, the favorable 
cardiovascular-selective activity of EDC may rely not only on its capacity to selectively activate 
the extra-nuclear pathway of ER signaling, but also from an inherent pharmacokinetically 
selective, ER-directed biodistribution that favors vascular targets over reproductive targets. 
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V. METHODS 
Materials 
All reactions were carried out under a nitrogen atmosphere with dry solvents using anhydrous 
conditions unless otherwise stated. Solvents used in the reactions were dried in a solvent 
delivery system (neutral alumina column). Reagents were purchased from Aldrich and used 
without further purification, unless otherwise stated. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogeneous materials, unless otherwise stated. Reactions were 
monitored by thin layer chromatography (TLC) carried out on Merck silica gel 60 F254 
precoated plates (0.25 mm) using UV light as the visualizing agent and ceric ammonium 
molybdate and heat as developing agents. Flash column chromatography was performed on 
Silica P Flash silica gel (40-64 μM, 60 Å) from SiliCycle. 1H NMR spectra were recorded at 23 
oC on a Varian Unity-400, Varian Inova-500 or Varian Unity-500 spectrometers and are reported 
in ppm using residual protium as the internal standard (CHCl3, δ = 7.26, CD2HCN, δ = 1.94, 
center line, acetone-d6, δ = 2.05, center line). The following abbreviations were used to explain 
the multiplicities: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = 
multiplet and b = broad. Proton-decoupled 13C NMR spectra were recorded on a Varian Unity-
500 (126 MHz) spectrometer and are reported in ppm using solvent as an internal standard 
(CDCl3, δ = 77.16, CD3CN, δ = 1.30, center line, acetone-d6, δ = 29.80, center line). High 
resolution mass spectra were obtained at the University of Illinois Mass Spectrometry 
Laboratory. No-carrier added [18F]fluoride was produced at Washington University Medical 
School by the 18O(p,n)18F reaction through proton irradiation of enriched (95%) [18O]H2O using a 
RDS111 cyclotron. Screw-cap test tubes used for drying fluoride and radiolabeling were 
purchased from Fisher Scientific (Pyrex No. 9825). Radiochemical purification utilized a 
reversed-phase semi-preparative HPLC column (HPLC: Thermo P2000, Column: Agilent 
Zorbax SB-C18, 5 µm, 9.4 X 250 mm, Product #: 880975-202, λ = 254 nm, ACN/H2O). For 
quality control, the radiochemical purity was determined by analytical HPLC (HPLC: P4000, 
Column: Altima C18, 5 µm, 250 mm, Product #: 88056). C18 Sep-Pak cartridges were 
purchased from Waters Corporation (Milford, MA, USA). For the thin-layer chromatography 
(TLC) analyses, EM Science Silica Gel 60 F254 TLC plates were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Radio-TLC was accomplished using a Bioscan 200 imaging 
scanner (Bioscan, Inc., Washington, DC, USA). Radioactivity was counted with a Beckman 
Gamma 8000 counter containing a NaI crystal (Beckman Instruments, Inc., Irvine, CA, USA). 
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Estrogen Receptor Binding Affinity Assays 
Relative binding affinities were determined by a competitive radiometric binding assay 
using 10 nM [3H]estradiol as tracer (Amersham BioSciences, Piscataway, NJ), and purified full-
length human ERα and ERβ (PanVera/InVitrogen, Carlsbad, CA). Compounds were assayed 
from 10-4 to 10-9 M as equivalents of estradiol (20-fold lower than the molar concentration of the 
dendrimer itself). Incubations were for 18-24 h at 0 °C, and the receptor-dendrimer complexes 
were absorbed onto hydroxyapatite (BioRad, Hercules, CA), and the unbound dendrimer was 
washed away. The binding affinities are expressed as relative binding affinity (RBA) values, with 
the RBA of estradiol for both receptors being set at 100. The values given are the average ± 
range or SD for two or more independent determinations. Estradiol binds to ERα with a Kd of 0.2 
nM and to ERβ with a Kd of 0.5 nM. 
 
Radiochemical Syntheses 
[18F]-EDC (8): 51 mCi of [18F]fluoride in 200 µL [18O]H2O was eluted into Pyrex vial (No. 9825) 
and used as is without any drying step or added base. The syringe was rinsed with dry 500 µL 
CAN, and any residual activity was added to vial. 6 (1 mg) was dissolved in dry 300 µL ACN, 
added to reaction vial, capped firmly and placed in oil bath at 105 oC for 10 minutes (RCY: 
94.7% by radio-TLC). After 10 minutes, the vial was cooled at room temperature for 2 minutes 
and then injected directly into the semi-preparative HPLC. The reaction vial was rinsed with 3 
mL of the HPLC eluting solvent (80% ACN/ 20% H2O) and added to the initial reaction mixture 
before injecting into HPLC. The purification was carried by a semi-preparative HPLC system 
(Agilent Zorbax SB-C18, 5 µm, 9.4 X 250 mm, Product #: 880975-202), eluting with a gradient 
(A: 80% ACN 20% H2O   B: 90% ACN 10% H2O over 15 mins) at a flow rate of 4 mL/min and 
the UV detector set at 254 nm. The radioactive peak corresponding to 7 was detected at 14 to 
16 min by the radioactivity detector and was collected. The collected activity was diluted with 30 
mL H2O and passed through a C18 column to capture the activity. The reaction vial was rinsed 
with 3 mL H2O, which was also passed through the C18 column. A nitrogen line was connected 
to the cartridge to dry as best as possible residual H2O captured in cartridge. The activity (30.9 
mCi) was eluted from the column with 0.8 mL Et2O, and nitrogen was used to remove the 
solvent. To a solution of 7 in 40 µL MeOH was added EDC (1, 6 nmol in 10 µL MeOH) at room 
temperature and left to stir for 10 mins. The reaction mixture was added directly to a G25 
column (PD Minitrap G-25, Sephadex G-25 medium, Product #: 28-9180-07), and 8 was eluted 
with PBS buffer (~1.5 mL, in 0.5 mL increments) to obtain 15.1 mCi in ca. 1.5 h. The portion 
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containing ~5 mCi was used for the final dose preparation. The isolated yield (without decay 
correction) was 29.4%, with a radiochemical purity of >99% and specific activity of 2500 
mCi/µmol (92.5 GBq/µmol).  
Radio-TLC of the radiofluorination of 6 with [18F]fluoride ion after 10 minutes: 
DONG: 81520111.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 5.3% 
Region 2 ([18F]fluoroproduct; 55 mm): 94.7% 
 
Prep HPLC purification of crude material: 
Conditions: A: 80% ACN 20% H2O   B: 90% ACN 10% H2O over 15 mins, flow rate = 4 mL/ 
min, λ = 254 nm 
 
UV Trace: 
 
 
Radioactivity Trace (Product: 15.2 min): 
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Quality Control (QC) analysis after purification: 
Conditions: 80% ACN, 20% H2O flow rate = 2 mL/ min, λ = 254 nm 
 
UV trace used for specific activity determination (Product: 4.51 min): 
 
UV trace of co-injection with cold standard for product (31) confirmation (Product: 4.56 
min): 
 
Radioactivity trace of co-injection with cold standard for product (31) confirmation and 
radiochemical purity: 
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[18F]-EDC purity determined by radio-TLC: 
DONG: 81520113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% MeOH 
Region 1 (35 mm; [18F]-EDC): 100% 
 
 [18F]-XDC (21): By following procedure above, the radiochemical synthesis yielded 10.9 mCi of 
21 in high radiochemical purity (>99%) and specific activity (1820 mCi/µmol, 67.3 GBq/µmol)) in 
1.5 h. The portion containing 5.72 mCi was used for final dose preparation.  
[18F]-XDC purity determined by radio-TLC: 
DONG: 10520111.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
 
TLC Eluting Conditions: 100% MeOH 
Region 1 (35 mm): 100% 
 
1-Azido-2-[18F]fluoromethane (10): [18F]fluoride (62 mCi in 200 µL [18O]water) was transferred 
to a BD vacutainer (13 × 75 mm, 5 mL, glass, no additives) containing K222 (5.6 mg, 14.9 µmol) 
and K2CO3 (1 mg, 7.2 µmol), then the mixture was dried by azeotropic distillation at 105 ºC 
using ACN (3 × 1 mL) under a gentle flow of N2 gas. When the drying was close to finish, the 
vacutainer was removed from the oil bath and the solvent residue (< 100 µL) was removed by a 
flow of N2 at room temperature. The vacutainer was capped and connected to a dry ice trap (10 
mL Pyrex tube with screw-cap) via Teflon tubing. After a solution of 9 (2 mg, 8.3 µmol) in ACN 
(200 µL) was added to the vacutainer, it was shaken and heated at 88 ºC for 5 min, directly 
followed by vacuum distillation which was achieved by a 50 mL syringe. The distillation lasted 
for 1 min, after which N2 gas (10 mL) was released to the vacutainer. After this distillation 
procedure was repeated, the Pyrex tube was removed from the dry ice bath and warmed to 
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room temperature in a water bath for the subsequent click labeling (37 mCi). The processing 
time is about 10 min from the beginning of the labeling reaction, and the isolated yield is >80 %, 
determined by measuring the distilled activity (decay corrected).   
2,5-Dioxopyrrolidin-1-yl 4-((1-(2-[18F]fluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzoate 
(12): A solution of CuSO4·5H2O (1 mg, 4.0 µmol) in water (10 µL) and a solution of sodium 
ascorbate (3 mg, 15.1 µmol) in water (10 µL) were mixed; when the color of the mixture 
changed from black to yellow, the copper salt solution was mixed with a solution of BPDS (1.2 
mg, 2.0 µmol) in 1 : 4 DMF/H2O (20 µL). A portion of above mixture (25 µL), along with 11 (1 
mg, 3.66 µmol) in DMF (200 µL), was added to the distilled 10 in ACN (200 µL). After 5 min at 
room temperature, the reaction mixture was diluted with a solution of 10% ACN, 90% water, 
0.1% TFA(3 mL) for reversed-phase HPLC purification using column A and mobile phase (32% 
ACN, 68% water, 0.1% TFA) at 4 mL/min, and UV at 240 nm. 12 was collected at 15 min in 90% 
yield (decay corrected). The HPLC fraction containing 12 was diluted in water (50 mL), then 
[18F]7 was isolated by solid-phase extraction using a C18 SepPak by passing the diluted sample 
through the SepPak. The SepPak was rinsed with water (10 mL), and dried under a stream of 
N2 gas. 12 can be eluted from the SepPak in DMF for immediate conjugation, or in either 
dichloromethane or diethyl ether, to afford a dried form of 12 (15.71 mCi) after drying over 
Na2SO4 and removal of solvents. 
[18F]-EDC-Click purity determined by radio-TLC: 
DONG: 41120122.R01 
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TLC Eluting Conditions: 100% MeOH 
Region 1 (35 mm): 100% 
 
Biodistribution Experiments 
Female BALB/c mice were obtained from Charles River Laboratories and were housed in the 
Division of Comparative Animal Facility at Washington University Medical School. Animals were 
anesthetized in a Plexiglas induction chamber flowing with oxygen and 1-2% isoflurane. 15-20 
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µCi of 8, 13 or 21 in 100 µL PBS buffer pre-weighed in a 0.300cc, 29 gauge x ½’’ insulin 
syringe. The mouse was injected via the tail vein, and the syringe was post-counted to 
determine the total injected volume in grams. All injections were tolerated well. The mouse was 
weighed and returned to the cage to restore the animal to a normal, awake state. A spare, 
control dose was injected into a total volume of 100 mL of saline to disperse 1 mL aliquots into a 
vial for each animal that was counted along with each group of organs to create a standard. At 
30 min and 2 h, the mice were sacrificed by cervical dislocation.  Samples or whole organs were 
collected from blood, lung, liver, spleen, kidney, muscle, heart, abdominal aorta, uterus, bone 
and bone marrow. Organs were individually counted on a Beckmann gamma counter for 1 
minute per sample. Calculations were then performed to determine % injected dose per gram 
and per organ. All measurements were properly corrected for decay. 
Blocking Experiments 
Animals were prepared and treated as discuss previously. Before injection of tracer, PBS 
solutions of cold EDC (1, 40 µg, 500-fold excess) or estradiol (20-60 µg, 100-500-fold excess) 
were introduced into the mice.  
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Numerical Values of Biodistribution (Figure 3.9) for [18F]-EDC-Si-18F (Female; %ID/gram): 
 30 min 2 hour 2 hour Block (E2) 
Organ %ID/gram SD %ID/gram SD %ID/gram SD 
Blood 11.5617 0.8457 3.0666 0.7052 2.2074 0.9256 
Lung 26.0679 10.2063 13.5434 2.6317 22.0802 5.1329 
Liver 39.6676 4.9527 68.0836 7.6045 61.4188 9.0476 
Spleen 255.7602 37.0547 460.6485 72.375 388.6927 37.7974 
Kidney 3.4063 0.3721 3.2370 0.7161 2.6122 0.5103 
Muscle 0.9513 0.2086 0.6170 0.1296 0.6250 0.1477 
Heart 19.6690 1.4342 16.2298 2.9426 10.9753 1.7948 
Bone 5.7072 0.2562 8.3166 1.9434 7.6491 1.4159 
Uterus 0.6049 0.3238 0.3358 0.1512 0.8235 0.4174 
Abd. Aorta 8.1464 2.6876 6.5009 2.3213 5.2284 1.4757 
 
Numerical Values of Biodistribution for [18F]-EDC-Si-18F (Female; %ID/organ): 
 30 min 2 hour 2 hour Block (E2) 
Organ %ID/organ SD %ID/organ SD %ID/organ SD 
Blood 16.2055 1.3237 4.1718 0.7856 2.9529 1.0425 
Lung 3.6072 1.3777 2.0018 0.3391 3.0777 0.5913 
Liver 34.5596 3.5457 55.3582 4.0014 48.1138 2.5438 
Spleen 17.3475 3.0852 33.1527 4.1012 25.3507 3.7858 
Kidney 0.4279 0.0803 0.3632 0.0598 0.3058 0.0896 
Muscle 7.7454 1.2479 4.9146 0.7785 4.9174 0.8850 
Heart 2.0643 0.1271 1.6251 0.2462 1.1555 0.1444 
Bone 12.4810 1.1056 17.6862 3.7442 16.0541 2.1163 
Uterus 0.0437 0.0231 0.0348 0.0179 0.0411 0.0172 
Abd. Aorta 0.0805 0.0122 0.0819 0.0587 0.0595 0.0242 
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Numerical Values of Biodistribution for [18F]-EDC-Si-18F (Male; %ID/gram): 
 30 min 2 hour 2 hour Block (E2) 
Organ %ID/gram SD %ID/gram SD %ID/gram SD 
Blood 4.4978 1.7960 1.6116 0.3812 1.5946 0.2301 
Lung 26.1280 11.5194 19.9430 3.6527 21.0828 4.0406 
Liver 21.2623 7.3078 42.6931 3.7662 38.3988 3.2665 
Spleen 84.8652 38.1032 230.5541 32.7841 237.2420 22.1027 
Kidney 2.1468 0.7517 2.5679 0.4692 2.0270 0.1861 
Muscle 0.7827 0.2846 0.7730 0.1641 0.7415 0.0916 
Heart 17.2210 7.8135 15.6428 3.1304 16.1561 3.1632 
Bone 6.8779 1.9062 10.1312 1.3382 8.3705 1.1216 
Abd. Aorta 4.5541 1.6574 5.2080 2.4742 4.2915 0.8526 
 
Numerical Values of Biodistribution for [18F]-EDC-Si-18F (Male; %ID/organ): 
 30 min 2 hour 2 hour Block (E2) 
Organ %ID/organ SD %ID/organ SD %ID/organ SD 
Blood 6.8814 2.5906 2.4177 0.6022 2.3815 0.2869 
Lung 3.7986 1.6084 2.7518 0.5618 3.0157 0.7317 
Liver 23.8014 8.0007 42.7630 4.5811 35.6260 1.8567 
Spleen 6.4565 2.8316 14.0281 1.8753 14.0830 0.8566 
Kidney 0.2980 0.0963 0.3693 0.0682 0.2783 0.0310 
Muscle 7.0447 2.5373 6.7766 1.5213 6.4980 0.7727 
Heart 2.0262 0.8755 1.7095 0.3545 1.7286 0.3618 
Bone 16.4561 4.4628 23.6522 3.6493 19.4811 2.2915 
Abd. Aorta 0.0294 0.0138 0.0269 0.0166 0.0279 0.0080 
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Numerical Values of Biodistribution (Figure 3.10) for [18F]-EDC-Click (Female; %ID/gram): 
 30 min 2 hour 
Organ %ID/gram SD %ID/gram SD 
Blood 13.2763 4.3466 2.4183 0.4952 
Lung 21.6783 4.9191 12.0557 2.7106 
Liver 39.9442 2.0635 53.9221 6.3387 
Spleen 240.6968 38.1327 319.1434 78.3605 
Kidney 4.3545 0.8784 3.5402 0.4672 
Muscle 0.7859 0.2007 0.6593 0.1142 
Heart 13.2138 1.9454 12.6973 2.1333 
Brain 0.3379 0.1100 0.0961 0.0234 
Bone 1.2983 0.2029 1.2563 0.1538 
Marrow 1.8816 1.7191 3.7777 2.3665 
Uterus 0.4777 0.5048 0.5607 0.3724 
Abd. Aorta 7.8991 2.2757 6.7233 1.3971 
 
Numerical Values of Biodistribution for [18F]-EDC-Click (Female; %ID/organ): 
 30 min 2 hour 
Organ %ID/organ SD %ID/organ SD 
Blood 18.3398 5.4995 3.2783 0.7466 
Lung 3.2468 0.5963 1.8265 0.4122 
Liver 37.0714 3.4032 47.7170 4.9140 
Spleen 15.1994 2.1507 20.2292 4.2161 
Kidney 0.5902 0.1007 0.4721 0.0588 
Muscle 6.3973 1.5613 5.2131 0.8789 
Heart 1.5091 0.1983 1.4633 0.1222 
Brain 0.1302 0.0491 0.0376 0.0108 
Bone 2.8123 0.4013 2.6456 0.3579 
Marrow 0.0063 0.0036 0.0050 0.0015 
Uterus 0.0284 0.0309 0.0296 0.0201 
Abd. Aorta 0.0664 0.0209 0.0678 0.0249 
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Numerical Values of Biodistribution (Figure 3.12) for [18F]-XDC-Si-18F (Female; %ID/gram): 
   30 min 2 hour 
Organ %ID/gram SD %ID/gram SD 
Blood 4.7034 0.5973 0.2027 0.1774 
Lung 7.0214 2.4218 2.2039 1.0308 
Liver 74.2952 8.9768 85.9090 7.4361 
Spleen 84.8318 30.3325 76.0455 27.0040 
Kidney 1.3145 0.2342 0.6222 0.0862 
Muscle 0.1812 0.0241 0.0482 0.0148 
Heart 1.5001 0.2845 0.2161 0.0493 
Brain 0.1578 0.0175 0.0167 0.0101 
Bone 1.4457 0.1795 1.6438 0.5637 
Marrow 2.0014 0.6785 4.0009 3.4947 
Uterus 0.3057 0.0526 0.1876 0.2002 
Abd. Aorta 1.6118 0.3538 0.3590 0.4215 
 
Numerical Values of Biodistribution for [18F]-XDC-Si-18F (Female; %ID/organ): 
   30 min 2 hour 
Organ %ID/organ SD %ID/organ SD 
Blood 6.7759 0.6870 0.2913 0.2470 
Lung 0.9492 0.2813 0.3287 0.1653 
Liver 74.0380 6.6605 81.0654 2.7261 
Spleen 7.0069 1.6299 6.5437 2.0763 
Kidney 0.1649 0.0243 0.0856 0.0213 
Muscle 1.5314 0.1956 0.4082 0.1146 
Heart 0.1554 0.0246 0.0229 0.0038 
Brain 0.0626 0.0047 0.0067 0.0039 
Bone 3.2387 0.2428 3.7303 1.3515 
Marrow 0.0024 0.0012 0.0045 0.0047 
Uterus 0.0218 0.0080 0.0131 0.0171 
Abd. Aorta 0.0087 0.0037 0.0020 0.0023 
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Numerical Values of Biodistribution (Figure 3.11) for [18F]-EDC-Click 30 min block 
(Female; %ID/gram): 
 30 min High Dose 30 min Low Dose 30 min E2 Block 30 min EDC Block 
Organ %ID/gram SD %ID/gram SD %ID/gram SD %ID/gram SD 
Blood 14.4020 3.4107 5.2622 0.6678 6.9652 2.3877 0.4445 0.2580 
Lung 13.6754 4.7922 5.7999 0.6310 9.2502 1.5521 6.4220 0.6113 
Liver 27.9916 2.9665 38.3925 2.4497 39.7293 8.2372 78.0321 13.7196 
Spleen 276.7966 39.2418 164.7847 10.0198 253.6580 30.9604 66.5555 14.2317 
Kidney 3.4732 0.4287 3.6322 0.2811 3.4290 0.5995 20.5397 4.2353 
Muscle 0.7231 0.1832 0.6095 0.1802 0.6947 0.1257 0.1923 0.1398 
Heart 13.8879 2.2980 14.5021 2.6936 14.4835 2.6270 0.6416 0.1819 
Bone 1.2921 0.3073 1.5970 0.3408 1.6274 0.2152 2.7976 0.4360 
Uterus 0.3293 0.1173 0.3290 0.1495 0.4859 0.2145 1.1937 0.3873 
Abd. Aorta 6.7090 1.7659 7.7939 0.5328 4.9989 0.8999 3.7690 2.4894 
 
Numerical Values of Biodistribution for [18F]-EDC-Click 30 min block (Female; 
%ID/organ): 
 30 min High Dose 30 min Low Dose 30 min E2 Block 30 min EDC Block 
Organ %ID/organ SD %ID/organ SD %ID/organ SD %ID/organ SD 
Blood 19.4566 4.3494 7.1185 0.9208 9.4879 3.4319 0.5902 0.3212 
Lung 1.8661 0.6068 0.8495 0.1985 1.3660 0.3112 0.8691 0.1123 
Liver 26.2894 2.9303 32.2982 1.9601 36.3072 7.9931 70.6540 8.5146 
Spleen 20.5277 2.0437 12.2187 1.2697 19.8937 2.6393 4.9708 1.1179 
Kidney 0.4215 0.0690 0.4678 0.0290 0.4022 0.0686 2.5734 0.5546 
Muscle 5.7290 1.3983 4.8216 1.3871 5.5215 1.0177 1.5227 1.1391 
Heart 1.2577 0.1584 1.2707 0.2567 1.2926 0.1979 0.0558 0.0163 
Bone 2.7235 0.6398 3.3570 0.6668 3.4446 0.5358 5.8664 0.8290 
Uterus 0.0318 0.0075 0.0365 0.0246 0.0401 0.0208 0.0941 0.0459 
Abd. Aorta 0.0559 0.0068 0.0863 0.0068 0.0476 0.0193 0.0321 0.0363 
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Numerical Values of Biodistribution (Figure 3.11) for [18F]-EDC-Click 2 hr block (Female; 
%ID/gram): 
 2 hr High Dose 2 hr Low Dose 2 hr E2 Block 2 hr EDC Block 
Organ %ID/gram SD %ID/gram SD %ID/gram SD %ID/gram SD 
Blood 3.3067 0.6453 1.0119 0.3471 1.2020 0.0434 0.1058 0.0255 
Lung 9.3528 2.3708 6.9731 2.1549 4.4163 1.8373 3.4417 0.8115 
Liver 44.9795 7.1587 41.4023 1.8900 45.8173 7.2316 79.5245 11.9594 
Spleen 345.9963 27.7805 185.7553 24.4289 217.1845 82.3742 60.3171 9.3595 
Kidney 2.9919 0.2015 2.7899 0.1400 2.6151 0.2209 20.3701 2.4284 
Muscle 0.4642 0.1056 0.4559 0.1721 0.4622 0.2471 0.1488 0.0795 
Heart 10.5887 1.9170 8.2754 1.0681 8.5800 0.8972 0.4593 0.1231 
Bone 1.9091 0.3344 1.6217 0.3252 1.7204 0.0302 3.1844 0.6919 
Uterus 0.2236 0.0392 0.2494 0.0451 0.1908 0.0111 1.3920 0.4801 
Abd. Aorta 4.0470 1.0894 3.7275 1.7127 4.5092 0.5749 0.9734 0.7313 
 
Numerical Values of Biodistribution for [18F]-EDC-Click 2 hr block (Female; %ID/organ): 
 2 hr High Dose 2 hr Low Dose 2 hr E2 Block 2 hr EDC Block 
Organ %ID/organ SD %ID/organ SD %ID/organ SD %ID/organ SD 
Blood 4.4895 0.8347 1.3595 0.4803 1.6585 0.1075 0.1455 0.0340 
Lung 1.4060 0.2169 0.9577 0.2775 0.6687 0.2699 0.4847 0.1154 
Liver 38.3207 1.0643 38.0456 2.2391 41.7374 4.7256 66.1783 7.4003 
Spleen 28.8584 4.3638 15.1268 1.0892 17.7193 4.1551 5.0899 0.7014 
Kidney 0.3682 0.0494 0.3341 0.0593 0.3119 0.0291 2.5314 0.4036 
Muscle 3.6879 0.7919 3.5982 1.4061 3.7620 2.1027 1.2092 0.6733 
Heart 1.0314 0.1013 0.7345 0.0815 0.9260 0.2308 0.0440 0.0125 
Bone 4.0443 0.7337 3.3923 0.7114 3.6951 0.1708 6.8252 1.4647 
Uterus 0.0173 0.0061 0.0211 0.0041 0.0209 0.0085 0.1062 0.0242 
Abd. Aorta 0.0173 0.0199 0.0344 0.0159 0.0448 0.0167 0.0074 0.0035 
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CHAPTER 4 
SYNTHETIC APPROACHES TOWARDS THE 18F-LABELLING OF 
2-[18F]FLUOROESTRADIOL VIA COMPLEX DIARYLIODONIUM SALTS 
 
I. INTRODUCTION 
A. Background 
Molecular imaging has become a key component in biomedical research and diagnostic 
clinical studies.1 Imaging the presence and functionality of diseased states provides significant 
insight into the mechanisms leading to disease onset and progression.2 Although similar 
information can be obtained through tumor biopsies and immunohistochemical evaluations, 
some tumor sites (i.e., brain) cannot be accessed for biopsy and thus, demand a less invasive 
approach. Additionally, tumor heterogeneity, biopsy sampling errors, and varying expression 
profiles between primary and metastatic sites further complicate matters and may not yield an 
accurate description of the diseased state.3-7 Advances in medical imaging, however, can 
provide detailed biochemical information through minimally invasive procedures at the earliest 
stages of disease onset, before any observable symptoms are seen in the patient. 
B. PET Imaging and the Estrogen Receptor 
The measurement of estrogen receptor (ER) levels in breast cancer by using PET 
imaging using the compound our group developed, 16α-[18F]fluoroestradiol (1, Figure 4.1, 
[18F]FES), appears to be a better predictor of benefit from endocrine therapies than are standard 
immunohistochemical assays of ER.8-13 As a result, these [18F]FES-PET studies can assist in 
the proper selection of patients to undergo less toxic endocrine therapies instead of the more 
costly and morbid cytotoxic therapy.8,12 By individualizing treatment plans such as this one, the 
expectation is that patient outcomes will be greatly improved. However, despite the initial 
successes of FES, it is likely that PET measurements of ER in breast tumors can be vastly 
improved by developing other ER imaging agents having higher tumor-to-background-tissue 
activity, as this would extend the usefulness of the agent to detect smaller tumors and identify 
regions of lower ER concentrations. 
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Figure 4.1. Structure of [18F]FES (1), an agent used for ER-targeted PET imaging studies. 
 
[18F]FES (1) binds to ER as well as estradiol, but its affinity to an important serum 
protein, sex hormone binding globulin (SHBG), is less than 10% that of estradiol.14 SHBG 
binding is thought to facilitate uptake into hormone target tissues and tumors in humans through 
a specific cell membrane receptor, megalin, which is distinct from ER.15,16 Curiously, SHBG is 
not present in the blood of rats or mice, the species typically used for the development of PET 
imaging agents.15,17 As further evidence of the importance of SHBG in target tissue uptake of F-
18 labeled steroids in humans, we found some estrogens and androgens with high affinity for 
their receptor targets, but low affinity for SHBG, had high target tissue uptake in rodents, but 
very poor target tissue uptake in primates or humans.14,18,19 Thus, we believe that F-18 labeled 
estrogens with high affinity for both ER and SHBG would be better ER imaging agents than 
[18F]FES. 
In this respect, 2-[18F]fluoroestradiol ([18F]2FES, 2, Figure 4.2) appears promising: Its 
affinity for ER is 110% that of estradiol, similar to that of FES, but its affinity for SHBG is 3700%, 
whereas that for FES is only 9%.14 It was originally thought that the design of agents with high 
affinity for SHBG was to be avoided since it might retard the release of these estrogens to the 
target tissue and restrict their bioavailability by excessive binding in blood.20 However, recent 
evidence has indicated that binding to SHBG actually protects these agents from metabolism 
and subsequently, increases the bioavailability of estrogens to ER-rich target tissues.16,21-23 
 
Figure 4.2. Structure of [18F]2FES (2), a potentially useful ER-targeted radiopharmaceutical. 
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C. Radiosynthetic Challenges Associated with [18F]2FES (2) 
The phenol function is ubiquitous in both naturally occurring and synthetic bioactive 
compounds.24,25 In drugs, the phenolic function is often substituted with fluorine because fluorine 
substitution, particularly at the ortho position, enhances receptor target binding affinity, perhaps 
by adjusting the phenol pKa, and/or in vivo potency, by blocking the ortho-hydroxylation 
metabolism, extending drug clearance profile and increasing drug exposure.24,25 In any case, 
fluorine substitution is either beneficial to bioactivity or, in the worst case, well-tolerated. 
While there are many methods for labeling small molecules with F-18 at aliphatic 
positions and on electron-deficient aromatic rings, there are essentially no reliable and practical 
methods to label electron-rich aromatic rings, such as phenols, with F-18 at high specific 
activity. This is disappointing: Fluorine-labeled phenols are found in many drugs, because 
fluorine substitution often improves drug binding and pharmacokinetic properties; also, there are 
many interesting plant metabolites and hormones that contain either phenols or other electron-
rich aromatic systems such as indoles, whose metabolism, transport, and distribution would be 
interesting to study if they could readily be prepared in F-18 labeled form (Figure 4.3).24 
 
Figure 4.3. Phenolic and electron-rich molecules of interest for labeling with [18F]fluoride ion. 3: 
ERB-041, ERβ selective ligand; 4: ERα selective ligand; 5: Genistein, a plant isoflavone, 6: 
Auxin, a plant hormone. F = already present on molecule; (F) = potential site of F-18 
substitution.  
 
Most approaches to label phenols with F-18 involve the labeling of electron-poor arenes 
by nucleophilic aromatic substitution, followed by subsequent conversion to phenols by 
oxidation or other multi-step sequences that are often inefficient and time consuming. Thus, the 
lack of good methods for labeling phenols and other electron-rich aromatics with F-18 at high 
specific activity represents a significant methodological gap in F-18 radiochemistry. 
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In our experience, preparing 2-[18F]fluoroestradiol (2) is a prime example of the types of 
challenges present in the F-18 labeling of electron-rich aromatic systems.26 We examined many 
A-ring estrogen precursors and after several trials, we were able to prepare 2-
[18F]fluoroestradiol by the three-step process shown in Scheme 4.1.26 [18F]Fluoride ion was 
introduced into the 2 position by displacement of a trimethylammonium group (7) that was 
activated by a carbonyl group introduced into the steroid system at C-6, para to the leaving 
group. Although the first radiofluorination step proceeded satisfactorily, the next two steps were 
time-consuming and inefficient, but mainly in the additional manipulations required to remove 
the activating group (8) and deprotection of the methyl ethers (9) to afford the diphenol 2. 
Overall, the multistep transformations required to produce [18F]2FES proved sufficiently 
awkward that further biological evaluations of this compound awaits improvements in the 
synthesis of F-18 labeled phenols.  
 
Scheme 4.1. Synthesis of [18F]2FES (2) by nucleophilic aromatic substitution-reduction-
deprotection sequence.26 
 
D. Radiofluorination of Electron-Rich Arenes with Diaryliodonium Salts 
 The available methodology for the incorporation of [18F]fluoride ion into electron-rich 
arenes is extremely limited, with only a few methods being reported. The Balz-Schiemann 
reaction, the classical method for aromatic fluorination, is unsuitable for 18F-labelling at high 
specific activity because the radiofluorine is extensively diluted by the large excess of unlabeled 
[19F]fluoride in the counteranions. Although the use of other non-fluorine containing 
counteranions have been explored, the transition to tracer levels has been less than ideal.27 The 
use of aryl triazenes as precursors for aromatic fluorination, known as the Wallach reaction, 
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actually predates the Balz-Schiemann reaction, and although it has been investigated as a 
method for radiofluorination, it is very inefficient at the tracer level, especially with electron-rich 
aromatic systems.28,29  
A more recently described method for the preparation of [18F]fluoroarenes is through the 
use of diaryliodonium salts. Hypervalent iodine compounds have tremendous utility in many 
aspects of mainstream organic chemistry as mild, nontoxic alternatives30 to the commonly used 
oxidants and expensive organometallic catalysts. Although these agents have been known to 
exist since 1894, only recently have they been used for arene radiolabeling with [18F]fluoride 
ion.31 To date, the use of diaryliodonium salts represents the lone method by which electron-rich 
arenes can be radiofluorinated in sufficiently high RCYs and specific activities.  
First reported by Pike,31 the use of these salts has enabled reliable 18F-labelling of both 
unactivated or electron-rich [18F]fluoroaromatic compounds, although most have been relatively 
simple substrates. Nucleophilic [18F]fluoride attack occurs at the electrophilic iodine atom, and 
upon the release of one of the ligands, reductive elimination of the corresponding intermediate, 
Ar-I(Ar)(18F), affords the desired [18F]fluoroarene.32 [18F]Fluorination tends to favor the more 
electron-deficient ring, and as a result, the use of unsymmetrical diaryliodonium salts where one 
aryl group is an electron-rich p-methoxyphenyl or 2-thienyl group results in selective fluorination 
to the other, less electronically rich arene.33,34 Moreover, in the case of ortho-substituted 
diaryliodonium salts, the ortho-substituted arene is preferentially attacked by fluoride, even if it is 
more electron-rich, and this effect is further enhanced in the presence of doubly substituted 
arenes.35 Initially, a “turnstile” mechanism36 was proposed to account for the ortho effect, but 
subsequent theoretical studies have postulated other mechanisms and intermediates, including 
the formation of bridged dimers37 or trimers,38 before reductive elimination occurs. However, 
others have claimed a standard nucleophilic aromatic substitution mechanism based on 
Hammett plots.33 Consequently, not all reactions show a correlation towards a presumed 
mechanism and are most likely dependent on the electronic and steric nature of the particular 
substrate for each reaction.  
Access to diaryliodonium salts typically involves multi-step syntheses (Scheme 4.2) in 
which an aryl iodide (10) is oxidized to an aryliodine(III) (11) compound by treatment with an 
inorganic oxidant under acidic conditions. The diacetoxy reagents 11 are quite stable and can 
be isolated, and subsequent ligand exchange with arylstannanes, -silanes, or boronic acids (12) 
affords the desired salts (13). The anion (X-) in these instances originates from the acid used 
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(typically from TsOH), and anion exchange with salts (i.e., KBr, KI) generates other variations in 
the final structure. Until now, this 18F-labelling approach has been largely applied to relatively 
simple diaryliodonium salts, and only a few complex examples have been reported.34,39    
 
Scheme 4.2. Standard synthesis of unsymmetrical iodonium salts. 
 
As part of our ongoing investigations in developing improved ER-targeted 
radiopharmaceuticals, we wished to explore facile approaches towards the radiosynthesis of 2-
[18F]fluoroestradiol. Herein, we describe a rapid strategy to access this promising ER imaging 
agent through diaryliodonium salts within 25 minutes with nucleophilic [18F]fluoride ion in 
synthetically useful yields. This study demonstrates the critical dependence of multiple factors in 
the successful radiofluorination of unsymmetrical iodonium salts, and in our case, the bromide 
salt with K[18F]F.K222 in PhH was found to be the optimal conditions. 
 
II. RESULTS and DISCUSSION 
A. Synthesis of the Diaryliodonium Salts for [18F]Fluorination 
The synthesis of the diaryliodonium salts (Scheme 4.3) commenced with a dimethylation 
of commercially available 17β-estradiol (14) with NaH and MeI in high yields. A subsequent 
regioselective bromination of 15 with NBS afforded bromide 16 in a 4:1 ratio of the desired 
regioisomer (2-position over the 4-position).40 Two additional recrystallizations significantly 
increased the ratio to a synthetically useful proportion of 96:4 of the 2-position isomer over the 
4-position one. Attempts to append the required tin moiety on the ring through palladium-
mediated processes generated only the reduction product. However, dehalogenation of bromide 
16 with nBuLi and subsequent capture of the lithium intermediate with trimethyltin chloride 
yielded 17 in good yields. Unfortunately, the tin species (17) was sensitive to protio-
destannylation during purification and as a result, could not be obtained as a single product. 
Nevertheless, 17 was recovered in high crude chemical purity (>90%) after passing through a 
silica gel plug and could be used as it in the next step without any problems.  
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Scheme 4.3. Synthesis of the unsymmetrical diaryliodonium salts. (a) NaH, THF, 0 oC rt, 18 h; 
(b) NBS, DCM, ACN, rt, 18 h; (c) nBuLi, TMEDA, Me3SnCl, THF, -78 
oC rt, 2 h; (d) 
RI(OAc)2, TsOH, ACN, rt, 18 h. (18) Aryl = 4-methoxyphenyl or 2-thiophene. 
 
The required (diacetoxy)arenes (18) were prepared by oxidation of the corresponding 
iodoarenes with sodium perborate in acetic acid in synthetically useful yields.41 The 
aryliodine(III) compounds are unreactive to the standard reaction conditions for the formation of 
iodonium salts, and only upon treatment of the diacetoxy derivatives to the Koser’s reagent with 
tosylic acid monohydrate in acetonitrile can the salts (19) be formed.40 These derivatives form 
readily with TsOH addition, but are difficult to isolate due to their instability; thus, they were used 
as is upon formation with the tin compound (17). We were interested in preparing salts 
containing one aryl ring that is electron-rich, such as a 4-methoxyphenyl or 2-thiophene groups, 
because fluorination tends to prefer the more electron-deficient ring. However, the exceptionally 
rich nature of the A-ring phenol of estradiol complicates fluorination onto the desired ring since it 
is difficult to synthesize iodonium salts that contain a more electron-rich second ring. Attempts 
to append additional electron donating groups such as methoxy groups onto these electron-rich 
rings were unsuccessful as these substrates were incompatible with the oxidizing conditions 
required to form the diacetoxy derivatives. As a result, the 4-methoxy and 2-thienyl arenes are 
two of the more commonly used dispensable arene rings for selective fluorination of 
unsymmetrical diaryliodonium salts and would serve as the basis of our precursors.33 
The diaryliodonium tosylates (19) contained either a 4-methoxy or 2-thiophene aryl 
group and were readily converted into other salts (PF6
-, Br-, I-) in moderate to high yields by 
anion exchange reactions, as shown in Figure 4.4.40 In each case, metathesis was confirmed by 
the absence of the tosylate signals in the 1H NMR spectrum. The preparation of the salts was 
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simple and straightforward and each precipitated from solution under the metathesis conditions 
to afford bench stable solids. Preparation of other salts was attempted (Cl-, CF3CO2
-, BPh4
-) but 
yielded none of the desired material.  
 
Figure 4.4. Representative structures of the prepared unsymmetrical diaryliodonium salts. 
 
The reported diaryliodonium salts have involved relatively simple substrates, intended to 
investigate [18F]fluorination selectivity, and of these, only a few have been applied to potential 
PET tracers.39 Since this was relatively new territory for these substrates, we undertook an 
exhaustive screen of every potential factor in the fluorination of these salts (Figure 4.4), 
including the effect of fluoride source, temperature, solvent, anion, and aryl group. 
B. Influence of the Counteranion 
 Counteranions in diaryliodonium salts can have a drastic effect on the radiochemical 
yields with [18F]fluoride ion. This is mainly the result of how these anions contribute to the 
structures of the salt in solution during the reaction. At times, inorganic counterions induce an 
effective salt separation between the two, which results in a “naked” iodonium cation,42 while 
other research suggests partially dimeric and trimeric structures of the iodonium salt.37,38 
Moreover, anions with high nucleophilicity also compete with [18F]fluoride ion for the substitution 
reaction, which can significantly reduce the availability of precursor to undergo the desired 
reaction. Nonetheless, radiochemists tend to prefer the use conjugate bases of strong acids      
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(-OTs, -OTf) due to their low nucleophilicity; however, recent evidence has suggested the use of 
the more nucleophilic bromides and chlorides as optimal counteranions.43,44 The exact influence 
of the anions on these reactions is still unknown, but at least for the more nucleophilic 
examples, this may be related to the enhanced stability of these precursors, thus suppressing 
undesired decomposition reactions that reduce the availability of these substrates for reaction 
with [18F]fluoride ion.  
We initially studied the counterion effect more closely with our unsymmetrical 
diaryliodonium salts in which each substrate underwent the same reaction conditions with only 
the anion being varied.  As shown in Scheme 4.4. (top half), the model reaction involved TBAF 
as the fluoride source and PhH as the solvent at 140 oC for 20 minutes, and the yields were 
determined by integrating the ratios of the aromatic regions of the steroid products, the fluoro- 
(29) and iododimethoxyestradiol (31) in the 1H NMR spectrum. The use of benzene differs 
considerably from traditional [18F]fluorination radiochemistry, which typically prefers the more 
polar, aprotic solvent, such as DMSO, ACN, DMF. However, recent reports have suggested the 
use of low polar, noncoordinating media, which can suppress side product formation, similar to 
those seen in transition metal complexes, is the preferred approach for improving the yields of 
fluorinated aromatic compounds.40,45  
 As shown in Scheme 4.4. (bottom two), the yields of the desired fluorinated compound 
(29) greatly depended on the counterion present, especially when the 4-methoxyphenyl group 
was used. Yields favor the use of the more nucleophilic (Br-, I-) over the non-nucleophilic 
counterions (-OTs), which is consistent with previous examples,33,35 but not with others,46 and 
further supports the notion each substrate must be screened individually. By contrast, the yield 
of 29 from the thienyl compound (32) was surprisingly low. A recent report demonstrates the 
use of the 2-thiophene group as the preferred dispensable aryl group for the ortho-
[18F]fluorination of phenols33 and yet, in our case, minimal or no yields of the desired compound 
were obtained with the 2-thiophene group. Consequently, our efforts on future reactions focused 
solely on the 4-methoxy derivative (30). 
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X- Counteranion NMR Ratio of 29 NMR Ratio of 31 
PF6
- 50 50 
Br- 35 65 
I- 25 75 
-OTs 0 100 
 
 
X- Counteranion NMR Ratio of 29 NMR Ratio of 31 
PF6
- 10 90 
Br- 0 100 
I- 0 100 
-OTs 0 100 
 
Scheme 4.4. Investigations on the counterion effect on the different diaryliodonium salts. Yields 
are calculated from integration of the aromatic peaks of 29 to 31 in the 1H NMR spectrum. 
 
To further confirm PhH as the optimal solvent (data not shown), the same reactions were 
repeated with DMSO, DMF, ACN, PhCH3, and cyclohexane. Again, PhH exhibited the highest 
yields of 29 and was used as the preferred solvent in all other reactions. 
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C. Screening for the Fluoride Source 
 We next studied the fluorination of diaryliodonium PF6
- (22) and bromide (26) salts with 
different fluoride sources. Of the available [18F]fluorination sources, TMA[18F]F, Cs[18F]F, 
K[18F]F.K222, and TBA[
18F]F are four of the more well-known ones, with the latter two being the 
most commonly used. Overall, in both cases (Scheme 4.5), yields of 29 are fairly comparable 
with all fluoride sources, except for the use of TMAF and 22. In contrast, TMAF afforded the 
highest yields of 29 with bromide derivative 26. Nevertheless, the screen proved to be quite 
useful since it showed that these salts were reactive to a variety of fluoride sources; so, we were 
not constrained to a single source. This is significant especially since the transition to tracer 
level chemistry with [18F]fluoride ion is highly unreliable, and variations in the original protocol 
are often required to achieve success.  
 Aside from the TMAF reaction, the PF6
- salt (22) showed slightly higher yields of 29 
when compared to the bromide 26 yields. The increase is most likely attributed to the PF6
- 
anion, which can release fluoride anions from PF6
-, and these ions can attack the iodine to form 
the desired compound (29). Since this side reaction would dilute the specific activity of the 18F-
radiotracer, this substrate is not useful for us, and subsequently, all 18F-studies were conducted 
with bromide 26. 
 Nevertheless, these findings proved significant since the fluorination can proceed to the 
unanticipated more electron-rich arene in sufficiently high yields, especially for 18F-chemistry 
and is most likely the result of the ortho effect. 
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Fluoride Source NMR Ratio of 29 NMR Ratio of 31 
TBAF 50 50 
TMAF 0 100 
KF, K222 49 51 
CsF 45 55 
 
 
Fluoride Source NMR Ratio of 29 NMR Ratio of 31 
TBAF 35 65 
TMAF 51 49 
KF, K222 43 57 
CsF 36 64 
 
Scheme 4.5. Investigations of fluoride sources on the different diaryliodonium salts. Yields are 
calculated from integration of the aromatic peaks of 29 to 31 in the 1H NMR spectrum. 
 
D. Problems Associated with Methyl Ether Deprotection 
 One of the main problems associated with C-18F bond formation is the need for 
protecting groups, which adds to the technical difficulty in synthesizing short-lived isotope 
tracers through multistep sequences. The protecting groups are required due to the dual 
base/nucleophile nature of the fluoride, and the presence of acidic functionality can severely 
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affect the nucleophilicity of [18F]fluoride ion and radiochemical yields. However, the rapid 
reaction times demanded by short-lived isotopes require fast deprotections and use of harsh 
conditions for their removal, which, in turn, causes additional problems in the process. In our 
case, methyl ethers are notorious in mainstream organic chemistry for the difficulty involved in 
their removal, and the difficulty is only further exacerbated with F-18 work. Initial deprotection 
attempts of the crude reaction mixture after fluorination with HCl and AlCl3 proved to be futile. 
However, switching to pyridine.HCl revealed rapid removal of the methyl ethers within 10 
minutes. Unfortunately, the harsh conditions required by the reaction (180-220 oC) not only 
cleaved the iodine off the aryl ring, but strikingly, fluorine also proved sensitive, with the 
subsequent 1H NMR spectra showing only estradiol as the sole compound in the crude reaction 
mixture. After extensive screening and optimization, it was eventually discovered that AlBr3 and 
dodecanethiol (CH3(CH2)11SH) was the optimal combination for rapid and efficient deprotection 
of the methyl ethers (Scheme 4.6). 
 
Scheme 4.6. Deprotection of the methyl ethers to afford 2-fluoroestradiol (32). (a) 
CH3(CH2)11SH, AlBr3, rt, 5 min. 
 
 Overall, the cold chemistry revealed the following sequence for the synthesis of 2-
[18F]fluoroestradiol. The bromide salt 26 proved to be the best salt for the fluorination, and after 
passing through a silica gel plug, the crude material can be utilized in the deprotection step 
without the need for HPLC purification. This allows for 32 to be accessed rapidly within only 25 
minutes of reaction time. 
 
Scheme 4.7. Overall sequence for the synthesis of 2-fluoroestradiol (32). (a) KF, K222, PhH, 120 
oC, 20 minutes; (b) CH3(CH2)11SH, AlBr3, rt, 5 minutes. 
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E. Radiosynthesis of 2-[18F]Fluoroestradiol (2) 
 From our original cold screen, bromide 26 and PhH were the preferred substrate and 
solvent, respectively, with no considerable differences in yields with varying temperatures (80-
140 oC) or fluoride sources (Scheme 4.5). We next studied the application of these conditions to 
the synthesis of 2-[18F]fluoroestradiol (2).  
 Since the [18F]fluoride source is produced as an aqueous solution from the cyclotron, a 
drying step must be performed to remove the water in order to restore the nucleophilicity of the 
anion. Key to this drying step is the addition of an appropriate base to afford a reactive, organic 
soluble [18F]fluoride source. Typically, alkali (i.e., K, Cs) or quaternary ammonium [18F]fluoride 
salts are obtained from their respective carbonates, bicarbonates, or hydroxides, albeit with 
varying success. Overall, the appropriate choice of cation and base can have a critical role in 
the success of these reactions; however, definitive guidelines for the proper choice do not exist, 
and one must screen the reaction for the optimal base. 
 We initially investigated the use of quaternary ammonium salts, TMA[18F]F and 
TBA[18F]F, formed from TMA[HCO3] and TBA[HCO3], respectively, and our model reaction 
involved bromide 26 and PhH at 105 oC for 20 minutes (Scheme 4.8). Not surprisingly, the 
successes seen previously in cold chemistry with these fluoride sources were not repeated, and 
no product (33) was formed. This was largely attributed to the low solubility of the [18F]fluoride 
salts in PhH. After the drying step is performed and all the solvent is removed, the [18F]fluoride 
source becomes adhered to the surface of the glass vial and must be resolubilized for the 
reaction to proceed. Polar, aprotic solvents (i.e., DMSO, DMF) tend to dissolve these salts quite 
readily, which explains their widespread use; however, these solvents were inferior to PhH in 
the original screen in terms of product formation. Attempts to use DMSO, instead of PhH, with 
TBA[18F]F also yielded no success. 
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Salt  Oil Bath (105 oC)  Microwave  
TMAHCO3  0 0 
TBAHCO3  0 4 
Cs2CO3  0 14 
CsHCO3  0 17 
K2CO3/K222  19 10 
KHCO3/K222  0 7 
 
Scheme 4.8. Evaluation of the effect of different salts on the radiofluorination of bromide 26. 
Radiochemical yields were based on radio-TLCs and HPLC traces.  
 
 However, upon switching to Cs2CO3 and CsHCO3 (Scheme 4.8), acceptable amounts of 
33 were obtained through microwave heating. Unfortunately, a closer inspection of the reaction 
revealed similar solubility issues: after removal of the solvent, a majority of the Cs[18F]F 
remained stuck to the vessel wall of the original vial. The minor, soluble amounts were 
sufficiently reactive to give the desired compound (33), but since over 85% of all of the original 
activity was retained on the vessel wall, Cs[18F]F offers limited utility. This also demonstrates the 
dangers of interpreting reaction success based solely on radio-TLCs. 
 By far, the most commonly used [18F]fluoride source is the K[18F]F.K222 cryptate, due to 
its superior organic solubility and fluoride nucleophilicity as compared to the other salts. K[18F]F 
can be prepared from either the potassium carbonate or bicarbonate salt, but the presence of 
an additional protic hydrogen seems to have a critical effect on the reaction, since no product 
formed with KHCO3. Nevertheless, acceptable RCYs of 33 were obtained with the K2CO3/K222 
approach in the preferred oil bath method. Further modification of the method with the addition 
of radical scavenger, TEMPO, afforded a 4-5% increase in yields. TEMPO is a common radical-
scavenger additive for the radiofluorination of iodonium salts since these precursors are 
unstable to basic conditions and can generate aryl radicals by homolytic fragmentation of 
precursor. Although addition of TEMPO in the cold chemistry screen resulted in a significant 
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reduction in product formation, gratifyingly, its addition in the presence of F-18 increased the 
desired yields. 
 Additional investigations revealed that the reaction was complete within 10 minutes, and 
after elution through a silica gel plug, methyl ether deprotection proceeded rapidly with the 
original conditions (AlBr3, CH3(CH2)11SH) to generate 2-[
18F]fluoroestradiol (2) within 20 
minutes. The overall sequence is shown in Scheme 4.9. 
 
Scheme 4.9. Overall sequence for the radiosynthesis of 2-[18F]fluoroestradiol (2). (a) K[18F]F, 
K2CO3, K222, TEMPO, PhH, 105 
oC, 10 min, RCY = 23%; (b) CH3(CH2)11SH, AlBr3, rt, 5 min. 
 
 Again, these findings are significant since we are obtaining [18F]fluorination of the 
unanticipated more electron-rich ring, and although the yields are compared to mainstream 
organic chemistry, this is not unusual for F-18 chemistry (typically radiochemical yields range 
from 10-30%). Lower yields are not a significant problem for PET agent production since the 
sensitivity of PET imaging is extraordinarily high and only relatively low amounts of 18F-material 
are needed for biological evaluations. Although the yields are still not ideal, they are workable 
and sufficiently high to evaluate 2 in future animal studies.  
III. CONCLUSION 
 In summary, we have developed an experimentally simple method for the rapid and 
efficient preparation of a complex diaryliodonium bromide salt that can be used to afford 2-
[18F]fluoroestradiol within 20 minutes of reaction time in synthetically useful radiochemical 
yields. The reaction proved highly dependent on multiple factors (i.e., counteranion, solvent, 
fluoride source) and illustrates the lack of generality when utilizing these particular substrates to 
radiofluorinate electron-rich arenes. Current efforts have focused on scaling up the reaction with 
higher amounts of activity to generate sufficient amounts of the desired radiotracer for 
evaluation in the appropriate animal models. 
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IV. METHODS 
Materials 
All reactions were carried out under a nitrogen atmosphere with dry solvents using anhydrous 
conditions unless otherwise stated. Solvents used in the reactions were dried in a solvent 
delivery system (neutral alumina column). Reagents were purchased from Aldrich and used 
without further purification, unless otherwise stated. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogeneous materials, unless otherwise stated. Reactions were 
monitored by thin layer chromatography (TLC) carried out on Merck silica gel 60 F254 
precoated plates (0.25 mm) using UV light as the visualizing agent and ceric ammonium 
molybdate and heat as developing agents. Flash column chromatography was performed on 
Silica P Flash silica gel (40-64 μM, 60 Å) from SiliCycle. 1H NMR spectra were recorded at 23 
oC on a Varian Unity-400, Varian Inova-500 or Varian Unity-500 spectrometers and are reported 
in ppm using residual protium as the internal standard (CHCl3, δ = 7.26, CD2HCN, δ = 1.94, 
center line, acetone-d6, δ = 2.05, center line, DMSO-d6, δ = 2.50, center line). The following 
abbreviations were used to explain the multiplicities: s = singlet, d = doublet, dd = doublet of 
doublets, t = triplet, q = quartet, m = multiplet and b = broad. Proton-decoupled 13C NMR 
spectra were recorded on a Varian Unity-500 (126 MHz) spectrometer and are reported in ppm 
using solvent as an internal standard (CDCl3, δ = 77.16, CD3CN, δ = 1.30, center line, acetone-
d6, δ = 29.80, center line, DMSO-d6, δ = 40.1, center line). High resolution mass spectra were 
obtained at the University of Illinois Mass Spectrometry Laboratory. No-carrier added 
[18F]fluoride was produced at Washington University Medical School by the 18O(p,n)18F reaction 
through proton irradiation of enriched (95%) [18O]H2O using a RDS111 cyclotron. Screw-cap test 
tubes used for drying fluoride and radiolabeling were purchased from Fisher Scientific (Pyrex 
No. 9825). Radiochemical purification utilized a reversed-phase semi-preparative HPLC column 
(HPLC: Thermo P2000, Column: Agilent Zorbax SB-C18, 5 µm, 9.4 X 250 mm, Product #: 
880975-202, λ = 254 nm, ACN/H2O). For quality control, the radiochemical purity was 
determined by analytical HPLC (HPLC: P4000, Column: Altima C18, 5 µm, 250 mm, Product #: 
88056). C18 Sep-Pak cartridges were purchased from Waters Corporation (Milford, MA, USA). 
For the thin-layer chromatography (TLC) analyses, EM Science Silica Gel 60 F254 TLC plates 
were purchased from Fisher Scientific (Pittsburgh, PA, USA). Radio-TLC was accomplished 
using a Bioscan 200 imaging scanner (Bioscan, Inc., Washington, DC, USA). Radioactivity was 
counted with a Beckman Gamma 8000 counter containing a NaI crystal (Beckman Instruments, 
Inc., Irvine, CA, USA). 
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(13S,17S)-3,17-Dimethoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta- 
[a]phenanthrene (15): To a solution of 14 (2.01 g, 7.38 mmol) in THF (100 mL) at 0 oC was 
added NaH (1.35 g, 33.9 mmol, 60% dispersion in mineral oil) and left at this temperature for 15 
minutes. MeI (4.59 mL, 73.8 mmol) was then added at 0 oC and left to stir to room temperature 
overnight before being quenched with H2O (50 mL). The crude reaction was extracted with 
EtOAc (2 X 100 mL), and the combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. Purification by column chromatography (Hex:EtOAc, 10:1) afforded 15 
(1.68 g, 75.7%) as a white solid; mp 154-155 oC. Rf = 0.85 (Hex:EtOAc, 5:1). 
1H NMR (500 
MHz, CDCl3):  7.21 (d, J = 8.5 Hz, 1H), 6.72 (dd, J = 8.5, 2.7 Hz, 1H), 6.64 (d, J = 2.7 Hz, 1H), 
3.79 (s, 3H), 3.39 (s, 3H), 3.32 (t, J = 8.3 Hz, 1H), 2.95-2.78 (m, 2H), 2.34-2.25 (m, 1H), 2.24-
2.16 (m, 1H), 2.13-2.02 (m, 2H), 1.93-1.84 (m, 1H), 1.76-1.65 (m, 1H), 1.56-1.16 (m, 7H), 0.80 
(s, 3H); 13C NMR (126 MHz, CDCl3):  157.4, 138.0, 132.7, 126.3, 113.8, 111.4, 90.8, 57.9, 
55.2, 50.3, 43.9, 43.2, 38.6, 38.1, 29.8, 27.8, 27.2, 26.4, 23.0, 11.5; HRMS (ESI) calc’d for 
C20H29O2 [M + 1] 301.2168; found 301.2179. 
 
(13S,17S)-2-Bromo-3,17-dimethoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenanthrene (16): To a solution of 15 (50.3 mg, 0.17 mmol) in DCM (1.5 mL) at 
room temperature was added NBS (32.5 mg, 0.18 mmol) in ACN (0.6 mL). The round bottom 
flask was wrapped in foil and left to stir at room temperature for 18 hours. The solvent was 
removed in vacuo, CHCl3 was added and the suspension was filtered through a silica gel plug. 
The eluent was evaporated to afford a crude yellow oil. The oil was triturated with warm MeOH 
(30 mL) to yield an off-white solid; repeating the step with the crude solid with more MeOH (20 
mL) yielded 16 (23.3 mg, 36.8%, 96:4) as an off-white solid; Rf = 0.75 (Hex:EtOAc, 7:1). 
1H 
NMR (500 MHz, CDCl3):  7.44 (s, 1H), 6.62 (s, 1H), 3.86 (s, 3H), 3.39 (s, 3H), 3.32 (t, J = 8.4 
Hz, 1H), 2.86-2.78 (m, 2H), 2.29-2.21 (m, 1H), 2.21-2.14 (m, 1H), 2.13-2.03 (m, 2H), 1.94-1.85 
(m, 1H), 1.75-1.64 (m, 1H), 1.58-1.27 (m, 6H), 1.25-1.15 (m, 1H), 0.80 (s, 3H); 13C NMR (126 
MHz, CDCl3):  157.4, 138.0, 132.7, 126.3, 113.8, 111.4, 90.8, 57.9, 55.2, 50.3, 43.9, 43.2, 
38.6, 38.1, 29.8, 27.8, 27.2, 26.4, 23.0, 11.5; HRMS (ESI) calc’d for C20H28BrO2 [M + 1] 
379.1273; found 379.1261. 
 
((13S,17S)-3,17-Dimethoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclo 
penta[a]phenanthren-2-yl)trimethylstannane (17): To a solution of 16 (0.50 g, 1.32 mmol) 
and TMEDA (0.79 mL, 5.27 mmol) in Et2O (10 mL) at -78 
oC was added nBuLi (1.39 mL, 1.39 
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mmol, 1.6 M in hexanes) and left to stir at this temperature for 5 minutes. This solution was then 
cannulated into another flask containing Me3SnCl (1.32 mL, 1.32 mmol, 1.0 M in hexanes) and 
Et2O (10 mL), cooled to -78 
oC, and the resulting mixture was left to stir to room temperature 
over 2 hours. The solution was then passed through a silica gel plug (Hex:EtOAc, 1:1) and 
concentrated in vacuo. The crude product was used as is in the next step as this intermediate 
was prone to protio-destannylation during column chromatography and on the bench. 1H NMR 
(500 MHz, CDCl3):  7.30 (s, 1H), 6.56 (s, 1H), 3.76 (s, 3H), 3.39 (s, 3H), 3.33 (t, J = 8.3 Hz, 
1H), 2.98-2.79 (m, 2H), 2.40-2.31 (m, 1H), 2.27-2.17 (m, 1H), 2.13-2.01 (m, 2H), 1.94-1.82 (m, 
1H), 1.76-1.64 (m, 1H), 1.59-1.17 (m, 7H), 0.80 (s, 3H), 0.25 (s, 9H). 
 
General procedure for the formation of the diaryliodonium salts (20, 21): To a partially 
dissolved solution of 18 (0.11 g, 0.32 mmol, 4-methoxyphenyl) in ACN (2 mL) was added TsOH 
(0.62 mg, 0.32 mmol) in ACN (2 mL) and the resulting solution was added to a flask containing 
17 (0.15 g, 0.32 mmol) in THF (2 mL). The light yellow mixture was left stirring for 18 hours at 
room temperature in foil.  The solution was evaporated to dryness to afford an oily product. The 
crude product was redissolved in EtOAc (1.5 mL) and MeOH (dropwise added until product 
dissolves fully) and the product was precipitated with hexanes (~3.0 mL). The mixture was left in 
a freezer for 3 hours until the mother liquor turned clear. The liquid was removed and the 
precipitation process was repeated once more to afford pure diaryliodonium salts. The 
procedure was repeated with the thiophene derivative the same way.  
 
20: From 17 (0.15 g, 0.32 mmol), 20 (0.094 g, 40.9%) was obtained as an off-white solid. 1H 
NMR (500 MHz, CD3CN):  7.93 (d, J = 9.3 Hz, 2H), 7.83 (s, 1H), 7.53 (d, J = 8.3 Hz, 2H), 7.17 
(d, J = 8.3 Hz, 2H), 6.98 (d, J = 9.0 Hz, 2H), 6.90 (s, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 3.30 (s, 3H), 
2.90 (dd, J = 8.5, 4.2 Hz, 2H), 2.42-2.33 (m, 4H), 2.26-2.18 (m, 1H), 2.11-1.95 (m, 2H), 1.91-
1.81 (m, 1H), 1.72-1.62 (m, 1H), 1.52-1.13 (m, 8H), 0.74 (s, 3H); HRMS (ESI) calc’d for 
C27H34IO3 533.1553; found 533.1545. 
 
21: From 17 (0.101 g, 0.22 mmol), 21 (0.123 g, 82.6%) was obtained as a light brown solid. 1H 
NMR (500 MHz, CD3CN):  7.89 (s, 1H), 7.84 (dd, J = 3.9, 1.2 Hz, 1H), 7.78 (dd, J = 5.4, 1.2 
Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.10 (dd, J = 5.4, 3.9 Hz, 1H), 6.91 
(s, 1H), 3.92 (s, 3H), 3.30 (s, 3H), 2.97-2.83 (m, 2H), 2.34 (s, 3H), 2.28-2.15 (m, 2H), 2.12-1.95 
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(m, 2H), 1.91-1.79 (m, 2H), 1.76-1.58 (m, 2H), 1.54-1.07 (m, 8H), 0.73 (s, 3H); HRMS (ESI) 
calc’d for C24H30IO2S 509.1011; found 509.1009. 
 
General procedure for anion exchange (22-27): Salts (20, 21) were dissolved in ACN (2 mL) 
and heated to 60 oC. If the solid does not dissolve, a few drops of water were added until a clear 
solution forms.  An aqueous solution of KBr ((or KI or NaPF6) 120 mg in 1 mL H2O) was added 
and left to cool in the dark to room temperature. The mother liquor was removed to afford a 
white solid. Impure salts were further recrystallized from EtOAc:MeOH:Hex as discussed 
previously.  
 
22: From 17 (0.142 g, 0.31 mmol), 22 (0.072 g, 34.3%) was obtained as a light brown solid. 1H 
NMR (500 MHz, CD3CN):  7.93 (d, J = 9.0 Hz, 2H), 7.83 (s, 1H), 6.98 (d, J = 9.0 Hz, 2H), 6.89 
(s, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.30 (s, 3H), 2.90 (dd, J = 8.5, 4.0 Hz, 2H), 2.26-2.18 (m, 1H), 
2.18-2.11 (m, 1H), 2.10-1.99 (m, 2H), 1.89-1.81 (m, 1H), 1.73-1.60 (m, 1H), 1.52-1.12 (m, 7H), 
0.74 (s, 3H); HRMS (ESI) calc’d for C27H34IO3 533.1553; found 533.1543. 
 
23: From 17 (0.150 g, 0.32 mmol), 23 (0.091 g, 43.3%) was obtained as a light brown solid. 1H 
NMR (500 MHz, CD3CN):  7.90 (s, 1H), 7.83 (dd, J = 3.8, 1.2 Hz, 1H), 7.77 (dd, J = 5.4, 1.3 
Hz, 1H), 7.10 (dd, J = 4.9, 3.2 Hz, 1H), 6.90 (s, 1H), 3.92 (s, 3H), 3.30 (s, 3H), 2.90 (dd, J = 8.5, 
4.0 Hz, 2H), 2.24-2.17 (m, 2H), 2.11-2.00 (m, 2H), 1.90-1.81 (m, 1H), 1.74-1.60 (m, 1H), 1.52-
1.13 (m, 8H), 0.73 (s, 3H); HRMS (ESI) calc’d for C24H30IO2S 509.1011; found 509.1015. 
 
24: From 17 (0.101 g, 0.22 mmol), 24 (0.054 g, 37.8%) was obtained as a off-white solid. 1H 
NMR (500 MHz, DMSO-d6):  8.10 (s, 1H), 8.01 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 8.3 Hz, 2H), 
6.96 (s, 1H), 3.87 (s, 3H), 3.78 (s, 3H), 3.26 (s, 3H), 2.91-2.82 (m, 2H), 2.41-2.32 (m, 1H), 2.23-
2.09 (m, 1H), 2.05-1.91 (m, 2H), 1.85-1.75 (m, 1H), 1.68-1.56 (m, 1H), 1.48-1.12 (m, 8H), 0.70 
(s, 3H); HRMS (ESI) calc’d for C27H34IO3 533.1553; found 533.1548. 
 
25: From 17 (0.107 g, 0.22 mmol), 25 (0.041 g, 21.8%) was obtained as a light brown solid. 1H 
NMR (500 MHz, DMSO-d6):  8.12 (s, 1H), 8.03 (dd, J = 3.9, 1.3 Hz, 1H), 7.96 (dd, J = 5.4, 1.3 
Hz, 1H), 7.31 (dd, J = 4.6, 3.4 Hz, 1H), 6.98 (s, 1H), 3.87 (s, 3H), 3.26 (s, 3H), 2.91-2.84 (m, 
2H), 2.40-2.32 (m, 1H), 2.23-2.10 (m, 1H), 2.04-1.89 (m, 2H), 1.86-1.76 (m, 1H), 1.68-1.54 (m, 
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1H), 1.45-1.14 (m, 8H), 0.70 (s, 3H); HRMS (ESI) calc’d for C24H30IO2S 509.1011; found 
509.1013. 
 
26: From 17 (0.114 g, 0.25 mmol), 26 (0.087 g, 58.0%) was obtained as an off-white solid. 1H 
NMR (500 MHz, DMSO-d6):  8.11 (s, 1H), 8.01 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 9.3 Hz, 2H), 
6.97 (s, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 3.27 (s, 3H), 2.93-2.82 (m, 2H), 2.43-2.33 (m, 1H), 2.24-
2.10 (m, 1H), 2.08-1.91 (m, 2H), 1.86-1.75 (m, 1H), 1.71-1.61 (m, 1H), 1.50-1.10 (m, 8H), 0.71 
(s, 3H); HRMS (ESI) calc’d for C27H34IO3 533.1553; found 533.1544. 
 
27: From 17 (0.114 g, 0.25 mmol), 27 (0.067 g, 46.7%) was obtained as a brown solid. 1H NMR 
(500 MHz, DMSO-d6):  8.10 (s, 1H), 8.01 (dd, J = 3.9, 1.3 Hz, 1H), 7.95 (dd, J = 5.4, 1.3 Hz, 
1H), 7.31 (dd, J = 4.6, 3.4 Hz, 1H), 6.99 (s, 1H), 3.87 (s, 3H), 3.26 (s, 3H), 2.91-2.84 (m, 2H), 
2.40-2.32 (m, 1H), 2.23-2.10 (m, 1H), 2.03-1.89 (m, 2H), 1.86-1.75 (m, 1H), 1.69-1.54 (m, 1H), 
1.47-1.13 (m, 8H), 0.70 (s, 3H); HRMS (ESI) calc’d for C24H30IO2S 509.1011; found 509.1014. 
 
General procedure for the investigations of fluoride sources on the different 
diaryliodonium salts. To a heterogenous solution of salts (22 or 26, 1 mg) in PhH (0.3 mL) 
was added the fluoride source (1 equiv., K222 = 3 equiv.) and then sealed and heated at 140 
oC 
for 20 minutes. After the allotted time, the vial was cooled to room temperature, passed through 
a silica gel plug and the combined organic solvents were concentrated in vacuo. Product ratios 
of 29:31 were analyzed through integrations of the A-ring aromatic peaks in the 1H NMR 
spectrum. 
 
General procedure for the investigations on the counterion effect on the different 
diaryliodonium salts. To a heterogenous solution of salts (20-27, 1 mg) in PhH (0.3 mL) was 
added TBAF.3H2O (1 equiv.) and then sealed and heated at 140 
oC for 20 minutes. After the 
allotted time, the vial was cooled to room temperature, passed through a silica gel plug and the 
combined organic solvents were concentrated in vacuo. Product ratios of 29:31 were analyzed 
through integrations of the A-ring aromatic peaks in the 1H NMR spectrum. 
 
(Diacetoxy)-2-thiophene (18): 4-Iodothiophene (1.1 mL, 10 mmol) was dissolved in AcOH (90 
mL) and heated to 40 oC. NaBO3
.4H2O was added portion wise over 1 hour and left to stir at this 
temperature for an additional 8 h. After the allotted time, the heterogeneous mixture was 
evaporated to approximately half the volume of the original AcOH and then the product was 
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extracted with DCM (2 X 100 mL) after adding H2O (50 mL). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo to afford pure 18 (1.25 g, 38.1%)  as a light 
yellow solid. 1H NMR (500 MHz, CD3CN):  7.86 (dd, J = 3.9, 1.3 Hz, 1H), 7.79 (dd, J = 5.4, 1.3 
Hz, 1H), 7.18 (dd, J = 5.5, 3.8 Hz, 1H), 1.93 (s, 6H); 13C NMR (126 MHz, CD3CN):  219.8, 
136.9, 130.7, 129.9, 120.9, 20.5. 
 
(Diacetoxy)-4-methoxybenzene (18): 4-Iodoanisole (2.34 g, 9.99 mmol) was dissolved in 
AcOH (90 mL) and heated to 40 oC. NaBO3
.4H2O was added portion wise over 1 hour and left to 
stir at this temperature for an additional 8 h. After the allotted time, the heterogeneous mixture 
was evaporated to approximately half the volume of the original AcOH and then the product was 
extracted with DCM (2 X 100 mL) after adding H2O (50 mL). The combined organic extracts 
were dried over MgSO4 and concentrated in vacuo to afford pure 18 (2.27 g, 64.5%) as a light 
yellow solid. 1H NMR (500 MHz, CD3CN):  8.05 (d, J = 9.2 Hz, 2H), 7.06 (d, J = 9.2 Hz, 2H), 
3.87 (s, 3H), 1.91 (s, 6H); 13C NMR (126 MHz, CD3CN):  203.9, 139.4, 138.5, 130.7, 120.9, 
56.6, 20.5. 
 
Scheme 4.10. Synthesis of the iodine standard for 1H NMR analysis. (a) MOMCl, Hunig’s Base,  
THF, reflux, 16 h; (b) (i) sec-BuLi, THF, 30 min (ii) I2, Et2O, -78 
oC rt, overnight; (c) HCl, 
THF, reflux, 12 h; (d) (i) NaH, DMF, 0 oC, 10 min (ii) MeI, 0 oC rt, 5 h. 
 
(13S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenanthrene (34):  To a solution of 17β-estradiol (14, 2.01 g, 7.38 mmol) in 
THF (15 mL) was added Hunig’s base (6.5 mL) and MOMCl (2.8 mL, 36.9 mmol) and left at 
reflux for 16 h before being quenched with H2O (50 mL) at room temperature. The crude 
reaction was extracted with EtOAc (2 X 100 mL), and the combined organic extracts were dried 
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over MgSO4 and concentrated in vacuo. Purification by column chromatography (Hex:EtOAc, 
4:1) afforded 34 (2.49 g, 93.6%) as a clear oil; Rf = 0.95 (Hex:EtOAc, 2:1). 
1H NMR (500 MHz, 
CDCl3): 7.21 (d, J = 8.3 Hz, 1H), 6.84 (dd, J = 8.5, 2.9 Hz, 1H), 6.78 (d, J = 2.7 Hz, 1H), 5.15 
(s, 2H), 4.71-4.64 (m, 2H), 3.63 (t, J = 8.4 Hz, 1H), 3.48 (s, 3H), 3.39 (s, 3H), 2.91-2.80 (m, 2H), 
2.34-2.26 (m, 1H), 2.24-2.16 (m, 1H), 2.14-1.97 (m, 2H), 1.92-1.84  (m, 1H), 1.76-1.66 (m,  1H), 
1.64-1.16 (m, 7H), 0.82 (s, 3H). 
 
(13S,17S)-2-Iodo-3,17-bis(methoxymethoxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-deca- 
hydro-6H-cyclopenta[a]phenanthrene (35): To a solution of 34 (1.01 g, 2.80 mmol) in THF 
(25 mL) at -78 oC was added sec-BuLi (8 mL, 11.2 mmol, 1.4 M in cyclohexane) and left to stir 
for 30 min. This solution was cannulated into a solution of iodine (3.56 g, 14.01 mmol) in Et2O 
(25 mL) at -78 oC and left to stir at room temperature overnight before being quenched with H2O 
(50 mL). The crude reaction was extracted with EtOAc (2 X 100 mL), and the combined organic 
extracts were dried over MgSO4 and concentrated in vacuo. Purification by column 
chromatography (Hex:EtOAc, 6:1) afforded 35 (0.77 g, 56.3%) as a white solid; Rf = 0.70 
(Hex:EtOAc, 5:1). 1H NMR (500 MHz, CDCl3): 7.66 (s, 1H), 6.79 (s, 1H), 5.20 (s, 2H), 4.71-
4.56 (m, 2H), 3.62 (t, J = 8.4 Hz, 1H), 3.52 (s, 3H), 3.38 (s, 3H), 2.86-2.77 (m, 2H), 2.30-1.83 
(m, 5H), 1.76-1.12 (m, 8H), 0.81 (s, 3H). 
 
(13S,17S)-2-Iodo-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H cyclopenta[a]phena- 
nthrene-3,17-diol (36): To a solution of 35 (1.42 g, 2.92 mmol) in THF (30 mL) was added 12 M 
HCl (7 mL) and left to reflux for 12 h. The solution was cooled to room temperature and the 
crude reaction was extracted with EtOAc (2 X 100 mL), with the combined organic extracts were 
dried over MgSO4 and concentrated in vacuo. Purification by column chromatography 
(Hex:EtOAc, 2:1) afforded 36 (1.07 g, 92.1%) as a white solid; Rf = 0.19 (Hex:EtOAc, 4:1). 
1H 
NMR (500 MHz, CDCl3):  7.53 (s, 1H), 6.73 (s, 1H), 2.80 (dd, J = 8.9, 4.0 Hz, 2H), 2.30-2.08 
(m, 2H), 2.00-1.83 (m, 3H), 1.75-1.65 (m, 1H), 1.56-1.13 (m, 7H), 0.79 (s, 3H). 
 
(13S,17S)-2-Iodo-3,17-dimethoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenanthrene (37): To a solution of 36 (0.938 g, 2.36 mmol) in DMF (14 mL) at 
0 oC was NaH (0.44 g, 10.9 mmol, 60% oil dispersion) and left to stir at this temperature for 10 
min. To this solution, MeI (1.47 mL, 23.6 mmol) was added and left to stir to room temperature 
for 5 h before being quenched with H2O (20 mL). The crude reaction was extracted with EtOAc 
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(2 X 100 mL), and the combined organic extracts were dried over MgSO4 and concentrated in 
vacuo. Purification by column chromatography (Hex:EtOAc, 6:1) afforded 37 (2.49 g, 93.6%) as 
an off-white solid; Rf = 0.87 (Hex:EtOAc, 4:1). 
1H NMR (500 MHz, CDCl3):  7.65 (s, 1H), 6.55 
(s, 1H), 3.84 (s, 3H), 3.39 (s, 3H), 2.88-2.79 (m, 2H), 2.33-2.01 (m, 2H), 1.93-1.84 (m, 2H), 
1.75-1.64 (m, 1H), 1.56-1.14 (m, 7H), 0.79 (s, 3H). 13C NMR (126 MHz, CDCl3): 155.9, 138.4, 
136.4, 135.0, 111.4, 90.4, 90.7, 57.9, 56.3, 50.2, 43.6, 43.2, 38.3, 37.9, 29.7, 27.7, 27.0, 26.4, 
23.0, 11.5; HRMS (EI) calc’d for C20H27IO2 426.10561; found 426.10638.   
 
General procedure for the drying step: To a glass vial was added the carbonate or 
bicarbonate of the respective alkali or tetralkylammonium salt (0.1-1 mg, K222 = 1-5 mg) in water 
(25-200 µL). The vial was placed in an oil bath at 105 oC and the water was removed by 
azeotropic distillation with ACN (1 mL) using a stream of nitrogen. This was repeated twice 
more with 1 mL increments of ACN until the [18F]fluoride source was deemed dry. The 
corresponding diaryliodonium salt and PhH (0.3-0.5 mL) were added and then heated for the 
desired time period. The course of the reaction and yields were monitored by radio-TLC and      
-HPLC. 
Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and Cs18F (from Cs2CO3) 
after 20 minutes at 105 oC (oil bath): 
DONG: 71920111.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
1.4e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 78.47% 
Region 2 ([18F]fluoroproduct; 55 mm): 21.53% 
*Product did not co-elute with cold standard.  
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Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and Cs18F (from Cs2CO3) 
after 5 minutes in the microwave: 
DONG: 71920112.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0
1500
3000
4500
6000
7500
9000
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 86.28% 
Region 2 ([18F]fluoroproduct; 55 mm): 13.72% 
 
Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and Cs18F (from CsHCO3) 
after 20 minutes at 105 oC (oil bath): 
DONG: 71920113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 96.70% 
Region 2 ([18F]fluoroproduct; 65 mm): 3.30% 
 
Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and Cs18F (from CsHCO3) 
after 5 minutes in the microwave: 
DONG: 71920114.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 83.23% 
Region 2 ([18F]fluoroproduct; 55 mm): 16.77% 
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Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and K18F (from K2CO3 and 
K222) after 20 minutes at 105 
oC (oil bath): 
DONG: 71920115.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 81.32% 
Region 2 ([18F]fluoroproduct; 55 mm): 18.68% 
 
Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and K18F (from K2CO3 and 
K222) after 5 minutes in the microwave: 
DONG: 71920116.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0
1000
2000
3000
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 89.68% 
Region 2 ([18F]fluoroproduct; 60 mm): 10.32% 
 
Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and K18F (from KHCO3 and 
K222) after 20 minutes at 105 
oC (oil bath): 
DONG: 72120111.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
3.0e3
6.0e3
9.0e3
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 100% 
Region 2 ([18F]fluoroproduct; 55 mm): 0% 
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Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and K18F (from K2CO3 and 
K222) after 5 minutes in the microwave: 
DONG: 72120112.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 92.37% 
Region 2 ([18F]fluoroproduct; 55 mm): 7.63% 
 
Radio-TLC of the radiofluorination of 26 with [18F]fluoride ion and K18F (from K2CO3 and 
K222) and TEMPO (95 µg) after 20 minutes at 105 
oC (oil bath): 
DONG: 72120113.R01 
20.0 35.0 50.0 65.0 80.0 95.0 mm
cnts
0.0
2.0e3
4.0e3
6.0e3
8.0e3
1.0e4
1.2e4
 
TLC Eluting Conditions: 100% EtOAc 
Region 1 (unreacted [18F]fluoride; 35 mm): 77.45% 
Region 2 ([18F]fluoroproduct; 55 mm): 22.55% 
 
Deprotection to 2-[18F]fluoroestradiol (2): After cooling to room temperature, the solution was 
passed through a silica gel plug and the solvent was blown down to dryness. The crude product 
was dissolved in dodecanethiol (0.2 mL) and AlBr3 (10 mg) was added and left to stand at room 
temperature for 5 minutes. The reaction was quenched with 5% HCl and MeOH until the 
bubbling ceased and then passed through another silica gel plug.  
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UV trace with injected cold standard (Product: 4.11 min): 
 Conditions: 80% ACN 20% H2O 1.5 mL/min, λ = 254 nM 
 
Radioactivity trace (Product: 4.21 min): 
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